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Two one-pot oxidative cyclization strategies to spiroacetals are described herein. The first 
approach utilizes a Lewis acid-mediated Ferrier reaction for the initial fragment coupling 
followed by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)-initiated oxidative carbon–
hydrogen bond cleavage and cyclization. The second approach relies on a Heck cross coupling 
for fragment assembly followed by a DDQ-mediated dehydrogenation of enol ethers into enones 
and subsequent acid-induced cyclization. These methods provide mild convergent protocols to 
spiroketal subunits, which are ubiquitous in natural products, medicinal drugs, and chemical 
libraries. 
 
 
 
Cyclopropane-substituted allylic ethers undergo carbon–hydrogen bond cleavage to form stable 
oxocarbenium ions upon reaction with DDQ. Significantly, in the presence of an appending 
nucleophile, facile ring closure occurs to yield highly functionalized tetrahydropyrans with no 
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accompanied cyclopropane scission. This methodology was showcased during the total synthesis 
of the sponge-derived macrodiolide clavosolide A. 
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1.0  C–H FUNCTIONALIZATION 
1.1 INTRODUCTION 
In recent years, C–H bond activation[1] has emerged as an important area of research because of 
its potential to streamline syntheses and reduce waste. Due to the strength of a C–H bond[2] (∆H 
≈ 400 kJ/mol), cleavage of such bonds is not trivial and generally requires a metal catalyst to 
lower the barrier of activation. Substrates subjected to C–H bond activation also generally 
require an ancillary group for binding of the catalyst[3]; to ensure guided regioselective 
functionalization at the desired site. Notably, Baran[4] utilized a carbamate-directing group for 
accessing 1,3-diols via a modified Hofmann-Loffler-Freytag (HLF) reaction (Figure 1.1). In an 
attempt to mimic remote C–H functionalization displayed by enzyme catalysis, groups such as 
White[5] and Hartwig[6] have designed novel iron catalysts for site-selective functionalization 
(Figure 1.1). These catalysts differentiate C–H bonds by exploiting intrinsic subtle 
stereoelectronic variation within the molecules. However, generality in substrate scope is often 
not obvious and requires further optimization on a case-by-case basis.  
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Figure 1.1 State-of-the-art C–H bond activation 
1.2 DEVELOPMENT OF OXIDATIVE C–H BOND FUNCTIONALIZATION 
(FLOREANCIG GROUP)  
1.2.1 Pioneering work by Mukaiyama 
Oxidation is a one of the key transformations in an organic synthesis. While there are many 
reagents designed for selective oxidation, there are very few oxidants that can generate cationic 
species by hydride abstraction. This has significant consequences as these carbocations can be 
 3 
employed in cascade transformation by reaction with appropriate nucleophiles. As early as the 
late 1980s, Mukaiyama and co-workers[7] discovered that 2, 3-dichloro-5, 6-dicyano-1, 4-
benzoquinone (DDQ) 1.2 could be used to oxidize allyl ethers 1.1 into their corresponding 
cationic species which reacted readily with silyl carbon nucleophiles (Figure 1.2). 
 
 
Figure 1.2 Mukaiyama’s DDQ-mediated oxidative coupling 
 
A counter ion exchange between the initial DDQH- and LiClO4 generates a more electrophilic ion 
pair 1.4 that reacts with TMSCN to afford product 1.5 along with the regenerated LiClO4. This 
procedure enabled the oxidation and addition process to be performed in a one-pot manner and 
the isolation of cationic intermediates unnecessary. 
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1.2.2 Floreancig intramolecular oxidative C–H bond approach   
The Floreancig group has a long-standing interest in oxidative methods used for the formation of 
carbon-carbon as well as carbon-hydrogen bonds. In an oxidative carbon-bond activation 
proposal[8] initiated in 2008, Dr. Tu and Dr. Liu exploited the oxidative nature of DDQ to form 
aryl-substituted oxocarbenium ions from benzylic ethers. In the presence of an appended enol 
acetate nuceophile, an intramolecular carbon-carbon bond formation occurred with excellent 
diastereoselective control (Figure 1.3). 
 
 
Figure 1.3 DDQ-mediated metal-free C–H bond activation 
 
The proposed mechanism initiates by an initial one-electron oxidation of the PMB group on the 
enol acetate ether 1.6 into the radical cation 1.7 with the corresponding DDQ- radical counter 
anion. Due to the decreased bond strength of the adjacent C–H bond, the bond is activated and 
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undergoes C–H bond cleavage by rate-determining hydrogen atom transfer to give ion-pair 1.8. 
Oxocarbenium 1.8 adopts a stable (E)-conformation, minimizing potential diaxial interactions 
with all the substituents adopting the trans configuration. Subsequent cyclization and acetyl 
group cleavage affords 1.9.  
 
Table 1 Selected examples of THP accessible by DDQ C–H bond activation 
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Aromatic substrates (Table 1) generally perform well with electron-donating arenes having the 
highest reactivity due to lower oxidation potentials and better stability of the intermediate 
cations. The substrate scope was also expanded to allylic ethers (entries 3 and 4) with adjacent 
functional groups such as silyl ethers and electrophilic ester groups. 
 
Mr. Brizgys and Dr. Cui further expanded this DDQ-mediated oxidative C–H bond activation 
protocol into nitrogen[9]-and sulfur[10]-containing heterocycles respectively (Scheme 1.1). Some 
key differences noted were: 1) During the piperidine synthesis, N-vinyl amides/sulfonamides 
1.10 with lower oxidation potential were used instead as N-allyl amides were completely 
unreactive. 2) Oxidation of vinyl sulfides 1.11 generally gave lower stereoselectivity of the 
cyclized thiopyran 1.12 than the corresponding allylic ethers. This is due to the lower kinetic 
barrier to equilibrium between the (E)- and (Z)-geometry of the thiocarbenium ion caused by the 
longer carbon–sulfur bond. 
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Scheme 1.1 DDQ mediated transformations of heterocycles 
1.2.3 Oxidative C–H bond activation: Bimolecular coupling 
The facile DDQ-mediated C–H bond oxidation and subsequent trapping with a tethered π-
nucleophile has allowed for the stereodiversified synthesis of a wide variety of heterocycles. 
Though attractive, these protocols are not strategically ideal because a highly functionalized 
fragment must be prepared in advance before the actual oxidative cyclization reaction.   
 
Whitlock defines molecular complexity by the number of rings, stereocenters, functional groups 
and size as defined by the number of bonds or molecular weight[11]. As such, bimolecular 
coupling reactions are inherently advantageous processes for increasing molecular complexity 
and expediating complex molecules synthesis. The Floreancig group thus embarked on a 
 8 
program to investigate DDQ mediated oxidative bimolecular coupling. Dr. Clausen succeeded in 
oxidizing various analogs of chromene into oxocarbenium cation 1.13 and subsequent trapping 
by external nucleophiles[12] (Figure 1.4). Interestingly, he noticed that chromene possessing a 
flanking alcohol moiety could be trapped as spiroketal 1.14 under the oxidative DDQ conditions.   
 
 
Figure 1.4 Bimolecular chromene coupling 
 
Mr. Villafane also managed to access spiro-heterocycle 1.17 via a sequential one-pot fragment 
coupling of benzo[d][1,3]oxathiole 1.15 with allyl silane 1.16 (Scheme 1.2)[13]. These two 
examples are key precedents, which eventually led to the development of the current Ferrier 
oxidative spirocyclization project. 
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Scheme 1.2 Sequential oxidative addition and cyclization 
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2.0   [N+1] APPROACHES TO THE SYNTHESIS OF DIVERSE SPIROACETALS 
THROUGH OXIDATIVE CATION FORMATION  
2.1 INTRODUCTION 
2.1.1 The spiroacetal privileged structure 
Oxygen-containing spirocycles are important motifs in nature as evident in their abundance in 
natural products (Figure 2.1). The x-ray structure of the bistramide A 2.1 complex with actin 
reveals that the spiroketal subunit directly participates in the stabilization of the small molecule-
protein interaction affecting regulation of metastatic cancer cells via H-bonding and hydrophobic 
effects[14].  
 
 
Figure 2.1 Spiroketal containing compounds 
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Alotaketal A 2.2 is an important activator of the cAMP-signaling pathway vital for daily life 
processes[15]. The spiroketal subunit possessing a rigid, stereochemical defined sp3 stereocenter is 
also an excellent candidate for fragment-based drug design (FDBB). It has a more sp3-enriched 
structure that can reach out and access previously uncharted chemical spaces[16]. For instance, 
Tofogliflozin (CSG452) 2.3, a synthetic compound with an O-spiroketal C-arylglucoside core 
combined with another aromatic sp2 appendage, resulted in a highly potent phase III clinical lead 
for type 2 diabetes mellitus[17]. 
2.1.2 Notable strategies for spiroacetals synthesis 
This section will highlight some well-established as well as novel tactics for accessing 
spiroketals. 
2.1.2.1 Acid catalzyed cyclization (Brønsted and Lewis acids) 
 
The most commonly used protocol for spiroketal formation is based on a dehydrative 
approach[18] (Figure 2.2), which requires the preparation of a generic ketone-diol 2.4. In the 
presence of a catalytic acid, 2.4 cyclizes to form pyranol 2.5, followed by the loss of water to 
form the oxocarbenium ion intermediate 2.6, which readily undergoes ring closure to yield 
spiroketal 2.7. The entire process is reversible and the final conformation of the spiroketal is 
driven by thermodynamics.  
 
 12 
 
Figure 2.2 Dehydrative spiroketal strategy 
 
Recently, Yadav and co-workers applied this tactic during the synthesis of the spiroketal portion 
of ossamycin[19] (Scheme 2.1). The highly functionalized intermediate 2.8 underwent a one-pot 
concomitant sily-group deprotection and cyclization in the presence of p-TSA to afford the 6,6-
spiroketal 2.9. 
 
 
Scheme 2.1 Acid-catalyzed spiroketalization to the core of ossamycin 
 
Forsyth and co-workers[20] utilized a double intramolecular hetero-Micheal addition reaction for 
the racemic synthesize of a Dacus oleae olive fly pheromone 2.13 by the clever design of 
dihydroxy ynone 2.10 (Scheme 2.2). Treatment of ketone 2.10 with camphorsulfonic acid (CSA) 
in MeOH resulted in the cleavage of the silyl ether protecting groups followed by a solvent 
switch to benzene for facilitation of the bis-conjugate additions into the alkyne. Spiroketal 2.11 
was subsequently reduced with NaBH4 to give a mixture of alcohols, favoring the axially 
disposed alcohol 2.12. Nevertheless, in the presence of p-TSA-catalyzed equilibration, spiroketal 
2.12 was able to interconvert into the lower energy equatorial alcohol 2.13. This method 
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possesses the added advantage of providing a useful ketone handle for further manipulation 
following post-cyclization. 
 
 
Scheme 2.2 Intramolecular hetero-Micheal addition for spiroketal assembly 
 
Markó and co-workers[21] reported a highly facile tactic of synthesizing spirocycles exploiting an 
intramolecular Hosomi-Sakurai between a bis-silylated reagent with either an acetal 2.14, ketone 
or aldehyde to afford spiroketal 2.16, spirocycle or THP respectively (Figure 2.3). The process is 
catalyzed by TMSOTf and is proposed to involve the oxocarbenium ion intermediate 2.17.   
 
 
Figure 2.3 Intramolecular Sakurai coupling 
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They noted that by addition of another silyl ether 2.15 as an additive, they were able to quench 
any residual TfOH that might be formed by reaction with adventitious water. This was crucial 
because an even trace amount of this acid promoted undesired isomerization into exo isomers 
2.18 and 2.19. This protocol provides a simple yet adept, modular entry into the family of 
spirocycles. 
2.1.2.2 Reagent-controlled spiroketalization 
 
Tan and co-workers were able to utilize epoxide-opening spirocyclization (Scheme 2.3) to access 
a diverse library of spiroketals. Starting from glycal 2.20, a mild in-situ epoxidation with DMDO 
produced intermediate 2.21 which could undergo either a) methanol-assisted kinetic 
spiroketalization[22] to give 2.22 with stereochemical retention at the anomeric center or b) Ti(O-
iPr)4 catalyzed spirocyclization[23] to yield the opposite diastereomer 2.23 with stereochemical 
inversion of the C1 atom. The methanol-controlled epoxide opening transition state 2.24 is 
postulated to be under H-bonding catalysis with one molecule of methanol coordinating to the 
oxygen of the THP ring and directing the trajectory of the OH nucleophile and another molecule 
of methanol activating the epoxide electrophile via H-bonding. The Ti(O-iPr)4 catalyzed process 
is postulated to follow a chelation-controlled early transition state model 2.25, leading to the 
thermodynamic product 2.23. The ability to employ simple and widely available reagent-control 
to supersede any inherent thermodynamic bias in product formation makes this an extremely 
useful method for the rapid construction of stereodiversified spiroketals.   
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Scheme 2.3 Reagent-controlled epoxide-opening spirocyclization 
2.1.2.3 Periphery spiroketal functionalization 
 
Spiroketals with double anomeric effects are usually the most stable products in spirocyclization 
reactions. However, stereoelectronic and steric effects of substituents may also play an important 
role in dictating the final stereochemical outcome of some spiroketals. This is highlighted during 
the total synthesis of (–)-reveromycin A. Rizzacasa and co-workers[24] recognized that the 6,6-
spiroketal core 2.26 cannot be synthesized using conventional acid-mediated methods because 
the desired spiroketal 2.26 has an unfavourable syn-pentane interaction (Scheme 2.4). To relieve 
the steric strain, 2.26 is prone to a ring flip into an alternative axial-equatorial arrangement 2.27 
at the expense of sacrificing one anomeric effect. In addition, if a naked OH moiety is present, 
2.27 also has a propensity to revert to a more thermodynamic 5,6-spiroketal form 2.28. All these 
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combined effects resulted in complex mixtures as previously reported. Rizzacasa and co-workers 
worked around this issue by utilizing a convergent inverse demand HDA reaction between 2.29 
and 2.30 to establish the stereochemistry of spiroketal 2.31 followed by a 
hydroboration/oxidation sequence to finally arrive at the core 2.32 of (–)-reveromycin A.    
 
 
Scheme 2.4 Inverse demand HDA approach to spiroketals 
 
There are also examples of natural products, which possess unique axial-equatorial spiroketals 
subunits, which are inaccessible by direct acid-catalyzed spiroketalization due to the energetic 
penalty of losing anomeric stabilization. During the synthesis of altohyrtin A (Scheme 2.5), 
Crimmins and co-workers[25] deployed a pyrone approach by sequential addition of the lithiated 
pyrone 2.33 to aldehydes, followed by an acid-induced spirocyclization to give 2.34. 
Spiropyranone 2.35 was then hydrogenated on the less hindered face to yield 2.36a, which flips 
to the axial-equatorial spiroketal 2.36b due to unfavorable 1,3-diaxial interactions. By 
identifying and exploiting steric interactions within functionalized spiroketals, Crimmins and co-
workers were able to establish the spiroketal stereochemistry of altohyrtin A. 
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Scheme 2.5 Spiropyranone approach 
2.1.2.4  Metal-catalyzed hydroalkoxylation  
 
The most atom-economical and efficient route to spiroketal is the direct sequential addition of 
oxygen nucleophiles across an unsaturated alkyne 2.37 (Scheme 2.6). However, due to the 
relatively high enthalpy cost of cleaving the O-H sigma bond and the relatively weak 
nucleophilicity of OH groups, hydroalkoxylation requires the facilitation of a metal catalyst for 
overcoming the associated activation barriers. Metal complexes capable of mediating 
intramolecular dihydroalkoxylation include Pt complexes such as Zeise’s dimer[26], Rh[27] and Ir 
complexes[28]. There are many parameters including metal ligands, solvent and substituents’ 
steric that determines whether the addition goes through an exo-dig 2.38 or endo-dig 2.39 
transition state which ultimately leads to the 6,6-spirocycle 2.40 or the 5,7-spirocycle 2.41 
respectively. 
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Scheme 2.6 Metal catalyzed hydroalkoxylation 
 
Recently, gold halides complexes have also proved to be versatile and mild catalysts for 
effecting such transformations. The Aponick group was able to identify that a key spiroketal 
intermediate 2.42 within the spirastrellolide family can be constructed using an Au-catazlyed 
spiroketalization[29] (Scheme 2.7). By masking the 1,3-diol moiety as the acetonide, they were 
able to regulate the sequence and resultant regioselectivity of the spiroketalization event.  
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Scheme 2.7 Stereoconvergent Au-catalyzed spiroketalization 
 
Importantly, regardless of the stereochemistry at the progargylic position, both diastereomers 
2.43 and 2.44 were able to convert to the desired spiroketal 2.42 due to the excellent periplanar 
alignment of the gold complex sigma bond 2.45/2.46 with the OH leaving group. This process is 
facilitated by H-bonding and entropically driven by the extrusion of acetone, exposing the 2nd 
OH group for spiroketalization. 
2.1.2.5 Oxidative radical spiroketalization 
 
Oxidative methods of generating radicals through intramolecular hydrogen abstraction (IHA) are 
well documented[30] and provide a complementary approach for accessing non-anomeric 
stabilized kinetic spiroketals, which are prone to equilibration in the presence of acids (Scheme 
2.8). The reagents of choice for promoting this oxidative cyclization have evolved from 
combinations of Pb(OAc)4/ I2 to HgO/ I2 and more recently to PhI(OAc)2 / I2 due to its higher 
reactivity (stoichiometric equivalents) and lower toxicity. This mechanism involves the 
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generation of alkyl-hypodite species 2.47, which is cleaved in the presence of UV light or heat to 
form an alkoxide radical 2.48. 2.48 then undergoes a 1,6-H shift to give 2.49, which is oxidized 
in the presence of iodine to the oxocarbenium species 2.50. Subsequent intramolecular attack by 
the hydroxyl group onto the oxocarbenium gives spiroketal 2.51. 
 
 
Scheme 2.8 Mechanism of oxidative radical cyclization 
 
During the total synthesis of bistramide C by Wipf and co-workers[31] (Scheme 2.9), they 
assembled the core of the spiroketal 2.53 by subjecting alcohol 2.52 under oxidative radical 
cyclization conditions. A 3.5:1 mixture of 2.53: 2.54 was obtained. Nevertheless, 2.54 could be 
readily converted into 2.53 using tin hydride reduction. Importantly, they noted a significant 
improvement in the cyclization step as compared to the saturated analog of 2.52, indicating that 
the double bond within the THP ring facilitates the formation of a stable oxocarbenium ion/ 
radical species for facile cyclization. 
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Scheme 2.9 Oxidative radical approach to core of bistramide C 
 
Brimble and co-workers[32] also utilized this oxidative protocol in their synthesis of the triad of 
spirocycles found within the shellfish toxins spirolide family (Scheme 2.10). In an exceptional 
showcase of thermodynamic equilibration under substrate control, they were able to carry 
forward diastereomeric mixtures 2.55 and 2.56 through two sequence of oxidative 
spiroketalization and eventually perform a one-pot epoxidation/ chlorobenzoic acid-mediated 
(present in m-CPBA) stereo-convergent transformation of four possible diastereomer into a 
single desired isomer 2.57. 
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Scheme 2.10 Tandem radical cyclization 
2.1.2.6  Telescoped cycloaddition and Carbon–Hydrogen activation (Floreancig approach) 
 
During the DDQ mediated bimolecular coupling study, Dr. Clausen documented the facile 
decomposition of chromenes 2.58 substituted at the 4-position as enol silane or vinyl acetate 
before it can be trapped by an external nucleophile (Scheme 2.11). Similarly, Paterson had 
previously reported the facile oxidative cleavage of electron rich vinyl silyl ether 2.59 in the 
presence of DDQ[33] (Scheme 2.11). 
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Scheme 2.11 DDQ mediated oxidative deprotection 
 
Base on these results, the Floreancig group subjected the intermediate enol silane THP adduct 
2.60 derived from the HDA reaction reaction under the oxidative conditions with DDQ to obtain 
the dehydrogenated enone 2.61 (Scheme 2.12). In the presence of p-TSA, the silyl group 
undergoes cleavage and liberates the tethered alcohol. Subsequently, this alcohol underwent an 
acid catalyzed intramolecular oxa-Micheal cyclization to yield the desired cyclized spiroketal 
2.62. Under optimized conditions, this transformation was carried out in a one-pot manner with 
sequential addition of reagents. Isolation of intermediates was unnecessary, with only one 
column chromatography purification performed towards the end. Two rings and three bonds 
were constructed in a highly stereoselective reaction. This telescoped cycloaddition and C–H 
functionalization protocol was eventually utilized as a key step during the convergent synthesis 
of bistramide A 2.1 (Scheme 2.12). 
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Scheme 2.12 Spiroketal formation: One-pot hetero Diel-Alder addition and C–H functionalization 
 
As discussed earlier, despite the vast repertoire of strategies available for construction of 
spirocycle motif, most of these methods require the pre-installation of highly elaborated 
intermediates in a linear fashion.  
 
Our DDQ-mediated oxidative protocol has proved viable and extremely useful in bimolecular 
annulation reactions for rapid generation of molecular complexity. Besides facilitating 
intermolecular C–C bond formation in chromene substrates (section 1.2.3), the incorporation of a 
C–H functionalization step (mediated by DDQ) in tandem with another fragment-coupling 
reactions (e.g., cycloaddition) also demonstrated the inherent versatility of our oxidative strategy. 
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2.2 TANDEM LEWIS ACID MEDIATED FERRIER COUPLING AND DDQ 
OXIDATIVE SPIROCYCLIZATION  
2.2.1 Design principles 
We have previously shown that the oxidative C–H bond activation of chromene systems occurs 
readily in the presence of DDQ (Figure 2.4). However, we were uncertain whether the THP ring 
2.63 with a single degree of unsaturation was capable of forming an oxocarbenium cation under 
our oxidative conditions. Once generated, a suitable coupling partner 2.64 of sufficient 
nucleophilicity must be present to drive the equilibrium towards 2.65. Upon the addition of a 
second equivalent of DDQ, we postulate that 2.66 will undergo a facile intramolecular 
annulation to yield spiroketal 2.67. 
 
 
Figure 2.4 Design principle of bimolecular oxidative coupling 
 
From the studies of Mr. Villafane (Scheme 1.2), we noticed that a sequential intermolecular 
followed by an intramolecular fragment coupling is feasible, despite only achieving a modest 
yield. Nevertheless, the second spirocyclization gave slightly higher yields than the first 
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intermolecular coupling, potentially due to the higher nucleophilicity of the alcohol moiety to 
thermodynamically trap the reversibly generated oxocarbenium cation and the faster rate of 
intramolecular annulation compared to intermolecular addition. Hence, we decided to utilize a 
type-I Ferrier rearrangement reaction[34] for the initial robust coupling of a glycal 2.68 with the 
protected allyl silane 2.69 (Figure 2.5). The resultant transposition of the double bond from the 
C2–C3 to C3–C4 bond also stabilizes the resultant oxocarbenium cation 2.70 by conjugation, 
which subsequently cyclizes in the presence of a pendent hydroxyl group.    
 
 
Figure 2.5 Tandem Ferrier-oxidative annulation  
2.2.2 Exploration of the reaction protocol 
We screened various promoters such as DDQ[35] and K-10 montmorillonite clay[36] for the initial 
Ferrier coupling reaction and obtained moderate yields of 59% and 70% respectively (Scheme 
2.13). The disadvantages of these protoctols include: 1.) an additional concession step is needed 
to convert the pyranol into the pyranol acetate 2.71 with a better leaving acetate group and 2.) the 
resultant tethered homoallylic alcohol is obtained primarily as the protected silyl form 2.74/2.75, 
which prohibited the subsequent spirocyclization step.  
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Scheme 2.13 Screening of catalysts for Ferrier coupling 
 
Toshima and co-workers[37] reported the use of TMSOTf for the C-glycosidation of unprotected 
glycals with allyl silanes (Scheme 2.14). Upon stirring pyranol 2.77 with allyl silane 2.73 and 
TMSOTf, the desired product 2.78 was obtained with concomitant OTMS deprotection upon 
quenching with aqueous NaHCO3.  
 
 
Scheme 2.14 TMSOTf catalyzed Ferrier Coupling 
 
After further optimization, the catalytic loading of the TMSOTf was reduced to 1-5 mol% 
without significant reduction in yield. The reduced loadings also circumvented the low 
temperature requirement. The proposed cycle for substoichiometric TMSOTf promoted Ferrier 
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coupling is depicted in Figure 2.6. We hypothesized that the combination of the allyl silane used 
in the reaction has a beneficial synergistic effect on the catalytic cycle because the departing 
TMS group from allylic oxocarbenium cation intermediate can combine with the triflate counter-
anion to regenerate the active TMSOTf catalyst. Upon quenching with aqueous NaHCO3, trace 
amounts of TMSHCO3 (carbonic acid derivative) formed after basic hydrolysis yield the 
desilylated alcohol.  
 
 
Figure 2.6 Proposed pathway for regeneration of TMSOTf 
 
Under the new optimized protocol, 2.81 was obtained in 61% moderate yield (Scheme 2.15). 
This catalytic one-pot two-component Ferrier coupling can be conveniently conducted at room 
temperature with no significant deleterious effects on yield. The small amount of TMSOTf can 
be quenched efficiently with saturated NaHCO3 to yield intermediate 2.80. The final oxidative 
spirocyclization mediated by DDQ is performed under neutral conditions and is highly 
compatible with adjacent functional groups.  
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Scheme 2.15 Optimized Ferrier tandem oxidative cyclization 
2.2.3 Design and synthesis of dihydropyrans 
The dihydropyranols were accessed by a hetero HDA reaction between Danishefsky’s diene[38] 
and the appropriate aldehyde (scheme 2.16), followed by an approcriate organometallic addition 
into the respective dihydropyranones (Schemes 2.17). Asymmetric versions of dihydropyrans 
such as pyranone 2.82b were analogously prepared using Jacobsen’s Cr(III)-salen complex[39] 
instead of BF3•Et2O in the HDA reaction. Pyranol 2.84 with a planar sp2 benzyloxymethyl 
appendage is an attractive candidate for diversity-orientated synthesis (DOS) when coupled 
together with the sp3-rich fragments of spiroketals. This is significant because current DOS 
libraries have been mostly limited to planar sp2-heteroaromatic fragments[40]. Dihydropyranol 
2.85 with a benzyloxy substituent at the 6-position was prepared to demonstrate the compatibility 
of our DDQ-mediated protocol with common functional groups. Similar to pyranol 2.77, pyranol 
2.86 with a phenyl substituent at the 4-position will have a higher oxidative potential to form the 
allylic oxocarbenium cation due to the increased conjugation stability. This could potentially 
enhance the rate of spirocyclization. Dihydrothiapyranol 2.88 was prepared in a four-step 
sequence from cinnamaldehyde 2.87 via a double thia-Micheal reaction[41] (Scheme 2.18).  
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Scheme 2.16 Synthesis of pyranones 
 
Scheme 2.17 Synthesize of dihydropyranols 
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Scheme 2.18 Synthesize of dihydrothiapyranol 
2.2.4 Design and synthesis of nucleophiles 
The highly modular nature of our fragment coupling approach allows for easy diversification of 
the spiroketal portion by simply varying of the allyl silane fragment (scheme 2.19). Allyl silanes 
were selected as the nucleophilic partner based on their benign chemical toxicity relative to allyl 
stannanes and also its facilitation in the regeneration of TMSOTf. Allyl silanes 2.73 and 2.89 
were prepared through a metallated dianion intermediate following Carlson’s procedure[42]. The 
seven-membered allyl silane 2.90 was prepared from the corresponding lactone by a CeCl3 
mediated addition of TMSCH2MgCl (Bunnell[43] protocol) into the lactone followed by silylation 
of the terminal alcohol. Allyl silane 2.91 was derived from a commercial chiral ester by initial 
silylation of the terminal alcohol followed by the Bunnelle-Peterson process. Similarly, allyl 
silane 2.92 was derived from L-malic acid by first capping the terminal acidic ends followed by a 
regioselective reduction of the methyl ester at the 1-position, silylation of the diols and finally 
conversion of the terminal ethyl ester into allyl silane. Allyl silane 2.93 containing a sterically 
challenging alcohol was prepared by an initial aldol reaction between ethyl acetate and acetone, 
followed by capping of the tertiary alcohol with TESOTf and finally conversion into the allyl 
silane.  
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Scheme 2.19 Preparation of allyl silanes (I) 
 
Allyl silane 2.94 (Scheme 2.20) was synthesized from ethyl chloroformate by initial insertion of 
lithiated propyne, followed by nucleophilic acyl substitution with the enolate of ethyl acetate.  
The resulting β-keto ester was reduced by Noyori’s asymmetric transfer hydrogenation[44] into 
the alcohol, which was subsequently silylated and converted to the desired allyl silane. Silyl 
ether 2.95 was prepared by a methylacetoacetate dianion alkylation with benzyl bromide. The 
resulting β-keto ester was subjected to asymmetric CBS reduction[45] to yield the alcohol in 74% 
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ee, which was subsequently converted to the allyl silane. Enol silane 2.96 was prepared from 4-
hydroxylbutanone in one step by kinetic deprotonation of the α-hydrogen and terminal alcohol 
altogether in one step followed by quenching with TMSCl. 
 
 
Scheme 2.20 Preparation of allyl silane (II) 
2.2.5 Scope of one-pot two component spirocyclization 
The scope of the one-pot TMSOTf mediated fragment coupling followed by DDQ-promoted 
oxidative cyclization is shown in Scheme 2.21.  For the [5.6] spiroketal 2.97, the 5-exo-trig 
cyclization of the tethered alcohol onto the allylic oxocarbenium cation was extremely facile at 
room temperature and eventually lead to undesired decomposition pathways. To overcome this, 
the reaction was performed at 0 °C with portion-wise addition of the oxidant. This exceedingly 
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facile ring closure in comparison to the 6-membered spiroketals can be attributed to the lower 
entropic penalty encountered in the transition state for ring closure due to its lower degrees of 
freedom[46].  
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Scheme 2.21 Substrate scope of DDQ-mediated spiroannulation 
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The fragment coupling protocol is compatible with various substitution patterns in the allyl 
silane partner as demonstrated by the formation of spiroketal 2.98 with a methyl branch at the 
allylic position, spiroketal 2.99 with a tertiary ether and spiroketal 2.102 with a functionalized 
ether. Particularly, for 2.99 the sterically hindered tertiary alcohol nucleophile does not seem to 
encounter much difficulty inserting into the allylic oxocarbenium cation. This example seems to 
indicate that the electronics of the tethered nucleophile may play a more dominant role over its 
inherent steric hindrance during the oxidative cyclization event. The mild and neutral conditions 
of the DDQ-mediated cyclization also allowed for the smooth spiroketalization to 2.102. Over-
oxidation of the terminal alcohol was not observed. This example also revealed that in the 
presence of two competing alcohol tethers, formation of the [6.6] spiroketal is favored over the 
[7.6] spiroketal.  
 
Spiroketals 2.100, 2.101, 2.102 and 2.104 resulting from the corresponding tethered secondary 
alcohols, cyclized smoothly during the oxidative spiro-annulation process. The coupling of 
enaniomerically pure pyranol 2.82 with allyl silane 2.95 (74% ee) gave 2.100 as a 6:1 mixture of 
diastereomers. In comparison, 2.101 without the 4-methyl stabilizing group, was obtained in 
41% yield. Spiroketals 2.103, 2.104 and 2.105 with a flexible sp2-benzoxylmethyl (BOM) group 
at the 4-position of the dihydropyran are attractive candidates for DOS when coupled together 
with the sp3 richness of the spiroketals. Spiroketal 2.104 containing an alkynyl functional group 
was obtained in 41% yield due to the reduced nucleophilicity of the intermediate propargylic 
alcohol and competing oxidation of the alkynyl alcohol by DDQ. Generally, the BOM-
containing spiroketals are isolated in slightly diminished yields as compared to the spiroketals 
with the 4-methyl substituent. This is probably due to the electronic destabilization of the 
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oxocarbenium intermediate conferred by the electron-withdrawing inductive effect of the BOM 
group.  
 
In contrast for spiroketal 2.106, the substitution of a conjugating phenyl group at the 4-position 
of the dihydropyran ring facilitates the generation of a longer-lived oxocarbenium cation, which 
is able to trap the longer-tethered alcohol leading to the formation of the [7.6] spiroketal. Enol 
silane 2.96 is also a competent nucleophile leading to the ketone-containing spiroketal 2.107. 
Despite having an inductively destabilizing ketone intermediate, the mesomeric resonance of the 
4-phenyl substituent seem to override that apparent deficiency resulting in productive spiro-
annulation to give the desired spiroketal in 66% yield.  For spiroketal 2.108, the placement of the 
BOM group at the 6-position of the dihydropyran seemed to have negligible detrimental 
consequence on the efficiency of the spirocyclization and the desired product was isolated in 
65% yield. Thia/oxa-spirocycle 2.109 was also accessible from our oxidative annulation 
protocol. Due to the lower electronegativity of the sulfur atom, it is more susceptible to oxidation 
as compared to its oxygen counterparts. Spiro-annulation was completed within 15 min with only 
one equivalent of the oxidant, yielding 63% of the thiaspiroketal.  
2.2.6 Post cyclization modifications 
The deprotection of the Bn group in spiroketal 2.103 (scheme 2.22) was not trivial because both 
the endocyclic and exocyclic alkenes were vulnerable under hydrogenolysis conditions. 
Similarly, Lewis acid protocols employed only led to the decomposition of the spiroketal due to 
competitive coordination of the Lewis acids onto the oxygen atoms of the spiroketal instead of 
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activating the benzyl ether for cleavage. Gratifyingly, under the reductive conditions with 
LiDBB[47], regioselective debenzylation was accomplished within 20 min at –78 °C. 
 
 
Scheme 2.22 Debenzylating conditions for spiroketals 
 
Spiroketal 2.104 with an alkynyl moiety was well suited for post cyclization manipulation. 
However, an attempted one-pot hydrozirconation of the internal alkyne with Schwartz’s reagent 
followed by sequential quenching with iodine did not afford the desired trans-vinyl iodide 2.111 
(Scheme 2.23). The absence of chemical reactivity was probably due to the presence of the 
neighboring electron deficient THP ring deactivating the alkyne. The alkynyl bond is unable to 
effectively σ-donate into the electrophilic Zr center and form the active vinyl zirconium 
intermediate. 
 
 
Scheme 2.23 Attempted hydrozirconation on spiroketal 2.104 
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As a result, an alternative two-step palladium-catalyzed cis-hydrostannylation protocol followed 
by a tin-iodide exchange was employed (Scheme 2.24). The hydrostannylation reaction catalyzed 
by PdCl2(PPh3)2 afforded a 1:1 isomeric mixture of distal alkene 2.112 and proximal alkene 
2.113, which was easily separable by column chromatography. The palladium catalyst was 
subsequently switched to a mixture of Pd(OAc)2 and PCy3 in hope that the bulkier phosphine 
ligated catalyst would have better differentiation between the terminal methyl group and the 
internal THP ring. However, the same ratio was obtained with this new catalyst albeit with a 
higher yield, lower loadings of Pd and a lower temperature. The stannyl exchange with tin was 
completed within 30 min using NIS at 0 °C. The resultant trans-vinyl iodide spiroketal was 
deployed in an alkyl-Suzuki cross coupling[48] with an in-situ generated alkyl boronate to yield 
the trisubstituted-alkene 2.114.  
 
 
Scheme 2.24 Post cyclization modifications of alkynyl-containing spiroketals (I) 
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Interestingly, when spiroketal 2.104 was subjected to hydrostannylation conditions using a 
ruthenium catalyst, a mixture of proximal and distal-cis vinyl stannyl spiroketals was obtained 
(Scheme 2.25). Due to scale issues, only proximal-trans vinyl stannyl 2.115 was isolated and 
characterized successfully. Nevertheless, this demonstrated that the masked alkynal moiety 
within the spiroketals could be potentially transformed into at least three isomers of tri-
substituted alkenes depending on the initial metal catalyst used for hydrostannylation and 
following through the sequence in Scheme 2.24.  
 
 
Scheme 2.25 Post cyclization modifications of alkynyl-containing spiroketals (II) 
 
2.2.7 Stereoelectronic analysis of Ferrier-coupling and DDQ mediated C-H activation 
2.2.7.1  5’-subsituted pyranol  
 
During the screening of the substrate scope for the tandem Ferrier coupling and oxidative 
cyclization, dihydropyranol 2.116 with a 5’–substituent tended to be sluggish, requiring more 
than five equivalents of DDQ and a longer reaction time to reach completion.  To investigate the 
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rationale behind this phenomenon, intermediate Ferrier product 2.117 was synthesized 
independently (Scheme 2.26).  
 
 
Scheme 2.26 Stereochemical analysis of Ferrier reaction 
 
Remarkably, in the presence of 2 mol% of TMSOTf at room temperature, the 2,5-anti Ferrier 
adduct was obtained as a diastereomeric mixture with >20:1 α/β selectivity.  
 
 
Figure 2.7 NMR determination of stereochemistry for 2.117 
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Figure 2.8 Negative control for nOe correlation 
 
The 2, 5-anti stereochemistry between the incoming nucleophile and the 5-substituent has been 
established by 2D NOESY between Ha and Hd. Coupling constants for Ha/Hb with Hc also 
indicates that the benzyl substituent flips into an axial orientation in order to minimize A1,2 
strain[49] with the adjacent methyl substituent at the 4-position (Figure 2.7). The high 
stereochemical fidelity of the Ferrier reaction indicated that the mechanism probably goes 
through an SN1 state. The incoming nucleophile attacks on the opposite face to the benzyl 
substituent, undergoing a lower energy chair-like transition state instead of the top face that 
would result in an unfavorable twist-boat transition state (Scheme 2.26).   
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Figure 2.9 Postive and negative nOe correlation for Ferrier intermediate 2.117 
 
The thermodynamic preferred conformer of the Ferrier product 2.118a (Figure 2.10) places the 
allylic hydrogen in a pseudo-equatorial position to minimize A1,2 strain of the benzyl substituent 
with the methyl substituent. However, the orbitals between the allylic hydrogen and the adjacent 
alkene are not in the correct spatial orientation for the oxidative cleavage event to occur. Instead, 
2.118a must undergo a ring inversion into the higher energy conformer 2.118b. Subsequent 
allylic hydrogen atom abstraction by DDQ generates a single electron occupied π-orbital, which 
can overlap favorably with the adjacent oxygen radical cation to form the oxocarbenium 
intermediate 2.119a. We hypothesize that C–H bond cleavage is the rate-determining step, which 
is followed up by a rapid equilibration to the more thermodynamically favorable intermediate 
2.119b and facile trapping of the tethered alcohol to yield 2.120.   
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Figure 2.10 Stereochemical outcome of DDQ mediated spirocyclization 
 
Similarly, the stereochemical orientation of 2.120 has been verified by coupling constants and 
NOESY spectroscopy (Figure 2.11). Both Hd and He have ca 3.7–4.0 Hz 3JH-H coupling with 
Ha, indicating that Ha is in the equatorial position. In addition, no large coupling was observed 
for Ha and He. The nOe correlation observed for Hf and Hg confirms the 2,5-anti stereochemistry 
between the benzyl group and the trajectory of the incoming tethered alcohol, corroborating with 
transition state 2.119b. 
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Figure 2.11 Stereochemical determination of 2.120 
 
Figure 2.12 Positive nOe correlation between Hf and Hg 
 
 
Figure 2.13 Negative nOe correlation control for alternative isomer 
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Figure 2.14 Negative control for nOe establishment 
2.2.7.2  5’ and 6’-disubstituted pyranol systems 
 
To understand how substituent effects within the elaborated dihydropyranols could affect the 
stereochemical outcome of the tandem Ferrier-DDQ fragment coupling reaction, dihydropyranol 
2.121 with a 5’-OBn and 6’-CH3 substituents was prepared from L-rhamnal (Scheme 2.27). The 
Ferrier coupling reaction was conducted using stoichiometric amount of TMSOTf at a lower 
temperature of –78 °C in hope of achieving higher diastereoselectivity.  This also served as a 
control because a subsequent experiment performed using OTBS instead of OBn might be 
deprotected even under catalytic loadings of TMSOTf at an ambient temperature.  
 
Under these reaction conditions (scheme 2.27), the α/β ratio was 5.9:1. After confirmation via 
NMR spectroscopy, the major diastereomer was determined to be dihydropyran 2.122 with the 
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2,6-substituents in an anti relationship. The minor diastereomer was determined to be 
dihydropyran 2.123 with the 2,6-syn configuration. Surprisingly, 2.122 has the 5’ and 6’ 
substituents orientated in the axial arrangement whereas in 2.123, they occupy the equatorial 
position.   
 
 
Scheme 2.27 Ferrier coupling of 2.121 
 
 
Figure 2.15 Stereochemical determination of Ferrier products: 2.122 and 2.123 
 
Analysis of the oxocarbenium ion intermediates (Figure 2.16) formed upon ionization with 
TMSOTf indicates that the more stable conformer 2.124b results in the formation of the minor 
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diastereomer 2.123 whereas the less stable conformer 2.124a leads to the formation of the major 
diastereomer 2.122. Conformers 2.124a and 2.124b are postulated to be in rapid equilibrium. 
Although 2.124b is the more stable oxocarbenium intermediate, interaction of the methyl group 
and the incoming allyl silane in the transition state results in unfavorable 1,3-syn pentane 
interactions, which substantially increased the barrier of activation in transition state 2.126. 
Formation of the 2,6-diaxial Ferrier product is followed by a rapid ring inversion into the minor 
diastereomer 2.123 with both methyl and the tethered alcohol in the equatorial position.  
 
Analogously, for DHP 2.122, although the oxocarbenium intermediate 2.124a leading to it is of 
higher energy due to A1,2 strain, the absence of a 1,3-syn pentane interaction between methyl and 
the incoming nucleophile renders transition state 2.125 as a comparatively lower activation 
energy barrier. Nevertheless, upon coupling the presence of the inherent A1,2 strain present is 
sufficient to trigger a ring flip into the more thermodynamically preferred configuration 2.122. 
 
 
Figure 2.16 Curtin-Hamett analysis of Ferrier coupling 
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Unlike DHP 2.118a (Figure 2.10) that must perform an unfavorable ring flip into DHP 2.118b 
for the oxidative C–H bond cleavage, diastereomers 2.122 and 2.123 have the H atom arranged 
in the optimum axial orientation for facile C–H bond cleavage and formation of the 
oxocarbenium cation. Independent treatment of the diastereomers under oxidative cyclization 
resulted in a reduced reaction time (1h) and lower loadings of DDQ (2.0 equiv) used.  The 
cyclized spiroketal products were obtained with comparable yields (69-72%) for both 
diastereomers. Spiroketals 2.127 and 2.128 were also consistently obtained with ca. dr of 10:3.  
 
 
Scheme 2.28 Stereoconvergent oxidative cyclization 
 
The structures of the spiroketals were elucidated by 2D nOe, COSY and coupling constants 
measurements (Figure 2.17). 
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Figure 2.17 Stereochemical determination of spiroketals 2.127 and 2.128 
 
The consistent dr value obtained for the DDQ-mediated oxidative cyclization regardless of the 
diastereomer used indicates that each diastereomer goes through the common allylic 
oxocarbenium cation intermediate 2.129 (Figure 2.18). However, due to the inherent A1,2 strain 
between the 4-phenyl and 5-OBn substituent, 2.129 equilibriates between 2.129a and 2.129b.   
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Figure 2.18 Stereochemical analysis of oxidative C–H cyclization 
 
According to the Curtin-Hammett principle, although 2.129b is the more favorable conformer, 
the transition state 2.131 leading to spiroketal 2.128 suffers from severe 1,3-syn pentane 
interaction between the methyl group and the tethered alcohol (Figure 2.18). The tethered 
alcohol can only approach from the bottom face to avoid an even higher energy twist-boat 
transition state.  In contrast, although 2.129a is the higher energy allylic oxocarbenium cation, 
the transition state 2.130 leading to 2.127 is of lower energy due to the tethered alcohol 
approaching in an anti-fashion with respect to the 6-methyl substituent through a chair-like 
transition state and avoiding any potential 1,3-syn pentane strain. In contrast to the Ferrier 
reaction where the kinetic products could undergo ring inversion to yield the more 
thermodynamic stable configuration, the spiroketals 2.127 and 2.128 trapped by oxidative 
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cyclization are stabilized by double anomeric effects and do not isomerize under the neutral 
environment of the DDQ system. 
 
 
Scheme 2.29 Ferrier coupling with bulkier substituent 
 
Substrate 2.132 was designed with a bulky OTBS group substituting the place of the OBn group 
in pyranol 2.121 (Scheme 2.29). The hypothesis was that A1,2 strain between the 4’-phenyl group 
and the 5’-OTBS would be greatly enhanced and possibly exceed the rate determining 1,3-syn 
pentane strain, hence potentially inverting the diastereomeric ratio of the resultant Ferrier 
products and the spiroketals. Subjecting 2.132 to TMSOTf at –78 °C, resulted in the formation of 
diastereomers 2.133 and 2.134 in 61% yield with α/β selectivity of 2.4:1.   
 
The mixture of products obtained indicated that OTBS did not manage to lock the intermediate 
allylic oxocarbenium in a preferred all axial conformation cf. 2.124b (cf. Figure 2.16) as 
intended. Instead equilibration with the higher energy conformer cf. 2.124a was still occurring. 
Spectroscopic identification of 2.133 in the conformation shown in Figure 2.19 reveals that 
avoidance of 1,3-syn pentane strain was still the dominant determinant in ∆G‡ activation for 
transition states. 
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Figure 2.19 Stereochemical determination of OTBS Ferrier products 
 
Interestingly, subjecting THP 2.134 under the DDQ-mediated oxidative conditions, resulted in 
>5% of spiroketal formation. We postulated that the steric bulk of the OTBS group was 
impeding the approach of DDQ for H atom abstraction. Contrastingly, for the trans-Ferrier 
product 2.133, as DDQ abstracts the H atom from the opposite face as the axial OTBS 
substituent, the cyclization proceeded as predicted albeit with diminished yield of 55%. The dr 
value of spiroketals obtained for the oxidative cyclization step was 4.6:1 (2.135 : 2.136). 
Stereochemical outcome of the spiroketalization can be rationalized in a similar manner as 
described for the OBn substituent in Figure 2.18. The comparable dr value obtained as the OBn 
substituent (10:3) indicates that both substrates go through similar transition states without much 
perturbation to the ∆G‡ values. Based on these independent ring closure studies of 2.133 and 
2.134, a crude mixture of both diastereomers after the Ferrier reaction was subjected to oxidative 
DDQ chemistry in one-pot. This resulted in kinetic resolution of the diastereomers as THP 2.133 
underwent spiroketalization at a much faster rate relative to THP 2.134. 
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Figure 2.20 Stereochemical determination of spiroketals 2.135 and 2.136 
2.2.8 Summary 
A highly convergent synthetic protocol to functionalized spiroketals has been developed.  Our 
method utilizes a catalytic Lewis acid initiated Ferrier transposition reaction for the fragment 
coupling of dihydropyranols with allyl/enol silanes. This is followed by a DDQ-mediated 
oxidative spiroketalization.  Studies on the relative geometry of the allylic hydrogen also indicate 
that C–H bond σ* orbital must be in the correct syn-alignment with the oxygen radical cation and 
the adjacent alkene for constructive orbital overlap. Otherwise, there will be no effective C–H 
bond cleavage as the initial electron on DDQ can be reversibly transferred[50] back to the oxygen 
on the glycal substrate. 
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Generally, the ring closure reaction for simpler substrates is stereoconvergent because the 
diastereoselectivity of the initial Ferrier reaction is inconsequential. Both diastereomers are 
oxidized to the same allylic oxocarbenium cation intermediate, which subsequently undergo a 
spirocyclization to yield the thermodynamically favorable spiroketals. However for more 
complex substrates, stereoelectronic properties of the Ferrier substrate, for example the 
installation of a bulky OTBS substituent at the 5’-position of the glycal ring, may impede the 
spatial approach of the DDQ oxidant, hence resulting in sluggish or null activity.  
2.3 TELESCOPED HECK AND OXIDATIVE COUPLING 
2.3.1 Design principles 
The Floreancig group and others[33, 51] have demonstrated that DDQ is a mild one-electron 
oxidant for the dehydrogenation of silyoxy dihydropyrans into dihydropyranones (Section 1.2). 
The potential of merging a transition metal-mediated cross coupling of an unsaturated glycal 
with an aryl electrophile followed by DDQ-mediated dehydrogenation and subsequent 
intramolecular oxa-Micheal addition would provide an attractive streamlined entry into the 
family of spiroketals containing an aryl sp2-scaffold (Figure 2.21). 
 56 
 
Figure 2.21 Telescoped transition metal cross-coupling with oxidative coupling 
2.3.2 Reaction optimization 
In the original report by Ye and co-workers[51], boronic acids (X= B(OH)2) (Figure 2.21) were 
used as the coupling partner in an oxidative Heck type C-glycosidation with silyl-protected 
glycals. While boronic acids are attractive candidates due to its numerous advantageous qualities, 
the preparation of boronic acids usually involves an aryl halide[52] as the starting basis and this 
additional transformation step is a concession step. The use of strong acid for some boronic acid 
preparations might also be incompatible with the tethered silyl alcohol. In addition, Ye’s 
chemistry uses dioxygen as the terminal oxidant for the regeneration of the palladium catalyst. 
Seemingly benign, dioxygen is actually highly flammable and volatile. This might pose potential 
explosive risk during scale up operations and degrade the user-friendliness of the protocol. To 
this end, we have decided to focus on aryl iodides as the donar coupling partner. Silyl-protected 
2.137 was selected as the unsaturated glycal for model studies due to its ease of accessibility 
from D-glycal.  
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The model reaction of 2.137 with 2.138 under Ye’s conditions gave only 20% of the Heck 
product (Table 2). Switching the base from K2CO3 to Ag2CO3 significantly increased the yield to 
68%. This marked increased in yield was attributed to the silver salt dual functions as both a base 
for sequestering the HI produced at the end of the Heck catalytic cycle and also facilitating the 
oxidative insertion of Pd(0) into the aryl iodide bond by precipitation of AgI salts  Interestingly, 
the omission of Cu(OAc)2 as additive resulted in a detrimental effect on yield with only 20-28% 
of the aryl 2-deoxy-C-glycoside 2.139 isolated. 
 
Table 2 Optimization of glycal Heck coupling 
 
Entry Base Additive Yield (%) 
1. K2CO3 Cu(OAc)2 20% 
2. Ag2CO3 Cu(OAc)2 68% 
3. Ag2CO3 none 20-28% 
 
Upon isolation of enol ether 2.139, the oxidative dehydrogenation to enone 2.140 occurred 
smoothly in the presence of DDQ at an ambient temperature to give 88% of the desired product 
(Scheme 2.30). Stirring with a stoichiometric amount of p-TSA resulted in concomitant 
desilylation of the tethered alcohol followed by an intramolecular oxa-Micheal to yield 94% of 
the desired spiroketal. Care was taken to ensure the reaction was quenched immediately with 
Et3N and purified by column chromatography upon completion on TLC (~45 min). Excessive 
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amounts of p-TSA used or prolonged stirring time usually resulted in decomposition of the 
spiroketal 2.141 accompanied by cleavage of the OTBS appendages. 
 
 
Scheme 2.30 Optimized DDQ mediated dehydrogenation and acid catalyzed oxa-Micheal 
 
Upon optimization of the individual steps for Heck coupling, dehydrogenation, and tandem 
desilylation with ring closure, a one-pot cyclization was attempted. Surprisingly, the DDQ-
dehydrogenation reaction appeared to be extremely sluggish with less than 20% of pyranone 
2.140 as estimated by TLC analysis even after 1.5 h. To this end, the reaction solvent was 
switched to 1,2-dichloroethane (DCE) due to its higher boiling point (84 °C) for the initial Heck 
coupling and also its comparable activity to dichloromethane for the subsequent dehydrogenation 
reaction. Using DCE as the optimum solvent, a net 55% yield was obtained for the one-pot 
telescoped Heck followed by DDQ-mediated cyclization reaction. Further optimization reveals 
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that a quick silica gel filtration after the initial Heck coupling actually improves the overall yield 
by (~5-7%). The extra filtration step is hypothesized to facilitate the reaction by the removal of 
extraneous amounts of Pd, Ag and Cu salts that might inhibit the efficacy of DDQ during the 
dehydrogenation step.  
2.3.3 Design and preparation of silylated glycals 
Tri-O-silylated-D-glycal 2.137 and di-O-silylated-L-rhamnal 2.142 were prepared from the 
corresponding commercially available sugars via a two-step deacetylation and silylation 
sequence. Enol ether 2.144 was prepared through an initial HDA reaction between 1,3-
pentadiene 2.143 and nonaldehyde catalyzed by Me2AlCl to give the 5’-6’-syn silyl enol ether 
containing a DHP ring. This intermediate was dehydrogenated to the pyranone, reduced via a 
Luche reduction[53] to the pyranol and finally silylated to yield 2.144 (Scheme 2.31).  
 
 
 60 
 
Scheme 2.31 Preparation of Heck glycal acceptors 
2.3.4 Design and preparation of Heck aryl iodide partner  
Silylated primary alcohols 2.145 and 2.138 were prepared from the corresponding 2-iodobenzoic 
acid and 2-iodophenylacetic acid via a two-step sequence of BH3•SMe2-mediated acid reduction 
to the corresponding alcohol followed by silyl protection. TES ether 2.147 was prepared by an 
initial DIBAL-H reduction of methyl 2-iodobenzoate 2.146 into the aldehyde followed by an 
asymmetric allylation utilizing the chiral boron reagent, (+)-(Ipc)2allylborane
[54]. The resultant 
allyl alcohol was reduced to the alkane using Wilkinson’s catalyst and subsequently protected as 
the silyl ether (Scheme 2.32). 
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Scheme 2.32 Preparation of Heck donar partner with tethered alcohol 
 
The size of the second ring forming within the spiroketal can be easily controlled by tapering or 
lengthening the tail (n = 0, 1) of the tethered alcohol. The triethylsilyl (TES) protecting group 
was chosen so that it can be selectively deprotected at a faster rate by p-TSA relative to other 
TBS functionalities. TES ether 2.147 was hypothesized to enhance the rate of the oxa-Micheal 
ring closure due to its nucleophilicity conferred by the adjacent aliphatic alkane chain. 
2.3.5 Substrate scope of telescoped Heck coupling with oxidative cyclization 
Replacing the CH2OTBS group at the 6’-position of the glycal with a methyl substituent did not 
seem to affect the net yield of the reaction (table 3, entry 1). The utilization of secondary silyl 
ether 2.147 gave slightly improved yield of the cyclized product 2.150 over the primary alcohol-
containing iodoarenes (table 3, entry 3). Significantly, the ability to apply secondary alcohols as 
nucleophiles greatly expanded the plethora of complex spiroketals accessible through this 
methodology.  
 
 62 
Spiroketal 2.151 possessing a [6.5]-spiroketal ring system is particularly attractive due to its 
close resemblance to type II diabetes lead compound, Tofogliflozin (CSG452) 2.3. However, 
shortening the aliphatic alcohol tether seemed to have a detrimental effect on the yield (32%) of 
the spiroketal (table 3, entry 4). Analysis of the individual steps revealed that the initial Heck 
coupling did not proceed to completion. We hypothesize that the initial oxidative insertion of the 
Pd (0) catalyst into iodoarene bond encountered increased steric hindrance from the neighboring 
silyl-protected alcohol, hence attributing to the low coupling yield. In addition, the combined 
deleterious effects of the metals salts and the starting materials might have further inhibited the 
oxidative cyclization step. In an attempt to improve the overall yield, the Heck intermediate was 
purified by column chromatography before subjecting to oxidative cyclization. The best run gave 
a yield of 63% for the Heck coupling with the subsequent dehydrogenation and acid catalyzed 
ring closure giving a yield of 74%. The net yield was improved to 47%.  
 
Notably, benzylic oxidation was not in direct competition with oxidative cyclization. We 
postulate that acid-mediated oxa-Micheal ring closure was faster than benzylic oxidation[55] 
under our experimental conditions. 
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Table 3 Further examples of tandem Heck oxa-Micheal fragment coupling 
 
a Please see the Supporting Information for details regarding substrate synthesis, reaction conditions, and product 
characterization. b Yields refer to isolated, purified materials of the one-pot protocol. Parenthetical yields refer to 
reactions that were filtered following the Heck reaction. c 40% based on recovered starting material. Parenthetical 
yield refers to a protocol in which the product from the Heck reaction was purified by flash chromatography. 
 
The conformation of spiroketal 2.149 (table 3, entry 2) is interesting because it has placed the 5’-
methyl substituent in the axial position with the 6’-alkyl aliphatic chain in equatorial orientation 
so as to minimize unfavorable 2,6-syn-pentane strain brought about by enhanced A-values of 
substituents occupying the 2’ and 6’ position of the THP ring. Concurrently, axial placement of 
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the 5’-methyl substituent also alleviates any 1,2-allylic strain with the adjacent 2’-carbonyl 
group. 
 
 
Figure 2.22 Stereochemical assignment for 2.149 
2.3.6 Post cyclization modifications 
Closer inspection of Tofogliflozin (CSG452) 2.3 reveals a triad of alternating stereogenic 
hydroxyl groups on the 3’, 4’ and 5’-backbone of the glycal fragment. We hypothesized that the 
hydroxyl group at the 3’-carbon, α to the carbonyl group can be easily introduced with a 
Rubottom oxidation. Provided that the newly generated hydroxyl group is in a 1,3-syn 
relationship with the 5’-OH group, the anti-hydroxyl group on the 4’-position can be readily 
installed through a stereoselective reduction.  
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Scheme 2.33 Rubottom oxidation of 2.166 
 
However, conformation analysis of 2.151 indicates that it exists in the configuration where the 5’ 
and 6’-substituents are equatorial orientated to minimize 1,3-diaxial interactions with the axial 
C–O bond at the 2’ position. Kinetic deprotonation of 2.151 with LiHMDS followed by trapping 
with TESCl generates enol silane of 2.152. Projection of 2.152 in the half-chair form (Figure 
2.23) dictates that subsequent m-CPBA epoxidation can only proceed from the bottom face to 
prevent clashing with the axially orientated C–O bond on the top face. Upon work up, 2.153 was 
obtained as a single diastereomer in 67% overall yield over two steps. Although the 3’-hydroxyl 
stereogenic center formed in 2.153 is in the opposite configuration as that in Tofogliflozin 2.3, 
the protocol presented provides a useful entry into possible analogs.    
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Figure 2.23 Substrate controlled stereoselective epoxidation 
 
 
Figure 2.24 Stereochemical determination of Rubottom oxidation 
 
The stereochemistry of the α-hydroxylated spiroketal 2.153 has been verified by 2D NMR and 
coupling constants analysis. In an unoptimized reaction, 2.153 was also reduced to 3’,4’-OH 
spiroketal 2.154 for further confirmation of its structural features  (Figure 2.24). 
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2.3.7 Stereoelectronic analysis of telescoped Heck-coupling cyclization 
2.3.7.1 Heck Coupling 
 
In order to establish a better understanding of the telescoped Heck coupling tandem oxo-Micheal 
reaction, the key intermediates were characterized and analyzed. The tri-O-silylated-glycal 2.137 
was chosen as the model substrate because Ye[51] and others[56] have shown that installation of a 
substituent such as a bulky TBS group at the 5’ and 6’-position of the glycal ring helps to lock it 
in a fixed configuration, preventing conformation flexibility (Figure 2.25). In addition, the OTBS 
group at the 4’-position is a poor leaving group in contrast to OAc. Synergistically, these factors 
facilitate in the syn β-H elimination of the Pd-σ-adduct as palladium hydride and prevent other 
undesirable decomposition pathways. 
 
In Figure 2.25, the palladium intermediate formed after oxidative addition undergoes π-
complexation with the double bond on the glycal on the opposite face of the 4’-allylic OTBS 
group. Subsequent migratory insertion gives Pd-σ-adduct 2.155, which can only partake in 
synclinal β-H elimination. 
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Figure 2.25 Stereochemical analysis of glycal-Heck coupling 
 
The 2,6–trans stereochemical outcome of the Heck product 2.156 formed between glycal 2.137 
and iodoarene 2.146 has been verified (Figure 2.26) by NMR spectroscopy.  
 
 
Figure 2.26 Stereochemical analysis of Heck intermediate 2.156 
 69 
2.3.7.2  DDQ mediated dehydrogenation 
 
The DDQ-mediated dehydrogenation (Figure 2.27) is postulated to involve an initial single 
electron abstraction of the electron rich TBS silyl enol ether to the allylic radical cation 2.157. 
The 2’-H atom on the glycal ring being in the axial orientation is well poised for a hydrogen 
atom abstraction by DDQ radical to yield the oxocarbenium ion 2.158. This is followed by 
isomerization into cation 2.159, which loses TBS cation to yield 5’, 6’-diaxial enone 2.160a. 
Subsequently, 2.160a undergoes ring inversion to yield the all-equatorial thermodynamic product 
2.160b. 
 
 
Figure 2.27 DDQ mediated dehydrogenation of glycal 
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Figure 2.28 Stereochemical correlation for 2.160b 
2.3.7.3  p-TSA catalyzed spiroketalization 
 
The p-TSA used in the reaction serves a dual role in facile deprotection of the TES group as well 
as rapid ionization of the carbonyl functionality within the unsaturated glycals into the allylic 
cation resonance forms (Figure 2.29). Similar to the Ferrier oxidative cyclization analysis, 
although 2.161a is the more stabilized intermediate due to the minimization of A1,2  strain, the 
eventual built up of 1,3-diaxial strain in transition state 2.162 resulted in a larger activation 
barrier to overcome relative to 2.163. Hence, 2.141 was formed as the major diastereomer. 
However, the absence of any minor diastereomer 2.164 indicates that transition state 2.162 must 
be highly unfavorable. This is coupled with the possibility that the 4’-allylic alcohol in 2.163 
might also imposes a lower energetic A1,2 strain penalty as compared to a phenyl group (cf. 
2.130, Figure 2.18) , thus further favoring its equilibrium. 
 
Nevertheless, under the acidic p-TSA conditions, even if a trace amount of the minor 
diastereomer 2.164 were to be formed, it is possible that it might equilibrate into the more 
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thermodynamic stable form 2.141 through a ring opening /ring closing equilibia that may be too 
rapid for detection on TLC. 
 
 
Figure 2.29 Acid catalyzed pseudo oxa-Micheal spiroketalization 
 
 
Figure 2.30 Stereochemical correlation for 2.141 
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2.3.8 Summary 
A telescoped Heck oxidative cyclization protocol to spiroketals has been developed. Unlike the 
tandem Ferrier-DDQ-oxidative cyclization mechanism, the role of DDQ serves to 
dehydrogenation the electron rich silyl enol ether into the α, β−dihydropyranone.  In the 
presence of p-TSA, the pyrananone readily ionizes to a transient allylic cation that is trapped by 
the tethered alcohol in a pseudo oxa-Micheal type reaction. The stereochemical outcomes of the 
products are dictated solely by thermodynamics. The resultant novel spiroketals possess a planar 
sp2-aromatic backbone coupled with a 3D spiroketal scaffold; making them an attractive 
chemical library to target for medicinal chemistry studies. 
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3.0  TOTAL SYNTHESIS OF CLAVOSOLIDE A: A SHOWCASE OF OXIDATIVE 
OXOCARBENIUM CATION COMPATIBILITY WITH CYCLOPROPANE  
3.1 INTRODUCTION 
3.1.1 Isolation of clavosolides A-D from marine organism 
Clavosolides A-D are metabolites isolated from the extracts of the marine sponge Myriastra 
clavosa off the coast of Philippines. Clavosolides A-B were reported by Faulkner and 
coworkers[57] in 2001 whereas clavosolide C and D were subsequently reported by Erickson and 
co-workers[58] in 2002. Previous investigation of M. clavosa collected in Palau afforded 
calvosines A-C, which are potent cytotoxins related to the calyculins[59]. However, chemical 
separation of the Philippines sample did not yield any calvosines but only four interesting 
dimeric macrolides, which are non-cytotoxic. The structures of these trace metabolites were 
assigned extensively by 2-D NMR spectroscopic analyses. This family of 16-membered 
macrolides differs only in the substitution of the THP ring at position 14’ and methylation of the 
glycosidic sugar core at position 20’ and 22’. Due to its C2 symmetrical architecture, clavosolide 
A (3.1) in particular has been the target of numerous synthetic groups. 
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Figure 3.1 Members of the clavosolide family 
3.1.2 Structural determination of clavosolide A 
According to the report by Faulkner and co-workers, clavosolide A (3.1), [α]D -48.5 (c 1, CHCl3), 
was isolated as a viscous green oil. Its molecular formula, C44H72O16 was established from 
HRFABMS measurement of [M + Na]+ peak at m/z 879.470. The 13C NMR spectrum only 
contained 22 signals, which is indicative of a symmetrical dimer. The IR spectrum also revealed 
an ester stretch at 1730 cm-1. The absence of hydroxyl bands meant that all the oxygen atoms 
were involved in either ester or ether linkages. Extensive 2D NMR techniques such as COSY, 
HMBC, ROESY as well as molecular modeling were used in peaks assignments.  
 
The relative stereochemistry of the glycosidic bond between C15 and C5 (Figure 3.2) was 
determined to be a β-linkage due to the large diaxial coupling (J = 8-9 Hz) between the 
oxymethine protons based on independent study on the elucidation of clavosolide C by Erickson 
and co-workers[60]. The relative stereochemistry of the cyclopropyl substituent was also 
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determined to be trans from its coupling constant of 4.4 Hz between H-10 and H-11. This was 
further confirmed by NOESY correlation between H3-12 and H-10 and also between H-11 and 
H-9. The methylene protons of H-6 at δ 1.56 appeared as a ddd with three large J–values of 
approximately 12 Hz, thus indicating the axial orientation of neighboring H-3, H-5 and H-7 
protons and placing the methyl group H3-14 in an equatorial position. 
 
 
Figure 3.2 Selected spectroscopic analysis for 3.1 
3.1.3 Previous syntheses of (–)-clavosolide A  
The total synthesis of (–)-clavosolide A was first attempted by Willis[61] and co-workers in 2005. 
Interestingly, the macrocycle cyclopropyl side-chains previously assigned 10S, 10’S, 11S, 11’S 
were incorrect. Following its total synthesis, it was proposed to possess the 10R, 10’R, 11R, 11’R 
configuration. In 2006, the proposed revised structure was confirmed by total synthesis credited 
to Lee and co-workers[62]. However, Lee misinterpreted the sign of the optical rotation, 
misleading them to believe that they had made the enantiomer of the natural product. This error 
was subsequently corrected by Smith et al.[63] as well as Willis et al.[64], who independently 
synthesized the same revised structure and unambiguously established that Lee had indeed made 
the naturally occurring (–)-clavosolide A. 
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3.1.3.1 Willis’s total synthesis of clavosolide A diastereomer 
 
Willis and co-workers[61] prepared the starting enol ether 3.2 from an asymmetric crotyl transfer 
reaction.  Subjection of 3.2 to a Prins cyclization under acidic conditions resulted in the 
formation of the THP ring with three continuous stereocenters in a one–pot reaction. Further 
manipulation gave 3.3, which was reacted with (E)-1-bromo-1-propene in a Nozaki-Hiyama-
Kishi reaction to give a diastereomeric mixture of allylic alcohols. Charette syn-directed 
cyclopropanation of the desired allylic alchohol gave intermediate 3.4.  
 
 
Scheme 3.1 Willis synthesis of (–)-clavosolide A diastereomer 
 
Macrolactonization followed by Nicolaou NBS-mediated bis-glycosidation gave a mixture of [α, 
α], [α, β] and [β, β]. Whilst there was good correlation between the synthetic and natural product 
in the 13C NMR, the cyclopropyl protons were clearly different. Based on spectroscopic data and 
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molecular modeling, the Willis group concluded that they synthesized the first reported proposed 
structure for clavosolide A, which turned out to be the antipode 3.5 of the natural product. 
3.1.3.2 Smith’s total synthesis of clavosolide A 
 
Smith and co-workers[63] exploited a Petasis-Ferrier rearrangement tactic to construct the THP 
core monomer 3.10 from enol ether 3.8, which was prepared from the condensation of 
cyclopropyl aldehyde 3.6 and β-hydroxyl acid 3.7. Smith screened a variety of Lewis acids and 
conditions for the Petasis-Ferrier rearrangement but only obtained low yields or decomposition 
of the THP ring due to the inherent instability of the cyclopropyl ring.  
 
 
Scheme 3.2 Smith's Petasis-Ferrier rearrangment tactic 
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However, the optimized use of 1.1 equivalent of Me2AlCl at room temperature for just one 
second, lead to 60% of the rearranged cyclized product 3.10 via intermediate 3.9. Further 
functional groups manipulations followed by lactonization, dimerization and bis-glycosidation 
eventually lead to 3.1 in 17 steps (longest linear sequence). 
3.1.3.3 Lee’s total synthesis of clavosolide A 
 
Lee’s strategy[62] for the construction of the THP ring system was through an intramolecular oxa-
Micheal attack of highly functionalized intermediate 3.15. Key intermediate 3.14 was assembled 
via a 1,5-anti-selective aldol reaction between cyclopropyl ketone 3.12 and 3.13.  Functional 
group manipulation followed by installation of the conjugated ester through a Horner-
Wadsworth-Emmons protocol afforded (E)-α,β-unsaturated ester 3.15. Acid-mediated 
deprotection of the acetonide followed by an intramolecular 1,5-conjugate addition under basic 
conditions gave the 2,6-cis THP intermediate 3.16 in good selectivity. Further protecting groups 
transformations followed by Yamaguchi’s macrolactonization and Schmidt’s glycosidation gave 
3.1 in a total of 20 total steps. 
 
 
Scheme 3.3 Lee’s intramolecular oxa-Micheal cyclization strategy 
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3.2 DESIGN PRINCIPLE: STABILIZATION OF CYCLOPROPYL RING 
THROUGH CONJUGATED OXOCARBENIUM CATION  
Cyclopropanes have an inherent strain energy of 27 kcal/mol, which results in a high propensity 
to undergo undesired ring-opening reactions not normally observed for other cycloalkanes[65]. 
Facile ring opening reactions occur readily in the presence of reactive intermediates such as a 
carbenium ion on the adjacent carbon atom[66]. This potentially limits the plethora of synthetic 
reactions that are compatible with substrates containing labile cyclopropyl functionalities. To this 
end, cyclopropanes are usually installed during the late stage of a sequence to avoid any 
unexpected ring cleavages.  
Interestingly, cationic cyclopropyl ring opening reactions can be mitigated or even completely 
nullified with an adjacent oxocarbenium such that the usual favorable strain release of the 
cyclopropane is countered by the formation of a highly unstabilized carbocation that renders the 
thermodynamics of the entire sequence unfavorable[67]. 
 
 
Figure 3.3 Stabilization of cationic cyclopropanes 
 
The stability of oxocarbenium cyclopropane can be exploited through nucleophilic trapping 
reactions. However, classical methods of oxocarbenium generation from acetals using Lewis 
acids often suffer from ionization of the resultant alkoxy group and subsequent cyclopropane 
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cleavage. The Floreancig group has demonstrated the feasibility of generating oxocarbenium 
intermediates under mild, non-acidic conditions using DDQ. This formal oxidative carbon-
hydrogen activation protocol has already demonstrated wide applicability in allylic, benzylic, as 
well as vinylic sulfides, amides and ethers systems[8-10, 68]. Herein, this project serves to extend 
the scope of the methodology to include cyclopropane containing allylic ethers and apply it in 
the wider context of the natural product, (–)-clavosolide A. 
3.2.1 Model substrate design and preparation 
The cyclopropane containing allylic ethers are designed with a tethered nucleophile so that the 
oxidative generated transient allylic cation from DDQ can be rapidly trapped in a fast step to 
yield the desired cyclized product (Figure 3.4). 
 
 
Figure 3.4 Nucleophilic addition into conjugated cyclopropyl oxocarbenium 
 
The long chain aliphatic allylic alcohol 3.17 was carried forward to the alkynyl propargylic ether 
3.18a through a sequence of Simmons-Smith cyclopropanation, oxidation, Corey-Fuchs 
homologation and etherification coupling with 3-butynol through a pyridinium salt intermediate 
employing a variation of Dudley’s protocol[69] (Scheme 3.4). 
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Scheme 3.4 En-route to alkynal propargylic ether 3.18 
 
The enol acetate functionality in 3.18b was readily installed using a ruthenium-catalyzed cis-
Markovnikov’s addition of acetic acid into alkynes following Gooßen’s protocol[70]. Enol acetate 
was chosen as a masked enolate nucleophile that is stable under DDQ oxidative conditions[8, 71]. 
Vinyl silanes (3.19, 3.20a, 3.20b) were selected as the model substrates because they can be 
readily accessed with high geometric selectivity from alkynes utilizing ruthenium or platinium 
mediated hydrosilylation reactions[72] (Scheme 3.5). 
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Scheme 3.5 Preparation of cyclopropane containing vinyl silanes 
 
Subjecting (Z)-vinyl silane 3.19 and (E)-vinyl silane 3.20a under our optimized DDQ oxidative 
conditions resulted in facile conversion into tetrahydropyrones 3.21 and 3.22 (Scheme 3.6).  
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Scheme 3.6 Oxidative cyclization of cyclopropane containing substrates 
 
While oxocarbenium formation usually occurs at room temperature or even lower temperatures, 
heating at 45 °C was required for the oxidation to proceed. This was primarily due to the steric 
bulk of the vinyl silanes hindering the association with the oxidant[68b]. In addition, due to the 
proximity of the silyl substituent to the alkoxy ether in 3.20b, no cyclization was observed even 
at 45 °C.  In addition, the cyclized tetrahydropyrones were obtained as inseparable 
diastereomeric mixture, indicating that the remote cyclopropane group was unable to impart any 
stereochemical induction on the newly formed stereogenic center. Despite the moderate yields 
obtained, the remainder of the mass accounting for these model substrates was attributed to 
nonspecific decomposition pathways not associated with cyclopropane ring opening. 
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3.3 RETROSYNTHETIC DISCONNECTION FOR (–)-CLAVOSOLIDE A 
The encouraging results of our DDQ-mediated oxidative cyclization on the model substrates 
prompted us to test the feasibility of our protocol in the more complex setting of a natural 
product. Due to the C2 symmetrical nature of 3.1, an initial disconnection at the ester linkages of 
the molecule will yield cyclopropyl THP 3.23. We postulate that 3.23 can be readily assembled 
from cyclopropyl allylic ether 3.24 generated from the union of 3.25 and 3.26 (Figure 3.5). 
 
 
Figure 3.5 Retrosynthetic analysis of 3.1 
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3.3.1 Synthesis of cyclopropyl containing subunit 
The cyclopropyl-containing segment was synthesized using Feringa’s CuI and (R)-TolBINAP-
catalyzed 1,4–conjugate addition[73] of MeMgBr into chloro enone 3.27, prepared in one step 
from commercially available allyl chloride and acetyl chloride[74]. The resultant chloro enolate 
3.28 can either be directly quenched with a proton source at –78 °C to yield β-methyl 
chloroketone 3.29 or cyclopropane ketone 3.30 upon warming up to room temperature.   
 
 
Figure 3.6 Feringa's tandem conjugate addition and cyclopropanation 
 
Cyclopropane ketone 3.30 was formed in 43% yield upon warming up to room temperature. 
Unfortunately, the protocol was not reproducible and the over addition of MeMgBr into the 
carbonyl was a persistent side reaction. Eventually, we decided to access 3.30 via a different 
route and quenched enolate 3.28 at –78 °C. Upon exposure of 3.29 to refluxing NaOH, the 
resultant carbanion displaces the γ-chloride through an intramolecular SN2 reaction to afford 3.30 
in 72% yield over 2 steps. The enantiomeric excess (% ee) calculated from the HPLC trace of 
intermediate 3.29 was determined to be at least >90%. This was estimated because baseline 
resolution of the enantiomeric peaks in the racemic control proved difficult (refer appendix B). 
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The trans-cyclopropyl ketone 3.30 was formed selectively over the cis-configuration due to 
minimization of eclipsing torsional strain in the transition state.  
 
 
Figure 3.7 Stereochemical analysis of intramolecular SN2 reaction 
 
Cyclopropyl ketone 3.30 was subsequently converted into the propargyl alcohol using Negishi’s 
protocol[75]. Quenching of the enolate with diethyl phosphoryl chloride afforded the enol 
phosphate 3.31 (Scheme 3.7). Treatment of 3.31 with 2 equivalent of LDA led to β-elimination 
of the phosphate group to give the terminal alkyne, which was deprotonated by another 
equivalent of LDA to give the acetylenic anion.  Subsequent quenching with paraformaldehyde 
affords the propargylic alcohol 3.32.  
 
Scheme 3.7 Cyclopropane subunit homologation 
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Conversion of the hydroxyl group into an appropriate leaving group proved challenging due to 
the incompatibility of cyclopropyl group with harsh halogenating reagents and elevated heating. 
Alcohol 3.32 was eventually mesylated under standard conditions to yield 3.33, which should be 
used quickly due to its high propensity for degradation and ionization. 
3.3.2 Synthesis of cyclization substrates 
The other half of the fragment 3.26 required for the formation of the cyclization substrate allylic 
ether was synthesized under Marshall’s conditions[76], which coupled aldehyde 3.34 with 
mesylate 3.35 that was conveniently prepared from Noyori reduction[44a] of the corresponding 
alkynyl ketone (Scheme 3.8).  Good diastereo and enantioselectivity were obtained using this 
protocol. Subsequent union of the cyclopropyl mesylate 3.33 with 3.36 using a modified 
Williamson etherification[77] afforded the desired ether with concomitant desilylation of the 
terminal TMS group.  
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Scheme 3.8 Fragment coupling and enol acetates formation 
 
Under the optimized ruthenium catalyzed enol acetate conditions, we observed the formation of 
the mono enol acetate 3.37 (55%) as well as the dienol acetate 3.38 (27%) in 6 h. Upon exposure 
to higher catalyst loadings and longer reaction time, 3.38 was obtained in a net yield of 69%. 
Subjection of 3.37 under Trost’s conditions[78] afforded vinyl silane 3.39, which has a useful silyl 
handle for post cyclization manipulation[68b]. 
 
Interestingly for 3.38, where a second equivalent of HOAc has inserted into the internal alkyne, 
it adds into the triple bond in a strictly cis-manner with excellent regioselectivity. The 
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stereochemical outcome has been corroborated through NMR analysis of 3.37 and nOe 
correlation of a subsequent intermediate. As Gooßen’s protocol usually exhibits a high 
selectivity for the terminal alkyne, we postulated that the cyclopropane group might be playing 
some activating role. 
 
 
Figure 3.8 Proposed directing group effect by cyclopropane 
 
A putative mechanism (Figure 3.8) for the directing effect involves ruthenium coordination with 
the alkyne triple bond followed by the acetate migratory inserting into the hindered end of the 
internal alkyne with the ruthenium catalyst and its bulky phosphine ligand migrating to the less 
hindered end. In addition, the adjacent oxygen of the ether may possess subtle bonding 
interactions with the electrophilic Ru center, thus further enhancing the regioselectivity of the 
acetic acid addition. 
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3.3.3 Oxidative cyclization and completion of the synthesis 
 
Scheme 3.9 DDQ mediated oxidative cyclization 
 
Under the optimized conditions of the DDQ-mediated oxidative C–H activation, cyclopropyl 
containing dienol acetate 3.38 underwent smooth ring closure at rt to yield a single stereoisomer 
of the cyclized product 3.40 in 62% yield within 1.5 h. In contrast, vinyl silane 3.39 was 
relatively inert to our oxidative method and required prolonged heating at 40 °C to give a 
comparatively lower yield of 51% (Scheme 3.9).  No further optimization was attempted for 3.39 
due to superiority of 3.38 in terms of ease of reaction, atom economy, and accessibility of 
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starting materials. The serendipitous observation that enol acetates are excellent stabilizing 
groups for oxidative oxocarbenium formation is significant as it offers an additional alternative 
for the formation of functionalized alkenyl THP rings that are very versatile for further structural 
diversification. In addition, 2D COSY and NOESY spectroscopic analysis of 3.40 also 
unambiguously confirmed the cis–regiochemistry of the acetic acid addition for intermediate 
3.38 as previously predicted. 
 
 
Scheme 3.10 Glycosidation and reduction of cyclopropyl ketone 
 
Cyclopropane-containing vinyl acetate 3.40 was first subjected to Crabtree’s hydrogenation[79] 
under substrate control (Scheme 3.10). The iridium catalyst was known to coordinate to the 
oxygen atom of the THP ring, aiding in facial selective hydrogenation of vinyl silanes as 
previously demonstrated[68b]. However, in the presence of a conjugated cyclopropyl subunit, 3.40 
rapidly decomposed with concomitant cyclopropyl ring cleavage. This is not unusual due to the 
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isosteric resemblance of cyclopropane to alkenes that can undergo double bond isomerization 
under Crabtree’s hydrogenation conditions[80].   
 
An alternative approach (Scheme 3.10) was taken where the 4’-ketone was reduced by sodium 
borohydride to give the equatorial alcohol. Subsequently, the vinyl acetate was hydrolyzed under 
basic conditions into the cyclopropyl enol, which readily tautomerized into the ketone form. 
Schmidt’s TMSOTf-catalyzed glycosidation[81] with trichloroacetimidate 3.43 was utilized to 
tether D-xylose, which gave a ca. 1:1 of the desired glycoside together with the other α-anomer. 
The sugar moiety was installed at this stage[82] because the glycosyl group can potentially 
function as a hydroxyl-protecting group and because a glycosidation after macrodiolide 
formation can result in a complex mixture of three anomeric stereoisomers due to the low 
selectivity of the glycosidation reaction. 
 
The substrate-controlled reduction of cyclopropyl ketone 3.44 on a similar compound[83] has 
been performed with good stereocontrol. Disappointingly, the reduction of 2.44 with LAH and 
Zn(BH4)2  gave no product at low temperatures and a mixture of diastereomeric alcohols upon 
warming up to ambient temperature. To this end, reagent-controlled CBS reduction[45] on 3.44 
was attempted and turned out to be the reagent of choice, giving the desired (S)-carbinol 3.46 in 
excellent yield and good diastereoselectivity. The high stereoselectivity of the CBS reduction 
was due to the stereoelectronic effects of the cyclopropyl group[84] behaving as both a stereo 
differentiating bulky group and also an electron-donating group that directs coordination of the 
anti lone pair on the carbonyl to the catalytic reactive boron center on the catalyst (Figure 3.9). 
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Figure 3.9 Stereochemical model for CBS reduction 
 
Careful triisopropyl silyl (TIPS) deprotection using 1% HCl in EtOH gave the primary alcohol, 
which was subjected to selective TEMPO oxidation[85] into carboxylic acid 3.47. Subsequent 
macrolactionization under Yamaguchi’s esterification conditions[86] gave the (–)-clavosolide A 
3.1 in 44%. The total synthesis of 3.1 has been accomplished in a total of 20 steps with 14 steps 
being the longest linear sequence. 
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Scheme 3.11 End game for (–)-clavoslide A 
3.3.4 Summary 
The proof of concept that cyclopropanes are compatible with oxocarbenium formation has been 
demonstrated through the synthesis of cyclopropane-substituted THP rings. The mild reaction 
conditions and functional group tolerance of the DDQ mediated C–H activation protocol has 
been applied in a convergent synthesis of the natural product, (–)-clavosolide A. Significant 
transformations in the synthesis include an early stage Feringa asymmetric cyclopropanation and 
an oxidation of the acetoxy-subsituted allylic ether into a highly functionalized stable 
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oxocarbenium ion. The ability to introduce the cyclopropyl moiety at an early stage of the 
synthetic route that survives through a carbocation forming reaction showcases the viability of 
oxidative C–H bond functionalization as a valuable strategy in the toolkit of synthetic chemists 
for complex molecule synthesis. 
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APPENDIX A 
[N+1] APPROACHES TO THE SYNTHESIS OF DIVERSE SPIROACETALS 
THROUGH OXIDATIVE CATION FORMATION  
General Information 
 
Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were recorded on a 
Bruker Avance 300 spectrometer at 300 MHz and 75 MHz, a Bruker Avance 400 spectrometer at 
400 MHz and 100 MHz, a Bruker Avance 500 spectrometer at 500 MHz and 125 MHz. The 
chemical shifts are reported in parts per million (ppm) on the delta (δ) scale. The solvent peak 
was used as a reference value, for 1H NMR: CDCl3 = 7.27 ppm, C6D6 = 7.16 ppm, for 13C NMR: 
CDCl3 = 77.23, C6D6 = 128.4 ppm. Data are reported as follows: (s = singlet; d = doublet; t = 
triplet; q = quartet; sept = septet; dd = doublet of doublets; ddd = doublet of doublet of doublets; 
dddd = doublet of doublet of doublet of doublet; td = triplet of doublets; dtd = doublet of triplet 
of doublets; br = broad). High-resolution mass spectra were recorded on a Thermo Scientific Q-
Exactive spectrometer. Infrared (IR) spectra were collected on a Mattson Cygnus 100 
spectrometer. Samples for IR were prepared as a thin film on a NaCl plate by dissolving the 
compound in CH2Cl2 and then evaporating the CH2Cl2. Tetrahydrofuran and diethyl ether were 
distilled from sodium and benzophenone. Methylene chloride was distilled under N2 from CaH2. 
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Analytical TLC was performed on E. Merck pre-coated (25 mm) silica gel 60F-254 plates. 
Visualization was done under UV (254 nm). Flash chromatography was done using ICN SiliTech 
32-63 60 Å silica gel. Reagent grade ethyl acetate, diethyl ether, toluene and hexanes 
(commercial mixture) were purchased from EM Science and used as is for chromatography.  
 
Lithiation route to simple allylsilanes 
 
 
 
Trimethyl(2-methylene-4-((trimethylsilyl)oxy)butyl)silane 
(2.73) 
1H NMR (500 MHz, CDCl3) δ 4.59 (s, 1H), 4.56 (s, 1H), 3.68 (t, J = 7.4 Hz, 2H), 2.20 (t, 
J = 7.4 Hz, 2H), 1.53 (s, 2H), 0.12 (s, 9H), 0.02 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 144.8, 
108.7, 62.1, 41.7, 27.7, –0.1, –1.1. These data are consistent with literature values.1  
 
Trimethyl((2-((trimethylsilyl)methyl)allyl)oxy)silane (2.89) 
1H NMR (601 MHz, CDCl3) δ 4.91 (s, 1H), 4.63 (s, 1H), 3.95 (s, 
2H), 1.49 (s, 2H), 0.13 (s, 9H), 0.02 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 146.2, 106.8, 66.7, 
23.0, –0.2, –1.1; IR (thin film) 2957, 1647, 1416, 1251, 1160, 1123, 1086, 882, 842, 749 693 cm–
1. These data are consistent with literature values.2  
 
                                                 
1 F. Alonso, M. Rodriguez-Fernandez, D. Sanchez, M. Yus, Synthesis 2010, 3013-3020. 
2 B. M. Trost, P. Renaut, J. Am. Chem. Soc. 1982, 104, 6668-6672. 
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3-((trimethylsilyl)methyl)but-3-en-1-ol  
1H NMR (601 MHz, CDCl3) δ 4.69 (s, J = 1.9 Hz, 1H), 4.67 (s, 1H), 3.71 (q, J = 6.1 
Hz, 2H), 2.24 (td, J = 6.2, 0.9 Hz, 2H), 1.55 (d, J = 0.9 Hz, 2H), 0.04 (s, 9H). These 
data are consistent with literature values3. 
 
tert-butyldimethyl((3-((trimethylsilyl)methyl)but-3-en-1-yl)oxy)silane (2.72) 
1H NMR (601 MHz, CDCl3) δ 4.59 (s, 1H), 4.55 (s, 1H), 3.71 (t, J = 7.2 Hz, 2H), 
2.19 (t, J = 6.8 Hz, 2H), 1.54 (s, 2H), 0.90 (s, 9H), 0.06 (s, 6H), 0.02 (s, 9H). 13C 
NMR (151 MHz, CDCl3) δ 144.8, 108.6, 62.7, 41.8, 27.5, 26.2, 18.6, -1.2, -5.0. IR (thin film) 
2955, 2859, 1634, 1472, 1417, 1388, 1252, 1157, 1098, 931, 837, 775 cm-1; HRMS (ES+) calcd 
for C14H33OSi2 [M+H] +: 273.2070, found: 273.2060. 
 
 
 
 
                                                 
3 Ahmed-Schofield, R.; Mariano, P. S. The Journal of Organic Chemistry 1985, 50, (26), 5667-5677. 
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(±)-2-hexyl-2,3-dihydro-4H-pyran-4-one  
1H NMR (601 MHz, CDCl3) δ 7.38 (d, J = 6.0 Hz, 1H), 5.42 (dd, J = 6.0, 1.1 Hz, 
1H), 4.45 – 4.39 (m, 1H), 2.54 (dd, J = 16.7, 13.5 Hz, 1H), 2.45 (ddd, J = 16.7, 
3.7, 1.2 Hz, 1H), 1.87 – 1.81 (m, 1H), 1.71 – 1.65 (m, 1H), 1.51 – 1.26 (m, 8H), 0.92 (t, J = 6.8 
Hz, 3H). These data are consistent with literature values4. 
 
 (±)-2-Octyl-2,3-dihydro-4H-pyran-4-one (2.82a) 
To a solution of Danishefsky's diene (1.15g, 6.65 mmol, 1.0 equiv) and nonanal 
(1.82g, 12.8 mmol, 1.93 equiv) in Et2O (25 mL) at –20 °C was added BF3•OEt2 
(840 μL, 6.78 mmol, 1.02 equiv) dropwise over 30 min. The mixture was stirred for 1h, then was 
warmed to 0 °C and carefully quenched with 10 mL of NaHCO3. The resultant organic layer was 
extracted with Et2O (2 x 15 mL). The combined organic layers were washed with brine (20 mL) 
and concentrated in vacuo. Flash column chromatography as above afforded the racemic 
pyranone (1.05 g, 75%) as a yellow viscous oil. All spectral data other than optical rotation 
matched those of the enantiomerically enriched material. 
 
 
 (R)-2-Octyl-2,3-dihydro-4H-pyran-4-one (2.82b) 
To a rapidly stirring mixture of nonanal (495 μL, 2.87 mmol, 1 equiv), 4 Å 
molecular sieves (60 wt%) and (1S, 2R)-Jacobsen's catalyst (71 mg, 0.14 mmol, 
0.05 equiv) under N2 at 0 °C was added Danishefsky's diene (620 μL, 3.20 mmol, 1.1 equiv). 
                                                 
4 Zulauf, A.; Mellah, M.; Guillot, R.; Schulz, E. Eur. J. Org. Chem. 2008, (12), 2118-2129. 
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The mixture was gradually warmed to rt and stirred for 16 h. The reaction was diluted with 
CH2Cl2 (5 mL) and cooled to 0 °C. One drop of TFA acid was added and the reaction was stirred 
for 15 min. The mixture was filtered through a short plug of celite, rinsed with CH2Cl2 (5 mL), 
and concentrated in vacuo. Flash column chromatography purification (20% EtOAc in hexanes) 
afforded the desired product (430 mg, 71%) as a viscous yellow oil. 1H NMR (601 MHz, CDCl3) 
δ 7.35 (d, J = 6.0 Hz, 1H), 5.39 (d, J = 6.0 Hz, 1H), 4.40 (ddd, J = 12.7, 8.6, 4.7 Hz, 1H), 2.51 
(dd, J = 16.7, 13.5 Hz, 1H), 2.43 (dd, J = 16.7, 3.7 Hz, 1H), 1.86 – 1.77 (m, 1H), 1.65 (ddd, J = 
14.8, 10.6, 5.4 Hz, 1H), 1.50 – 1.43 (m, 1H), 1.43 – 1.36 (m, 1H), 1.35 – 1.22 (m, 10H), 0.89 (t, 
J = 6.8 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 193.0, 163.5, 107.2, 79.8, 42.1, 34.6, 32.0, 29.6, 
29.5, 29.4, 25.0, 22.9, 14.3; IR (thin film) 2928, 2856, 1680, 1597, 1465, 1406, 1273, 1225, 
1038, cm–1; [α]D20 +100.4 (c 1.06, CHCl3); HRMS (ASAP) calcd for C13H23O2 [M+H]+: 
211.1698, found: 211.1697. 
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 (2R,4S)-2-hexyl-3,4-dihydro-2H-pyran-4-ol  
1H NMR (601 MHz, CDCl3) δ 6.37 (dd, J = 6.2, 1.3 Hz, 1H), 4.73 (dt, J = 6.2, 
1.9 Hz, 1H), 4.44 (t, J = 7.6 Hz, 1H), 3.93 – 3.89 (m, 1H), 2.16 (ddt, J = 13.1, 
6.6, 1.9 Hz, 1H), 1.60 – 1.57 (m, 1H), 1.55 – 1.49 (m, 1H), 1.37 – 1.25 (m, 9H), 0.88 (t, J = 6.7 
Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 145.6, 105.5, 75.2, 63.6, 38.4, 35.3, 32.0, 29.4, 25.3, 
22.8, 14.3; IR (thin film) 3340, 2928, 2859, 1643, 1465, 1234, 1108, 1036, 739 cm-1; HRMS 
(ES+) calcd for C11H19O2 [M-H]+: 183.1385, found: 183.1375. 
 
 (2S,4R)-2-Octyl-3,4-dihydro-2H-pyran-4-ol (2.79) 
To the pyranone 2.82b (2.81g, 13.3 mmol) in MeOH (130 mL) was added 
CeCl3•7H2O (5.96g, 16 mmol, 1.2 equiv). The reaction was stirred for 10 min at 
rt then was cooled to –40 °C. NaBH4 (606 mg, 16 mmol, 1.2 equiv) was added in one portion 
under nitrogen and the mixture was stirred for 1h.  The mixture was warmed to 0 °C, then was 
carefully quenched with a 1:1 mixture of brine/water (50 mL). The mixture was extracted with 
CH2Cl2 (3 x 25 mL). The combined organic layers were washed with brine (50 mL) and 
concentrated in vacuo. Flash column chromatography purification (30% EtOAc in hexanes) 
afforded the desired product as a colorless oil (2.32 g, 82%). 1H NMR (500 MHz, CDCl3) δ 6.36 
(d, J = 6.2 Hz, 1H), 4.72 (d, J = 6.2 Hz, 1H), 4.43 (t, J = 8.1 Hz, 1H), 3.90 (dt, J = 12.0, 6.2 Hz, 
1H), 2.15 (dd, J = 13.1, 6.6 Hz, 1H), 1.69 – 1.61 (m, 1H), 1.58 (dd, J = 12.1, 2.7 Hz, 1H), 1.56 – 
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1.46 (m, 2H), 1.32 – 1.23 (m, 12H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
145.6, 105.6, 75.3, 63.7, 38.5, 35.4, 32.2, 29.8, 29.8, 29.5, 25.4, 23.0, 14.4; [α]D20+5.8 (c 0.65, 
CHCl3); IR (thin film) 3338, 3062, 2926, 2856, 1643, 1465, 1379, 1234, 1110, 1032, 920, 875. 
739 cm–1; HRMS (ASAP) calcd for C14H25O [M-OH]+: 209.1905, found: 209.1897.  
 
(2R,4S)-2-hexyl-3,4-dihydro-2H-pyran-4-yl acetate (2.71) 
To a solution of the pyranol (717mg, 3.89 mmol) in CH2Cl2 (8 mL) under N2 at rt 
was added DMAP (50mg, 0.389 mmol, 0.1 equiv) and Et3N (1.2 mL, 0.817 
mmol, 2.1 equiv). The mixture was later cooled to 0 °C and Ac2O (700 μL, 3.20 mmol, 1.1 
equiv) was added drop-wise.  After 1.5 h, the mixture was quenched at 0 °C with MeOH (2 mL), 
washed with NaHCO3 (5 mL x 2), brine (5 mL) and dried over MgSO4. Flash column 
chromatography purification with basified silica gel (2% EtOAc in hexanes) afforded the product 
(506 mg, 57%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.44 (dd, J = 6.3, 1.3 Hz, 1H), 
5.41 – 5.36 (m, 1H), 4.71 (dt, J = 6.2, 2.0 Hz, 1H), 3.96 (dddd, J = 10.8, 7.4, 5.2, 2.1 Hz, 1H), 
2.23 (ddt, J = 13.3, 6.7, 1.9 Hz, 1H), 2.05 (s, 3H), 1.78 – 1.61 (m, 2H), 1.59 – 1.49 (m, 2H), 1.36 
– 1.21 (m, 4H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 171.2, 147.0, 101.0, 
74.8, 66.1, 35.0, 33.6, 32.0, 29.4, 25.3, 22.8, 21.5, 14.3; IR (thin film) 2931, 2859, 1741, 1645, 
1466, 1372, 1236, 1110, 1025, 741 cm-1; HRMS (ESIP) calcd for C13H23O3 [M+H] +: 227.1642, 
found: 227.1646. 
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tert-butyl(4-((2R,6R)-6-hexyl-5,6-dihydro-2H-pyran-2-
yl)butoxy)dimethylsilane (2.74) 
To a solution of the pyranyl acetate 2.71 (45 mg, 0.20 mmol) and OTBS 
allyl silane 2.72 (82 mg, 0.30 mmol, 1.5 equiv) in MeCN (1 mL) under N2 was added DDQ (23 
mg, 0.10 mmol, 0.5 equiv). The mixture was allowed to stir at 50 °C for 18h. Upon cooling 
down to rt, the reaction was quenched with Et3N (100 μL) and concentrated. Flash column 
chromatography purification (2% EtOAc in hexanes) afforded the product as a colorless oil (43 
mg, 59%). 1H NMR (601 MHz, CDCl3) δ 5.80 (dtd, J = 7.6, 5.0, 2.3 Hz, 1H), 5.72 – 5.68 (m, 
1H), 4.86 (s, 1H), 4.84 (s, 1H), 4.35 – 4.31 (m, 1H), 3.76 – 3.69 (m, 2H), 3.65 (tt, J = 7.9, 3.9 
Hz, 1H), 2.39 (dd, J = 14.1, 8.5 Hz, 1H), 2.31 (td, J = 7.0, 1.1 Hz, 2H), 2.21 (dd, J = 13.9, 5.5 
Hz, 1H), 1.46 – 1.39 (m, 2H), 1.33 – 1.24 (m, 8H), 0.89 – 0.87 (m, 12H), 0.05 (s, 6H). IR (thin 
film) 2928, 2857, 1645, 1469, 1390, 1254, 1094, 937, 889, 836, 776 cm-1; HRMS (ESI) calcd for 
C22H43O2Si [M+H] +: 367.3028, found: 367.3038. 
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((3-(((2R,6R)-6-hexyl-5,6-dihydro-2H-pyran-2-yl)methyl)but-3-en-1-
yl)oxy)trimethylsilane  (2.75) 
A solution of pyranyl acetate 2.71 (30 mg, 0.13 mmol) and allyl silane 2.73  
(37 mg, 0.16 mmol, 1.2 equiv) in DCE (500 μL) under N2 was cooled to 0 °C. K-10 clay (3 mg, 
10 wt%) was added and the mixture was allowed to warm up to rt over 1h.  The mixture was 
then filtered and concentrated. Flash column chromatography purification (2% to 20% EtOAc in 
hexanes) afforded 2.75 (9 mg, 20%) and 2.76 (17 mg, 50%) as colorless oils. 1H NMR (400 
MHz, CDCl3) δ 5.83 (dtd, J = 7.5, 4.9, 2.3 Hz, 1H), 5.73 (dtd, J = 10.2, 2.7, 1.4 Hz, 1H), 4.87 (s, 
1H), 4.85 (s, 1H), 4.35 (ddd, J = 7.4, 5.5, 2.7 Hz, 1H), 3.73 (td, J = 7.3, 1.1 Hz, 2H), 3.71 – 3.64 
(m, 1H), 2.42 (ddd, J = 14.1, 8.5, 1.0 Hz, 1H), 2.35 (t, J = 7.2 Hz, 2H), 2.23 (ddd, J = 14.1, 5.6, 
1.1 Hz, 1H), 2.06 – 2.03 (m, 1H), 2.00 (ddt, J = 5.1, 3.7, 1.4 Hz, 1H), 1.52 – 1.25 (m, 10H), 0.91 
(t, J = 6.5 Hz, 3H), 0.14 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 143.6, 129.7, 124.5, 113.5, 71.3, 
67.8, 61.9, 41.3, 39.3, 35.8, 32.1, 31.0, 29.6, 25.9, 22.9, 14.3, -0.2; IR (thin film) 2956, 2929, 
2858, 1644, 1433, 1391, 1250, 1092, 886, 841, 747 cm-1; HRMS (ESI) calcd for C19H37O2Si 
[M+H] +: 325.2557, found: 325.2561.  
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3-(((2R,6R)-6-hexyl-5,6-dihydro-2H-pyran-2-yl)methyl)but-3-en-1-ol 
(2.76) 
1H NMR (500 MHz, CDCl3) δ 5.82 (ddt, J = 10.1, 5.0, 2.3 Hz, 1H), 5.69 
(ddd, J = 10.3, 4.1, 2.3 Hz, 1H), 4.98 (s, 1H), 4.96 (s, 1H), 4.38 – 4.33 (m, 1H), 3.75 (t, J = 6.1 
Hz, 2H), 3.67 (tt, J = 8.4, 4.0 Hz, 1H), 2.44 – 2.39 (m, 1H), 2.36 (t, J = 6.1 Hz, 2H), 2.21 (dd, J = 
14.3, 5.0 Hz, 1H), 2.05 – 1.98 (m, 1H), 1.94 – 1.87 (m, 1H), 1.44 – 1.39 (m, 2H), 1.32 – 1.24 (m, 
8H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 143.3, 129.5, 124.6, 114.9, 71.2, 
68.0, 61.0, 40.9, 39.2, 35.6, 32.0, 30.8, 29.6, 25.8, 22.8, 14.3; IR (thin film) 3411, 2927, 2855, 
1734, 1645, 1465, 1377, 1183, 1088, 1047, 890, 715 cm-1; HRMS (ESI) calcd for C16H29O2 
[M+H] +: 253.2162, found: 253.2165. 
 
 
 
 (2R,4S)-4-Methyl-2-octyl-3,4-dihydro-2H-pyran-4-ol (2.77) 
To the pyranone 2.82b (300 mg, 1.43 mmol, 1.0 equiv) in THF (10 mL) at -
78 °C was added MeLi (1.6 M, 1.05 mL, 1.64 mmol, 1.15 equiv) dropwise 
over 10 min. The mixture was stirred for 1h then was quenched with NH4Cl (2 mL). The mixture 
was extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine (10 
mL) and concentrated in vacuo. Flash column chromatography purification (30% EtOAc in 
hexanes) afforded the desired product as a colorless oil (269 mg, 83%, 10:1 mixture of 
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diastereomers). This compound is unstable and should not be stored for prolonged periods. 
Major diastereomer: 1H NMR (500 MHz, CDCl3) δ 6.28 (d, J = 6.2 Hz, 1H), 4.69 (dd, J = 6.2, 
2.0 Hz, 1H), 3.86 – 3.77 (m, 1H), 1.89 (dt, J = 13.3, 2.1 Hz, 1H), 1.81 – 1.71 (m, 2H), 1.67 – 
1.59 (m, 1H), 1.54 – 1.37 (m, 2H), 1.35 (s, 3H), 1.31 – 1.22 (m, 10H), 0.86 (t, J = 6.7 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 144.2, 109.5, 75.5, 67.1, 44.6, 35.5, 32.1, 30.5, 29.8, 29.8, 29.5, 
25.5, 22.9, 14.4; [α]D20 +6.6 (c 2.20, CHCl3); IR (thin film) 2926, 2855, 1673, 1637, 1465, 1396, 
1236, 1138, 960 cm–1; HRMS (ASAP) calcd for C14H25O [M–OH]+: 209.1905, found: 209.1897.  
 
3-(((2R,6R)-4-methyl-6-octyl-5,6-dihydro-2H-pyran-2-yl)methyl)but-
3-en-1-ol (2.78) 
A solution of racemic pyranyl acetate 2.77 (20 mg, 0.09 mmol) and allyl 
silane 2.73  (41 mg, 0.18 mmol, 2.0 equiv) in CH2Cl2 (1 mL) under N2 was cooled to -78 °C. 
TMSOTf (16 μL, 0.09 mmol, 1.0 equiv) was added and the mixture was allowed to stir for 1h at 
this temperature. NaHCO3 (100 μL, 0.10 mmol) was added and the mixture was allowed to warm 
up to rt. The mixture was then concentrated. Flash column chromatography purification (5% to 
25% EtOAc in hexanes) afforded the prodcut (20 mg, 77%) as a colorless oil. 1H NMR (500 
MHz, CDCl3) δ 5.38 (d, J = 1.0 Hz, 1H), 4.96 (s, 1H), 4.94 (s, 1H), 4.32 (s, 1H), 3.73 (t, J = 6.1 
Hz, 2H), 3.69 – 3.62 (m, 1H), 2.36 – 2.33 (m, 2H), 2.16 (dd, J = 14.3, 4.7 Hz, 1H), 2.01 (s, 1H), 
1.87 – 1.81 (m, 2H), 1.69 (s, 3H), 1.59 – 1.49 (m, 1H), 1.46 – 1.36 (m, 2H), 1.34 – 1.20 (m, 
12H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 143.5, 132.2, 123.0, 114.7, 71.3, 
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68.1, 61.0, 41.1, 39.3, 35.7, 35.5, 32.1, 29.9, 29.8, 29.5, 25.9, 23.4, 22.9, 14.3; IR (thin film) 
3400, 2927, 2855, 1644, 1439, 1380, 1130, 1109, 1046, 889 cm-1; HRMS (ESIP) calcd for 
C19H35O2 [M+H]+: 295.2632, found: 295.2623. 
 
 
 
 (2R,6S)-10-Methylene-2-octyl-1,7-dioxaspiro[5.5]undec-4-ene (2.81)  
To a solution of tetrahydropyranol 2.79 (10 mg, 0.04 mmol, 1 equiv) and 
allylsilane 2.73 (12 mg, 0.05 mmol, 1.5 equiv) in CH2Cl2 (550 μL) under nitrogen was added 
TMSOTf (2 mol%, 8 μL, 0.8 μmol, 0.1M) dropwise at rt. Upon stirring for 45 min, the reaction 
was quenched by adding of a saturated aqueous solution of NaHCO3 (5 μL, 5 μmol). After 
stirring for 30 min, 4 ÅMS (10 mg was added and stirred for another 30 min. DDQ (36 mg, 0.16 
mmol) was added portion-wise. The oxidation step proceeded for 2 h and was quenched by Et3N 
upon complete consumption of starting material. The crude mixture was concentrated and 
purified by flash chromatography (5% EtOAc in hexane) to give the desired product (6.8 mg, 
61%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 5.98 – 5.92 (m, 1H), 5.67 (dd, J = 10.0, 
2.0 Hz, 1H), 4.81 (s, 1H), 4.77 (s, 1H), 3.86 – 3.79 (m, 2H), 3.72 (dd, J = 10.7, 5.9 Hz, 1H), 2.35 
– 2.30  (m, 3H), 2.17 (d, J = 13.6 Hz, 1H), 1.92 (dt, J = 5.2, 3.9 Hz, 2H), 1.61 – 1.52 (m, 1H), 
1.50 – 1.42 (m, 2H), 1.32 – 1.23 (m, 11H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
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δ 141.5, 129.8, 128.9, 110.4, 95.5, 67.7, 61.5, 44.5, 35.8, 34.2, 32.2, 31.0, 29.9, 29.9, 29.6, 26.0, 
23.0, 14.4; HRMS (ASAP) calcd for C18H31O2 [M+H]+: 279.2324, found: 279.2331; IR (thin 
film) 2927, 2855, 1658, 1463, 1396, 1370, 1238, 1176, 1115, 1069, 1049, 1017, 989, 886 cm–1. 
 
3-(((2R,6R)-6-octyl-5,6-dihydro-2H-pyran-2-yl)methyl)but-3-en-1-ol 
(2.80) 
Formed as a single diastereomer : 1H NMR (400 MHz, CDCl3) δ 5.81 
(dtd, J = 7.5, 4.9, 2.3 Hz, 1H), 5.71 – 5.66 (m, 1H), 4.97 (s, 1H), 4.95 (s, 1H), 4.37 – 4.31 (m, 
1H), 3.74 (t, J = 6.1 Hz, 2H), 3.66 (tt, J = 8.3, 4.0 Hz, 1H), 2.41 (dd, J = 14.3, 9.3 Hz, 1H), 2.35 
(t, J = 6.2 Hz, 2H), 2.20 (dd, J = 14.3, 5.0 Hz, 1H), 2.01 (dt, J = 17.4, 4.5 Hz, 1H), 1.94 – 1.85 
(m, 1H), 1.58 – 1.49 (m, 1H), 1.29 – 1.21 (m, 10H), 0.87 (t, J = 6.5 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 143.3, 129.4, 124.6, 114.9, 71.1, 67.9, 61.0, 40.9, 39.2, 35.6, 32.1, 30.8, 29.9, 
29.8, 29.5, 25.8, 22.9, 14.3; IR (thin film, neat) 3392, 2927, 2855, 1645, 1466, 1434, 1377, 1184, 
1087, 1048, 890, 713 cm-1; HRMS (ESIP) calcd for C18H33O2 [M+H] +: 281.2475, found: 
281.2475. 
 
 (2R,4S)-4-((Benzyloxy)methyl)-2-octyl-3,4-dihydro-2H-pyran-4-ol (2.84) 
To Bu3SnCH2OBn5  (244 mg, 0.594 mmol, 1.25 equiv) in THF (1 mL) at –78 
°C was added n-BuLi (1.6M, 360 μL, 0.571 mmol, 1.2 equiv) dropwise over 5 
min and the mixture was stirred for 15 min. A solution of the pyranone (100 mg, 0.475 mmol, 1.0 
                                                 
5 Still, W. C. J. Am. Chem. Soc. 1978, 100, 1481 
 
 109 
equiv) in THF (500 μL) was added by cannulation. The reaction was stirred at –78 °C for 1h, 
then was quenched with water (1 mL) and warmed to rt. The mixture was extracted with Et2O (2 
x 5 mL). The combined organic layers were washed with brine (10 mL) and concentrated in 
vacuo. Flash column chromatography purification (30% EtOAc in hexanes) afforded the product 
(198 mg, 91%) as a colorless oil. Formed as a 6.7:1 mixture of diastereomers. Major 
diastereomer: 1H NMR (601 MHz, CDCl3) δ 7.39 – 7.28 (m, 5H), 6.40 (d, J = 6.3 Hz, 1H), 4.66 
– 4.63 (m, 1H), 4.59 (ABq, 2H, ΔδAB = 0.08, JAB = 12.0 Hz), 3.49 (d, J = 9.3 Hz, 1H), 3.38 (d, J 
= 9.5 Hz, 1H), 2.12 (dt, J = 13.6, 2.1 Hz, 1H), 1.70 (m, 1H), 1.66 – 1.60 (m, 1H), 1.52 – 1.46 (m, 
1H), 1.45 – 1.37 (m, 1H), 1.34 – 1.25 (m, 12H), 0.89 (t, J = 6.9 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 146.3, 138.2, 128.7, 128.1, 127.9, 104.3, 76.5, 74.8, 73.6, 68.4, 38.5, 35.3, 32.1, 29.8, 
29.7, 29.5, 25.4, 22.9, 14.3; [α]D20 +40.8 (c 1.02, CHCl3); IR (thin film) 3437, 2926, 2856, 1644, 
1455, 1239, 1097 cm-1; HRMS (ASAP) calcd for C21H31O2[M–OH]+: 315.2324, found: 315.2352.  
 
 
 
 (2S,4S)-2-((Benzyloxy)methyl)-4-methyl-3,4-dihydro-2H-pyran-4-ol 
(2.85) 
Formed as a 17:1 mixture of diastereomers. Major diastereomer: 1H NMR 
(500 MHz, CDCl3) δ 7.30 – 7.25 (m, 4H), 7.25 – 7.20 (m, 1H), 6.27 (d, J = 6.2 Hz, 1H), 4.68 
(dd, J = 6.2, 1.6 Hz, 1H), 4.55 – 4.52 (m, 3H), 4.07 (ddt, J = 9.5, 5.5, 3.6 Hz, 1H), 3.55 (qd, J = 
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10.4, 4.8 Hz, 2H), 1.91 (ddd, J = 13.5, 3.4, 1.6 Hz, 1H), 1.85 (dd, J = 13.5, 10.0 Hz, 1H), 1.30 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ 143.7, 138.0, 128.7, 128.0, 109.4, 107.4, 74.1, 73.8, 72.6, 
65.9, 40.8, 30.3; IR (thin film) 3424, 2924, 1644, 1595, 1454, 1367, 1236, 1099, 1073, 1046, 
920, 748, 699 cm–1; HRMS (ASAP) calcd for C14H17O3 [M–H]+: 233.1178, found: 233.1179. 
 
 (2R)-2-Octyl-4-phenyl-3,4-dihydro-2H-pyran-4-ol (2.86) 
1H NMR (601 MHz, CDCl3) δ 7.61 – 7.58 (m, 2H), 7.38 – 7.35 (m, 2H), 7.30 – 
7.27  (m, 1H), 6.61 (d, J = 6.2 Hz, 1H), 4.84 (dd, J = 6.2, 2.1 Hz, 1H), 3.72 – 
3.67 (m, 1H), 2.18 – 2.06 (m, 2H), 1.62 – 1.55 (m, 1H), 1.46 – 1.34 (m, 2H), 1.29 – 1.20 (m, 
11H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 147.6, 145.6, 128.4, 127.7, 126.6, 
106.4, 74.1, 71.4, 45.2, 35.2, 32.0, 29.8, 29.7, 29.4, 25.3, 22.9, 14.3; IR (thin film) 3367, 2926, 
2855, 1644, 1448, 1239, 1034, 759, 701 cm-1; HRMS (ASAP) calcd for C19H27O [M–OH]+: 
271.2062, found: 217.2056. 
 
 
 
 (2R,4R)-4-Methyl-2-phenyl-3,4-dihydro-2H-thiopyran-4-ol (2.88) 
This compound was formed as a 6:1 mixture of diastereomers. It is unstable and 
should not be stored for prolonged periods. Major diastereomer: 1H NMR (500 
MHz, CDCl3) δ 7.36 – 7.25 (m, 4H), 7.25 – 7.20 (m, 1H), 6.06 (d, J = 10.2 Hz, 1H), 5.69 (dd, J 
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= 10.2, 1.2 Hz, 1H), 4.32 (dd, J = 12.5, 2.6 Hz, 1H), 2.33 (m, 1H), 2.23 (ddd, J = 13.1, 2.6, 1.2 
Hz, 1H), 1.36 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 140.7, 129.2, 128.2, 128.2, 127.9, 121.4, 
70.3, 45.9, 44.5, 29.5; HRMS (ASAP) calcd for C12H13S [M–OH]+: 189.0738, found: 189.0730; 
IR (thin film) 3368, 3028, 2969, 2927, 1666, 1603, 1494, 1452, 1371, 1115, 699 cm–1.  
 
 
 
Trimethyl(2-methylene-5-((trimethylsilyl)oxy)pentyl)silane 
(2.90) 
1H NMR (601 MHz, CDCl3) δ 4.59 (s, 1H), 4.52 (s, 1H), 3.58 (dd, J = 8.3, 5.0 Hz, 2H), 2.00 – 
1.97 (m, 2H), 1.67 (dt, J = 15.4, 6.7 Hz, 2H), 1.53 (s, 2H), 0.11 (s, 9H), 0.02 (s, 9H); 13C NMR 
(151 MHz, CDCl3) δ 147.5, 107.1, 62.6, 34.6, 31.1, 27.2, –0.2, –1.1; IR (thin film) 2955, 1634, 
1417, 1250, 1157, 1099, 981, 960, 841, 748, 693, 657 cm–1; HRMS (ASAP) calcd for 
C12H29OSi2 [M+H]+: 245.1757, found: 245.1761. 
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  (S)-Triethyl((2-methyl-3-((trimethylsilyl)methyl)but-3-en-1-yl)oxy)silane 
(2.91) 
1H NMR (601 MHz, CDCl3) δ 4.60 (s, 1H), 4.58 (s, 1H), 3.66 (dd, J = 9.8, 5.0 
Hz, 1H), 3.31 (dd, J = 9.7, 8.4 Hz, 1H), 2.10 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H), 0.96 (t, J = 8.0 
Hz, 9H), 0.60 (q, J = 7.9 Hz, 6H), 0.02 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 150.2, 106.4, 
67.9, 43.8, 27.4, 16.9, 7.0, 4.7, –1.1; [α]D20 –16.2 (c 0.9, CHCl3). IR (thin film) 2956, 2912, 2878, 
1632, 1460, 1416, 1248, 1080, 1014, 855, 743 cm–1; HRMS (ASAP) calcd for C14H31OSi2 [M-
CH3]+: 271.1913, found: 271.1909. 
 
 
 
 (S)-3,3,8,8-Tetraethyl-5-(2-((trimethylsilyl)methyl)allyl)-
4,7-dioxa-3,8-disiladecane (2.92) 
1H NMR (601 MHz, CDCl3) δ 4.64 (s, 1H), 4.57 (s, 1H), 3.80 (dq, J = 7.0, 5.6 Hz, 1H), 3.50 (dd, 
J = 10.0, 5.7 Hz, 1H), 3.45 (dd, J = 10.0, 5.8 Hz, 1H), 2.25 (ddd, J = 13.7, 5.2, 1.0 Hz, 1H), 2.00 
(dd, J = 13.7, 7.1 Hz, 1H), 1.54 (s, 2H), 0.99 – 0.91 (m, 18H), 0.62 – 0.57 (m, 12H), 0.02 (s, 9H); 
13C NMR (151 MHz, CDCl3) δ 144.5, 110.1, 72.6, 67.2, 43.6, 27.3, 7.0, 5.3, 4.6, –1.2; [α]D20 
+0.9 (c 0.76, CHCl3); IR (thin film) 2955, 2912, 2878, 1633, 1459, 1415, 1247, 1113, 1077, 
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1006, 856, 742 cm–1; HRMS (ASAP) calcd for C21H49O2Si3 [M+H]+: 417.3040, found: 
417.3058.  
 
 
 
Triethyl((2-methyl-4-((trimethylsilyl)methyl)pent-4-en-2-
yl)oxy)silane (2.93)  
1H NMR (601 MHz, CDCl3) δ 4.61 (s, 1H), 4.56 (s, 1H), 2.10 (s, 2H), 1.54 (s, 2H), 1.22 (s, 6H), 
0.99 – 0.91 (m, 9H), 0.62 – 0.54 (m, 6H), 0.01 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 145.4, 
111.0, 74.3, 53.0, 30.4, 28.2, 7.3, 7.0, –1.2; IR (thin film) 2956, 2912, 2878, 1629, 1460, 1416, 
1380, 1364, 1247, 1150, 1043, 1007, 851, 742 cm–1; HRMS (ASAP) calcd for C14H31OSi2 [M–
CH2CH3]+: 271.1913, found: 271.1927.  
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 (S)-Trimethyl(2-methylene-4-((trimethylsilyl)oxy)hept-5-yn-1-
yl)silane (2.94) 
1H NMR (500 MHz, CDCl3) δ 4.66 (s, 1H), 4.60 (s, 1H), 4.39 (dd, J = 
6.8, 2.0 Hz, 1H), 2.32 – 2.22 (m, 2H), 1.80 (s, 3H), 1.55 (s, 2H), 0.13 (s, 9H), 0.00 (s, 9H); 13C 
NMR (126 MHz, CDCl3) δ 143.7, 110.3, 81.1, 80.7, 62.8, 47.8, 27.6, 3.9, 0.5, -1.1. [α]D20 –34.1 
(c 0.83, CHCl3); IR (thin film, neat) 2956, 2921, 1634, 1419, 1343, 1250, 1158, 1083, 945, 844, 
754, 693 cm-1; HRMS (ASAP) calcd for C14H29OSi2 [M+H]+: 269.1757, found: 269.1769. 
 
1H NMR (500 MHz, CDCl3) δ 7.54 (m, 2H), 7.41 – 7.36 (m, 3H), 
5.93 (m, 1H), 4.11 – 4.00 (m, 2H), 3.58 (s, 3H), 2.85 (dd, J = 16.4, 9.2 
Hz, 1H), 2.76 (dd, J = 16.4, 4.7 Hz, 1H), 1.86 (d, J = 2.1 Hz, 3H), 
1.18 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 168.9, 165.6, 132.6, 129.9, 128.6, 127.8, 
123.52 (q, 1JC-F = 288.5 Hz, CF3), 84.7 (q, 2JC-F = 28.0 Hz), 84.2, 74.7, 62.9, 61.3, 55.8, 40.3, 
14.3, 3.9. The dr of this (S)-Mosher ester6 was found to be > 95:5 by both 1H and 19F NMR 
analysis. [δ –71.73 (major) and δ –71.86 (minor), in CDCl3]. 
 
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.50 (m, 2H), 7.42 – 7.37 (m, 
3H), 5.89 (ddq, J = 8.8, 4.3, 2.1 Hz, 1H), 4.18 – 4.09 (m, 2H), 3.54 (s, 
3H), 2.91 (dd, J = 16.6, 9.5 Hz, 1H), 2.79 (dd, J = 16.6, 4.4 Hz, 1H), 
1.82 (d, J = 2.1 Hz, 3H), 1.23 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.2, 165.7, 
                                                 
6 Dale, J. A.; Mosher, H. S. J. Am. Chem. Soc. 1973, 95, 512. 
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132.4, 129.9, 128.6, 127.8, 123.4 (q, 1JC-F = 288.6 Hz, CF3), 85.0 (dd, 2JC-F = 55.3, 27.6 Hz), 
84.1, 74.4, 63.1, 61.4, 55.9, 40.1, 14.4, 3.8. The dr of this (R)-Mosher ester was found to be > 
95:5 by both 1H and 19F NMR analysis. [δ –71.73 (minor) and δ –71.85 (major), in CDCl3]. 
 
 
 
 (R)-Trimethyl(2-methylene-6-phenyl-4-
((trimethylsilyl)oxy)hexyl)silane (2.95) 
1H NMR (500 MHz, CDCl3): δ 7.29 – 7.26 (m, 2H), 7.20 – 7.16 (m, 
3H), 4.63 (s, 1H), 4.57 (s, 1H), 3.84 (m, 1H), 2.76 (ddd, J = 13.3, 11.3, 5.4 Hz, 1H), 2.57 (ddd, J 
= 13.4, 11.1, 5.4 Hz, 1H), 2.18 (dd, J = 13.5, 6.2 Hz, 1H), 2.12 (dd, J = 13.6, 6.6 Hz, 1H), 1.84 
(m, 1H), 1.74 – 1.66 (m, 1H), 1.52 (s, 2H), 0.13 (s, 9H), 0.03 (s, 9H); 13C NMR (151 MHz, 
CDCl3) δ 144.5, 142.8, 128.7, 128.6, 126.0, 110.3, 71.6, 47.0, 39.2, 32.5, 27.5, 0.8, –1.0; IR (thin 
film) 3067, 3028, 2954, 1632, 1496, 1454, 1368, 1250, 1155, 1091, 1063, 986, 841, 748, 698 
cm–1; [α]D20 +3.8 (c 0.42, CHCl3); HRMS (ASAP) calcd for C18H31SiO2 [M-CH3]+: 319.1913, 
found: 319.1924. Mosher ester analysis (see below) show the compound to have an ee of 74%. 
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Major diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.49 (dd, J = 
6.2, 3.2 Hz, 2H), 7.35 – 7.33 (m, 3H), 7.21 (dd, J = 15.2, 7.8 Hz, 
3H), 7.14 (d, J = 7.5 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 5.45 (dq, 
J = 7.3, 5.1 Hz, 1H), 3.52 (s, 3H), 3.47 (s, 3H), 2.66 – 2.52 (m, 4H), 2.06 – 1.87 (m, 2H); 13C 
NMR (126 MHz, CDCl3) δ 170.4, 166.2, 140.9, 132.4, 129.9, 128.9, 128.7, 128.6, 127.8, 126.6, 
123.6 (q, JC-F = 289.2 Hz), 84.9, 73.3, 55.7, 52.1, 38.7, 35.9, 31.7; 19F NMR (CDCl3) δ –71.24 
(minor) and δ –71.36 (major). The dr of this (S)-Mosher ester was found to be 1.0:0.15 by both 
1H and 19F NMR analyses.  
 
Major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.44 
(m, 2H), 7.39 – 7.29 (m, 2H), 7.24 – 7.15 (m, 3H), 7.15 – 7.10 
(m, 1H), 7.01 – 6.98 (m, 2H), 5.45 (tt, J = 6.7, 5.1 Hz, 1H), 3.59 
(s, 3H), 3.49 (s, 3H), 2.68 (dd, J = 16.0, 7.9 Hz, 1H), 2.57 (dd, J = 15.9, 4.9 Hz, 1H), 2.45 (dt, J 
= 7.8, 6.2 Hz, 2H), 1.94 – 1.87 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 170.6, 166.3, 140.9, 
132.6, 130.0, 128.8, 128.7, 128.5, 127.7, 126.5, 123.5 (q, JC-F = 289.3 Hz), 84.9, 73.2, 55.8, 52.2, 
38.9, 35.8, 31.3; 19F NMR (CDCl3) δ  –71.23 (major) and δ –71.36 (minor). The dr of this (R)-
Mosher ester was found to be 1.0:0.15 by both 1H and 19F NMR analysis. 
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2,2,8,8-Tetramethyl-4-methylene-3,7-dioxa-2,8-disilanonane (2.96) 
1H NMR (400 MHz, CDCl3) δ 4.08 (s, 1H), 4.07 (s, 1H), 3.71 (t, J = 7.1 Hz, 
2H), 2.26 (t, J = 7.1 Hz, 2H), 0.20 (s, 9H), 0.11 (s, 9H). These data are consistent with literature 
values.7  
 
General protocol for Ferrier reaction-based [n+1] annulations 
 
To a solution of the tetrahydropyranol (1 equiv) and allylsilane (1.5 equiv) in CH2Cl2 (~0.15 M) 
under nitrogen was added TMSOTf (2-5 mol%, 0.1 M solution in CH2Cl2 stored over NaHCO3) 
dropwise at rt. Upon stirring for 45 min, the reaction was quenched by adding of a saturated 
aqueous solution of NaHCO3 (1.2 equiv). After stirring for 30 min, 4Å MS (150 wt%) was added 
and stirred for another 30 min. DDQ (5.0-8.0 equiv) was added portion-wise. The reaction was 
monitored by TLC and quenched by Et3N upon complete consumption of starting material. After 
concentration under vacuum, the reaction was purified by flash column chromatography to give 
the desired product.  
 
 (7R)-9-Methyl-3-methylene-7-octyl-1,6-dioxaspiro[4.5]dec-9-ene 
(2.97) 
The general cyclization procedure was followed with 2.89 (29 mg, 0.13 
mmol), 2.77 (20 mg, 0.09 mmol), TMSOTf (2 mol%, 20 μL, 1.8 μmol), NaHCO3 (sat) (30 μL, 
                                                 
7 Martin, V. A.; Murray, D. H.; Pratt, N. E.; Zhao, Y. B.; Albizati, K. F. J. Am. Chem. Soc. 1990, 112, 6965. 
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0.03 mmol), 4Å MS (45 mg), dichloromethane (0.9 mL), and DDQ (120 mg, 0.53 mmol). The 
oxidation proceeded at 0 °C for 5 h. The crude mixture was purified by flash chromatography 
(10% EtOAc in hexane) to give the desired product (17 mg, 68%) as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 5.41 (s, 1H), 4.99 (s, 1H), 4.92 (s, 1H), 4.38 (ABq, 2H, ΔδAB = 0.008, JAB = 
2.0 Hz), 3.89 (ddd, J = 11.5, 8.1, 4.1 Hz, 1H), 2.57 (ABq, 2H, ΔδAB = 0.01, JAB = 2.4 Hz), 1.93 – 
1.76 (m, 2H), 1.74 (s, 3H), 1.58 – 1.49 (m, 1H), 1.49 – 1.39 (m, 2H), 1.35 – 1.24 (m, 11H), 0.88 
(t, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 147.6, 138.9, 121.8, 104.6, 104.2, 69.6, 68.6, 
44.7, 35.7, 35.5, 32.1, 29.8, 29.7, 29.5, 25.8, 23.0, 22.9, 14.3. ); IR (thin film) 2926, 2856, 1673, 
1459, 1379, 1323, 1225, 1459, 1102, 1025, 1001, 968, 880, 861 cm–1; HRMS (ASAP) calcd for 
C18H31O2 [M+H]+: 279.2324, found: 279.2319.  
 
 (2R,6S,9S)-4,9-Dimethyl-10-methylene-2-octyl-1,7-
dioxaspiro[5.5]undec-4-ene (2.98) 
The general cyclization procedure was followed with 2.91 (42 mg, 0.15 
mmol), 2.77 (30 mg, 0.13 mmol), TMSOTf (5 mol%, 70 μL, 7.0 μmol), NaHCO3 (sat) (140 μL, 
0.14 mmol), 4Å MS (210 mg), dichloromethane (1.5 mL), and DDQ (60 mg, 0.26 mmol). The 
oxidation proceeded at rt for 1.5 h. The crude mixture was purified by flash chromatography 
(10% EtOAc in hexane) to give the desired product (25 mg, 61%) as a colorless oil. 1H NMR 
(601 MHz, CDCl3) δ 5.38 (s, 1H), 4.79 (s, 1H), 4.75 (s, 1H), 3.80 (ddt, J = 11.7, 8.2, 3.9 Hz, 
1H), 3.57 (dd, J = 10.4, 5.5 Hz, 1H), 3.37 (t, J = 10.9 Hz, 1H), 2.33 (ABq, 2H, ΔδAB = 0.04, JAB 
= 13.2 Hz), 1.86 (dd, J = 17.2, 11.0 Hz, 1H), 1.78 (dd, J = 17.2, 3.6 Hz, 1H), 1.58 – 1.51 (m, 
1H), 1.48 – 1.40 (m, 2H), 1.32 – 1.22 (m, 11H), 0.98 (d, J = 6.6 Hz, 3H), 0.87 (t, J = 6.9 Hz, 
3H); 13C NMR (151 MHz, CDCl3) δ 146.2, 137.5, 124.0, 107.7, 96.2, 67.7, 67.6, 45.4, 36.0, 36.0, 
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35.7, 32.2, 29.9, 29.9, 29.6, 26.0, 23.1, 23.0, 14.4, 12.9; [α]D20 +28.6 (c 2.97, CHCl3); IR (thin 
film) 3085, 2927, 2856, 1682, 1654, 1458, 1380, 1248, 1220, 1174, 1042, 1010, 887, 621 cm–1; 
HRMS (ASAP) calcd for C20H35O2 [M+H]+: 307.2637, found: 307.2622. 
 
  (2R,6R)-4,8,8-Trimethyl-10-methylene-2-octyl-1,7-
dioxaspiro[5.5]undec-4-ene (2.99) 
The general cyclization procedure was followed with 2.77 (30 mg, 0.13 
mmol), 2.93 (52 mg, 0.17 mmol), TMSOTf (7.5 mol%, 70 μL, 7.0 μmol), NaHCO3 (sat) (140 
μL, 0.14 mmol), 4Å MS (210 mg), dichloromethane (2.0 mL), and DDQ (90 mg, 0.40 mmol). 
The oxidation proceeded at 0 °C for 1.5 h. The crude mixture was purified by flash 
chromatography (5% EtOAc in hexane) to give the desired product (19 mg, 44%) as a colorless 
oil. 1H NMR (601 MHz, CDCl3) δ 5.32 (s, 1H), 4.88 (s, 1H), 4.82 (s, 1H), 3.90 (ddt, J = 9.2, 7.6, 
5.3 Hz, 1H), 2.34 – 2.24 (m, 3H), 2.16 (d, J = 13.2 Hz, 1H), 1.83 – 1.79 (m, 2H), 1.70 (s, 3H), 
1.31 – 1.23 (m, 20H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 140.5, 136.5, 
125.6, 111.1, 96.9, 74.3, 67.9, 45.6, 44.1, 35.6, 35.3, 32.1, 31.9, 30.0, 29.7, 29.5, 27.7, 25.6, 23.2, 
22.9, 14.3; IR (thin film) 2926, 2855, 1466, 1379, 1223, 1155, 1024, 1007, 984 cm–1; HRMS 
(EI) calcd for C21H37O2 [M+H]+: 321.2788, found: 321.2793. 
 
 (2R,6S,8R)-4-Methyl-10-methylene-2-octyl-8-phenethyl-1,7-
dioxaspiro[5.5]undec-4-ene (2.100)  
The general cyclization procedure was followed with 2.95 (53 mg, 
0.16 mmol), 2.77 (30 mg, 0.13 mmol), TMSOTf (2 mol%, 30 μL, 
2.7 μmol), NaHCO3 (sat) (50 μL, 0.05 mmol), 4Å MS (75 mg), dichloromethane (1.3 mL), and 
DDQ (150 mg, 0.66 mmol). The oxidation proceeded for 2 h. The crude mixture was purified by 
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flash chromatography (5% EtOAc in hexane) to give the desired product (39 mg, 74%) as a 6:1 
mixture of diastereomers resulting from the use of an allylsilane with an ee of 74%. Rigorous 
separation of diastereomers provided pure product (26 mg, 49%) as a colorless oil. 1H NMR (601 
MHz, CDCl3) δ 7.29 (dd, J = 8.8, 6.2 Hz, 2H), 7.24 – 7.18 (m, 3H), 5.45 (s, 1H), 4.81 (s, 1H), 
4.79 (s, 1H), 3.83 (m, 2H), 2.86 (ddd, J = 14.0, 10.4, 5.6 Hz, 1H), 2.65 (ddd, J = 14.0, 10.2, 6.1 
Hz, 1H), 2.31 (s, 2H), 2.28 (dd, J = 13.2, 2.4 Hz, 1H), 2.02 (dd, J = 13.5, 11.3 Hz, 1H), 1.95 – 
1.87 (m, 2H), 1.84 (dd, J = 17.8, 4.3 Hz, 2H), 1.76 (s, 3H), 1.34 – 1.27 (m, 14H), 0.90 (t, J = 6.8 
Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 142.4, 142.0, 137.2, 128.5, 128.5, 125.9, 124.4, 110.1, 
96.0, 70.2, 67.8, 44.3, 40.1, 37.7, 35.9, 35.6, 32.3, 32.1, 30.0, 29.8, 29.6, 26.0, 23.1, 22.9, 14.3; 
[α]D20 +3.4 (c 1.41, CHCl3); IR (thin film) 2927, 2855, 1656, 1455, 1379, 1237, 1112, 994, 887, 
699 cm-1; HRMS (ASAP) calcd for C27H41O2 [M+H]+: 397.3107, found: 397.3089.  
 
(2R,6R,8R)-10-methylene-2-octyl-8-phenethyl-1,7-
dioxaspiro[5.5]undec-4-ene (2.101) 
The general cyclization procedure was followed with 2.95 (57 mg, 
0.17 mmol), 2.79 (30 mg, 0.14 mmol), TMSOTf (2 mol%, 30 μL, 2.8 μmol), NaHCO3 (sat) (50 
μL, 0.05 mmol), 4Å MS (75 mg), dichloromethane (1.4 mL), and DDQ (160 mg, 0.70 mmol). 
The oxidation proceeded for 2.5 h. The crude mixture was purified by flash chromatography (5% 
EtOAc in hexane) to give the desired product (21 mg, 39%) as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.29 – 7.24 (m, 3H), 7.22 – 7.16 (m, 2H), 5.96 (ddd, J = 9.9, 5.3, 2.4 Hz, 1H), 
5.69 (dt, J = 9.9, 2.1 Hz, 1H), 4.79 (d, J = 8.3 Hz, 1H), 3.87 – 3.77 (m, 1H), 2.85 (ddd, J = 13.9, 
10.4, 5.6 Hz, 1H), 2.63 (ddd, J = 14.0, 10.1, 6.2 Hz, 1H), 2.31 (s, 2H), 2.26 (dd, J = 13.2, 2.5 Hz, 
1H), 2.05 – 1.85 (m, 3H), 1.84 – 1.74 (m, 2H), 1.28 – 1.25 (m, 14H), 0.87 (t, J = 6.6 Hz, 3H). 13C 
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NMR (101 MHz, CDCl3) δ 142.4, 141.7, 130.2, 128.7, 128.5, 128.5, 125.9, 110.3, 95.6, 70.1, 
67.6, 44.0, 40.1, 37.8, 35.7, 32.3, 32.1, 30.9, 30.0, 29.8, 29.6, 25.9, 22.9, 14.3. [α]D20 +9.7 (c 
0.64, CHCl3); IR (thin film, neat) 2926, 2855, 1656, 1455, 1240, 1088, 1000, 887, 700 cm-1. 
HRMS (EI) calcd for C26H38O2 [M+H] +: 383.2950, found: 383.2952. 
 
 ((2R,6R,8R)-10-Methyl-4-methylene-8-octyl-1,7-
dioxaspiro[5.5]undec-10-en-2-yl)methanol (2.102) 
The general cyclization procedure was followed with 2.77 (30 mg, 0.13 
mmol), 2.92 (83 mg, 0.20 mmol), TMSOTf (5 mol%, 70 μL, 7.0 μmol), 
NaHCO3 (sat) (140 μL, 0.14 mmol), 4Å MS (210 mg), dichloromethane (1.9 mL), and DDQ 
(150 mg, 0.66 mmol). The oxidation proceeded for 2 h. The crude mixture was purified by flash 
chromatography (25% EtOAc in hexane) to give the desired product (25 mg, 58%) as a colorless 
oil. 1H NMR (601 MHz, CDCl3) δ 5.39 (s, 1H), 4.83 (s, 1H), 4.80 (s, 1H), 3.87 (ddd, J = 13.9, 
6.4, 3.3 Hz, 1H), 3.80 (ddt, J = 11.7, 8.1, 3.9 Hz, 1H), 3.66 (dd, J = 11.6, 3.1 Hz, 1H), 3.56 (dd, J 
= 11.5, 6.3 Hz, 1H), 2.28 (s, 2H), 2.17 – 2.09 (m, 2H), 1.91 – 1.78 (m, 2H), 1.73 (s, 3H), 1.31 – 
1.24 (m, 14H), 0.87 (t, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 141.0, 137.6, 123.9, 
110.9, 96.1, 71.2, 67.8, 66.1, 44.3, 35.8, 35.6, 35.4, 32.1, 29.8, 29.8, 29.5, 25.9, 23.0, 22.9, 14.3; 
[α]D20 +3.8 (c 1.2, CHCl3); IR (thin film) 3468, 2926, 2855, 1681, 1657, 1457, 1379, 1236, 1164, 
1097, 1042, 992, 936, 887, 856 cm–1; HRMS (EI) calcd for C20H35O3 [M+H]+: 323.2581, found: 
323.2590.  
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 (2R,6S)-4-((Benzyloxy)methyl)-10-methylene-2-octyl-1,7-
dioxaspiro[5.5]undec-4-ene (2.103) 
The general cyclization procedure was followed with 2.73 (28 mg, 0.12 
mmol), 2.84 (20 mg, 0.06 mmol), TMSOTf (1 mol%, 6 μL, 0.6 μmol), NaHCO3 (sat) (10 μL, 
0.01 mmol), 4Å MS (15 mg), dichloromethane (600 μL), and DDQ (102 mg, 0.45 mmol). The 
oxidation proceeded for 2 h. The crude mixture was purified by flash chromatography (5% 
EtOAc in hexane) to give the desired product (15 mg, 61%) as a colorless oil. 1H NMR (500 
MHz, CDCl3) δ 7.36 – 7.31 (m, 4H), 7.30 – 7.26 (m, 1H), 5.70 (s, 1H), 4.81 (s, 1H), 4.77 (s, 1H), 
4.49 (s, 2H), 3.95 (s, 2H), 3.88 – 3.80 (m, 2H), 3.72 (ddd, J = 10.6, 5.9, 1.7 Hz, 1H), 2.41 – 2.28 
(m, 3H), 2.18 (ddd, J = 13.3, 3.9, 2.0 Hz, 1H), 1.98 – 1.87 (m, 2H), 1.37 – 1.18 (m, 14H), 0.88 (t, 
J = 6.7 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 141.4, 138.4, 137.8, 128.6, 127.9, 127.8, 125.6, 
110.4, 95.6, 77.4, 73.0, 72.3, 67.8, 61.5, 44.5, 35.6, 34.2, 32.1, 31.7, 29.8, 29.8, 29.5, 25.9, 22.9; 
IR (thin film) 2985, 2934, 2857, 1736, 1370, 1332, 1271, 1151, 1036 cm–1; HRMS (EI) calcd for 
C26H39O3 [M+H]+: 399.2894, found: 399.2907. 
 
 (2R,6R,8S)-4-((benzyloxy)methyl)-10-methylene-2-octyl-8-(prop-1-
yn-1-yl)-1,7-dioxaspiro[5.5]undec-4-ene (2.104) 
The general cyclization procedure was followed with 2.94 (41 mg, 0.15 
mmol), 2.84 (48 mg, 0.15 mmol), TMSOTf (5 mol%, 75 μL, 7.5 μmol), 
NaHCO3 (sat) (150 μL, 0.15 mmol), 4Å MS (220 mg), dichloromethane 
(2.5 mL) and DDQ (102 mg, 0.45 mmol). The reaction was stirred at rt for 2 h and then 
quenched by Et3N. The crude mixture was purified by flash chromatography (5% EtOAc in 
hexane) to give the desired product (26 mg, 41%) as a colorless oil. 1H NMR (500 MHz, CDCl3) 
δ 7.37 – 7.30 (m, 4H), 7.30 – 7.27 (m, 1H), 5.70 (s, 1H), 4.84 (d, J = 1.9 Hz, 1H), 4.80 (d, J = 1.9 
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Hz, 1H), 4.50 (t, J = 2.5 Hz, 1H), 4.48 (s, 2H), 3.94 (s, 2H), 3.89 (tt, J = 9.3, 4.8 Hz, 1H), 2.47 – 
2.32 (m, 3H), 2.29 – 2.23 (m, 1H), 1.92 (dd, J = 8.1, 3.1 Hz, 2H), 1.85 (d, J = 2.1 Hz, 3H), 1.61 – 
1.52 (m, 1H), 1.50 – 1.41 (m, 2H), 1.34 – 1.23 (m, 11H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 140.2, 138.4, 137.9, 128.6, 127.8, 127.8, 125.3, 111.4, 96.0, 81.1, 78.7, 73.0, 
72.4, 67.9, 61.7, 43.8, 40.9, 35.5, 32.1, 31.6, 29.8, 29.5, 25.8, 22.9, 14.3, 4.0. [α]D20 -24.5 (c 1.2, 
CHCl3); IR (thin film, neat) 2926, 2855, 1723, 1657, 1454, 1356, 1260, 1165, 1113, 1036, 985, 
738, 698 cm-1. HRMS (APCI) calcd for C29H41O3 [M+H] +: 437.3056, found: 437.3045. 
 
 (2R,6S,8R)-4-((Benzyloxy)methyl)-10-methylene-2-octyl-8-
phenethyl-1,7-dioxaspiro[5.5]undec-4-ene (2.105) 
The general cyclization procedure was followed with 2.95 (36 mg, 
0.11 mmol), 2.84 (30 mg, 0.09 mmol), TMSOTf (2 mol%, 20 μL, 
1.8 μmol), NaHCO3 (sat) (30 μL, 0.03 mmol), 4Å MS (45 mg), dichloromethane (0.9 mL) and 
DDQ (154 mg, 0.68 mmol). The oxidation proceeded for 2 h. The crude mixture was purified by 
flash chromatography (10% EtOAc in hexane) to give the desired product (23 mg, 51%) as a 
colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.40 – 7.36 (m, 4H), 7.35 – 7.27 (m, 3H), 7.25 – 
7.18 (m, 3H), 5.73 (s, 1H), 4.83 (s, 1H), 4.81 (s, 1H), 4.54 (ABq, 2H, ∆δAB = 0.01, J = 2.0 Hz), 
4.00 (s, 2H), 3.93 – 3.80 (m, 2H), 2.87 (ddd, J = 13.9, 10.3, 5.7 Hz, 1H), 2.66 (ddd, J = 13.9, 
10.0, 6.2 Hz, 1H), 2.35 (s, 2H), 2.30 (dd, J = 13.4, 2.5 Hz, 1H), 2.09 – 1.76 (m, 5H), 1.53 – 1.41 
(m, 2H), 1.36 – 1.26 (m, 12H), 0.91 (t, J = 6.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 142.4, 
141.7, 138.4, 137.5, 128.6, 128.5, 128.0, 127.9, 126.2, 125.9, 110.3, 95.8, 73.2, 72.4, 70.2, 67.8, 
44.2, 40.1, 37.8, 35.6, 32.3, 32.1, 31.8, 30.0, 29.9, 29.8, 29.6, 26.0, 22.9, 14.3; [α]D20 –2.3 (c 
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1.67, CHCl3); IR (thin film) 2927, 2855, 1746, 1456, 1253, 1176, 1111, 1068, 1017, 888 cm–1; 
HRMS (ASAP) calcd for C34H47O3 [M+H]+: 503.3525, found: 503.3527.  
 
 (2R,6S)-11-Methylene-2-octyl-4-phenyl-1,7-dioxaspiro[5.6]dodec-4-
ene (2.106) 
The general cyclization procedure was followed with 2.86 (30 mg, 0.10 
mmol), 2.90 (33 mg, 0.14 mmol), TMSOTf (3 mol%, 30 μL, 2.7 μmol), 
NaHCO3 (sat) (45 μL, 0.05 mmol), 4Å MS (68 mg), dichloromethane (1.0 mL), and DDQ (24 
mg, 0.10 mmol). The oxidation proceeded at 0 °C for 1 h. The crude mixture was purified by 
flash chromatography (5% EtOAc in hexane) to give the desired product (23 mg, 59%) as a 
colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.40 (m, 2H), 7.35 – 7.31 (m, 2H), 7.29 – 
7.24 (m, 1H), 6.24 (s, 1H), 4.94 (s, 1H), 4.82 (s, 1H), 4.06 – 4.00 (m, 2H, 3.69 (ddd, J = 12.8, 
4.1, 2.7 Hz, 1H), 2.61 (ABq, 2H, ΔδAB = 0.09, JAB = 14.3 Hz), 2.48 (dt, J = 13.4, 3.8 Hz, 2H), 
2.31 (dd, J = 7.2, 1.6 Hz, 2H), 1.78 – 1.71 (m, 2H), 1.70 – 1.62 (m, 2H), 1.38 – 1.23 (m, 12H), 
0.89 (t, J = 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.4, 140.4, 136.3, 128.6, 127.8, 125.5, 
124.7, 114.4, 97.6, 68.1, 62.1, 47.0, 37.8, 35.7, 33.4, 32.1, 30.6, 29.9, 29.8, 29.6, 25.9, 22.9, 14.3. 
IR (thin film, neat) 2927, 2855, 1720, 1449, 1097, 1040, 698 cm-1; HRMS (ESI) calcd for 
C25H37O2 [M+H]+: 369.27881, found: 369.27921.  
 
 (6S,8R)-8-Octyl-10-phenyl-1,7-dioxaspiro[5.5]undec-10-en-4-one 
(2.107) 
The general cyclization procedure was followed with 2.96 (50 mg, 0.22 
mmol), 2.86 (50 mg, 0.17 mmol), TMSOTf (2 mol%, 35 μL, 3.5 μmol), 
NaHCO3 (sat) (70 μL, 0.07 mmol), 4Å MS (100 mg), dichloromethane (1.7 mL) and DDQ (58 
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mg, 0.26 mmol). The oxidation proceeded at rt for 1.5 h. The crude mixture was purified by flash 
chromatography (15% EtOAc in hexane) to give the desired product (41 mg, 66%) as a white 
solid (mp = 97.5 – 99.5 °C). 1H NMR (400 MHz, CDCl3) δ 7.41 (m, 2H), 7.38 – 7.34 (m, 1H), 
7.34 – 7.29 (m, 2H), 6.04 (s, 1H), 4.14 (td, J = 11.6, 3.1 Hz, 1H), 4.05 (ddd, J = 11.1, 7.9, 1.3 
Hz, 1H), 3.95 (m, 1H), 2.70 – 2.60 (m, 2H), 2.52 (dd, J = 14.2, 1.9 Hz, 1H), 2.42 – 2.33 (m, 3H), 
1.71 – 1.59 (m, 1H), 1.56 – 1.46 (m, 1H), 1.31 – 1.25 (m, 12H), 0.88 (t, J = 6.7 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 205.4, 139.7, 139.5, 128.7, 128.5, 125.51, 123.2, 98.8, 68.7, 59.7, 
52.1, 41.3, 35.5, 32.7, 32.1, 29.8, 29.8, 29.5, 25.9, 22.9, 14.3; mp: 97.5–99.5 °C; IR (thin film) 
2925, 2850, 1716, 1467, 1314, 1247, 1158, 1059, 1011, 954, 873 cm–1; HRMS (EI) calcd for 
C23H33O3 [M+H]+: 357.2424, found: 357.2434; 
 
 (2S,6S)-2-((Benzyloxy)methyl)-4-methyl-10-methylene-1,7-
dioxaspiro[5.5]undec-4-ene (2.108) 
The general cyclization procedure was followed with 2.73 (64 mg, 0.28 
mmol), 2.85 (50 mg, 0.21 mmol), TMSOTf (3 mol%, 65 μL, 6.4 μmol), NaHCO3 (sat) (15 μL, 
0.013 mmol), 4Å MS (25 mg), dichloromethane (2.2 mL), and DDQ (195 mg, 0.85 mmol). The 
oxidation proceeded for 2 h. The crude mixture was purified by flash chromatography (10% 
EtOAc in hexane) to give the desired product (42 mg, 65%) as a colorless oil. 1H NMR (500 
MHz, CDCl3) δ 7.37 – 7.32 (m, 4H), 7.29 – 7.27 (m, 1H), 5.44 (s, 1H), 4.84 (s, 1H), 4.79 (s, 1H), 
4.63 (s, 2H), 4.16 – 4.10 (m, 1H), 3.88 (ddd, J = 12.3, 10.7, 3.0 Hz, 1H), 3.72 (ddd, J = 10.7, 5.9, 
1.6 Hz, 1H), 3.57 (m, 2H), 2.39 – 2.30 (m, 3H), 2.20 – 2.15 (m, 1H), 2.05 – 1.98 (m, 1H), 1.82 
(dd, J = 17.2, 3.6 Hz, 1H), 1.74 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 141.7, 138.8, 136.8, 
128.5, 127.7, 127.6, 123.9, 110.3, 95.8, 73.5, 72.6, 67.6, 61.5, 44.5, 34.1, 32.0, 23.0; IR (thin 
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film) 3070, 3030, 2915, 1680, 1658, 1452, 1379, 1254, 1233, 1173, 1123, 1100, 1017, 987, 889, 
855, 737, 698 cm–1; HRMS (ASAP) calcd for C19H25O3 [M+H]+: 301.1804, found: 301.1792.  
 
 (6S,8S)-10-methyl-4-methylene-8-phenyl-1-oxa-7-
thiaspiro[5.5]undec-10-ene (2.109) 
The general cyclization procedure was followed with 2.73 (51 mg, 0.23 
mmol), 2.88 (40 mg, 0.19 mmol), TMSOTf (2 mol%, 40 μL, 4.0 μmol), NaHCO3 (sat) (80 μL, 
0.08 mmol), 4Å MS (120 mg), dichloromethane (2.0 mL), and DDQ (44 mg, 0.19 mmol). The 
oxidation proceeded at rt for 15 min. The crude mixture was purified by flash chromatography 
(5% EtOAc in hexane) to give the desired product (33 mg, 63%) as a pale yellow oil. 1H NMR 
(601 MHz, CDCl3) δ 7.38 (broad app d, 2H), 7.34 (broad app t, 2H), 7.29 – 7.26 (m, 1H), 5.65 (s, 
1H), 4.84 (s, 1H), 4.81 (s, 1H), 4.23 (td, J = 11.8, 3.1 Hz, 1H), 4.15 (dd, J = 12.2, 3.8 Hz, 1H), 
3.87 (dd, J = 11.1, 6.0 Hz, 1H), 2.62 – 2.52 (m, 3H), 2.45 (dd, J = 17.7, 3.7 Hz, 1H), 2.36 (td, J = 
12.9, 5.8 Hz, 1H), 2.20 (dd, J = 13.6, 2.7 Hz, 1H), 1.86 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
141.5, 140.9, 139.4, 128.8, 127.8, 127.6, 126.2, 111.0, 85.0, 62.8, 47.3, 41.4, 39.6, 34.4, 24.7; IR 
(thin film) 3027, 2948, 2913, 2881, 1656, 1494, 1452, 1376, 1252, 1044, 1009, 980, 1009, 980, 
897, 809, 787, 766, 744, 698, 638 cm–1; HRMS (ASAP) calcd for C17H21OS [M+H]+: 273.1313, 
found: 273.1322. 
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Preparation of an LiDBB (0.4M) solution: A 25 mL 2-neck RBF was charged with 4,4’-di-tert-
butylbiphenyl (DBB) (374 mg, 1.36 mmol) and THF (3.4 mL). To the stirring solution was 
added (0.5 mg) of 1,10-phenanthroline. The mixture was cooled to 0 °C, then n-BuLi was added 
until a red coloration persisted. Active lithium wire (113 mg, 16.3 mmol) was prepared by filing 
away the surface lithium oxide layer under oil followed by rinsing with pentane, and drying with 
a paper towel. The active wire was quickly added into the solution under Ar. The mixture was 
stirred at 0 °C for 3 h to obtain a solution of LiDBB (~0.4M).  
 
((2R,6S)-10-Methylene-2-octyl-1,7-dioxaspiro[5.5]undec-4-en-4-
yl)methanol (2.110) 
Spiroketal 2.103 (14 mg, 0.04 mmol) was dissolved in THF (600 μL). 
The reaction mixture was cooled to –78 °C and the LiDBB (0.4M) solution was added dropwise 
until the green color persisted for >5 min. The mixture was quenched with (500 μL) of NH4Cl, 
then the organic layer extracted with EtOAc (2 x 5 mL) and dried with Na2SO4. The crude 
mixture was purified by flash chromatography (35% EtOAc in hexane) to give the desired 
product (7.8 mg, 72%) as a colorless oil. 1H NMR (601 MHz, CDCl3) δ 5.66 (s, 1H), 4.81 (s, 
1H), 4.77 (s, 1H), 4.07 (ABq, 2H, ΔδAB = 0.03, JAB = 14.0 Hz), 3.86 – 3.78 (m, 2H), 3.72 (dd, J = 
10.8, 5.8 Hz, 1H), 2.33 – 2.38 (m, 1H), 2.33 (ABq, 2H, ΔδAB = 0.05, JAB = 13.5 Hz), 2.18 (d, J = 
13.6 Hz, 1H), 1.94 (dd, J = 17.1, 3.8 Hz, 1H), 1.88 (dd, J = 17.3, 10.5 Hz, 1H), 1.64 – 1.56 (m, 
1H), 1.52 – 1.44 (m, 3H), 1.34 – 1.21 (m, 12H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 141.4, 140.7, 123.8, 110.6, 95.7, 67.9, 66.0, 61.6, 44.6, 35.7, 34.2, 32.2, 31.4, 29.9, 
29.9, 30.0, 26.0, 23.0, 14.4; IR (thin film, neat) 3380, 2926, 2855, 1688, 1659, 1462, 1370, 1333, 
 128 
1254, 1235, 1177, 1107, 1068, 1016, 986, 887, 856 cm-1; HRMS (ASAP) calcd for C19H34O3 
[M+H]+: 309.2430, found: 309.2423. 
 
 
 
Procedure for Pd-catalyzed hydrostannylation: To an oven dried vial fitted with a rubber 
septum was charged Pd(OAc)2 (1 mg, 4 μmol), tricyclohexylphosphine (2.5 mg, 9 μmol) and 
hexane (130 μL). The orange suspension was heated to 50 °C for 5 min to give a clear orange 
solution and subsequently cooled to rt. Alkynal spiroketal 2.104 (9 mg, 0.02 mmol) dissolved in 
(70 μL) of hexane was added dropwise followed dropwise addition of tributyltin hydride (25 μL, 
0.08 mmol) over 5 min. The reaction was stirred at rt for 2 h and filtered through celite and 
concentrated. The crude mixture was purified by flash chromatography (10% ether in pentane) to 
give the distal cis-vinyl stannane 2.112 (5.8 mg) and proximal cis-vinyl stannane 2.113 (5.7 mg)  
regioisomers with a combined yield of (11.5 mg, 78%). 
 
  ((E)-1-((2S,6R,8R)-10-((benzyloxy)methyl)-4-methylene-8-octyl-1,7-
dioxaspiro[5.5]undec-10-en-2-yl)prop-1-en-2-yl)tributylstannane 
(2.112) 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.31 (m, 4H), 7.31 – 7.27 (m, 1H), 
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5.71 (t, J = 1.6 Hz, 1H), 5.57 (dq, J = 7.9, 1.8 Hz, 1H), 4.85 (s, 1H), 4.74 (ddd, J = 11.1, 7.8, 2.9 
Hz, 1H), 4.48 (ABq, 2H, ΔδAB = 0.02, JAB = 11.9 Hz), 3.95 (ABq, 2H, ΔδAB = 0.02, JAB = 12.6 
Hz), 3.90 – 3.84 (m, 1H), 2.42 – 2.27 (m, 3H), 2.19 (ddd, J = 13.4, 2.9, 1.4 Hz, 1H), 2.10 – 2.05 
(m, 1H), 1.95 – 1.91 (m, 3H), 1.90 (d, J = 1.8 Hz, 3H), 1.58 – 1.41 (m, 12H), 1.37 – 1.21 (m, 
20H), 0.92 – 0.84 (m, 12H). 13C NMR (101 MHz, CDCl3) δ 142.0, 141.6, 140.9, 138.4, 137.6, 
128.6, 127.9, 127.8, 126.0, 110.3, 96.1, 73.2, 72.4, 68.0, 66.9, 44.0, 40.0, 35.8, 32.1, 31.8, 30.0, 
29.8, 29.5, 29.4, 27.6, 26.2, 22.9, 19.9, 14.3, 13.9, 9.3; [α]D20 -12.4 (c 0.3, CHCl3); IR (thin film, 
neat) 2956, 2925, 2854, 1738, 1656, 1456, 1377, 1261, 1168, 1095, 1039, 989, 885, 802, 735, 
697 cm-1; HRMS (APCI) calcd for C41H69O3Sn [M+H] +: 729.4269, found: 729.4288. 
 
 ((E)-1-((2S,6R,8R)-10-((benzyloxy)methyl)-4-methylene-8-octyl-1,7-
dioxaspiro[5.5]undec-10-en-2-yl)prop-1-en-1-yl)tributylstannane 
(2.113) 
1H NMR (500 MHz, CDCl3) δ 7.30 – 7.25 (m, 4H), 7.24 – 7.20 (m, 1H), 
5.52 (m, 1H), 4.75 (s, 1H), 4.72 (s, 1H), 4.70 (dt, J = 12.2, 2.5 Hz, 1H), 4.41 (ABq, 2H, ΔδAB = 
0.02, JAB = 11.9 Hz), 3.87 (s, 2H), 3.75 (qd, J = 7.5, 3.8 Hz, 1H), 2.23 (s, 2H), 2.19 – 2.10 (m, 
1H), 1.84 (d, J = 7.1 Hz, 3H), 1.67 – 1.58 (m, 3H), 1.45 – 1.32 (m, 6H), 1.27 – 1.16 (m, 26H), 
0.86 – 0.74 (m, 12H). 13C NMR (151 MHz, CDCl3) δ 149.0, 141.7, 138.5, 137.0, 132.7, 128.6, 
127.8, 126.4, 110.3, 96.0, 73.0, 72.3, 71.9, 67.7, 44.0, 39.2, 35.6, 32.1, 31.9, 30.0, 29.8, 29.5, 
27.8, 26.2, 22.9, 15.9, 14.3, 14.0, 10.9; [α]D20 +1.6 (c 0.3, CHCl3); IR (thin film, neat) 2955, 
2925, 2854, 1656, 1456, 1376, 1260, 1095, 1026, 987, 886, 802, 697 cm-1. HRMS (APCI) calcd 
for C41H69O3Sn [M+H] +: 729.4269, found: 729.4297. 
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General procedure for tin-iodide exchange: To an oven dried vial charged with distal vinyl 
stannane 2.112 (5 mg, 7 μmol) was added THF (500 μL) followed by cooling to -15°C. N-
iodosuccinimide (NIS) (2.5 mg, 0.01 mmol) dissolved in (100 μL) of THF was added drop-wise 
over 5 min. The reaction was stirred at -15°C for 10 min followed by warming up to rt and 
stirring for an additional 30 min. Upon completion of reaction, the mixture was quenched with a 
sat. solution of Na2S2O3 (100 μL) and sat. NaHCO3 (100 μL), extracted with (3 x 5mL) of 
EtOAc and the combined organic layer dried with Na2SO4. The crude mixture was purified by 
flash chromatography (10% ether in pentane) to give the desired distal vinyl iodide (3.2 mg, 
82%). 
 (2R,6R,8S)-4-((benzyloxy)methyl)-8-((E)-2-iodoprop-1-en-1-yl)-10-
methylene-2-octyl-1,7-dioxaspiro[5.5]undec-4-ene 
1H NMR (601 MHz, CDCl3) δ 7.37 – 7.31 (m, 4H), 7.31 – 7.27 (m, 1H), 
6.22 (dq, J = 8.7, 1.5 Hz, 1H), 5.67 (s, 1H), 4.84 (s, 1H), 4.81 (s, 1H), 
4.52 – 4.49 (m, 1H), 4.49 (ABq, 2H, ΔδAB = 0.01, JAB = 11.9 Hz), 3.94 (s, 
2H), 3.85 – 3.80 (m, 1H), 2.46 (d, J = 1.5 Hz, 3H), 2.33 – 2.29 (m, 2H), 2.23 (dd, J = 3.0, 1.2 Hz, 
1H), 2.21 (dd, J = 2.9, 1.2 Hz, 1H), 1.94 – 1.91 (m, 2H), 1.37 – 1.23 (m, 14H), 0.88 (t, J = 7.0 
Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 141.6, 140.4, 138.4, 138.0, 128.6, 127.9, 127.9, 125.3, 
111.2, 99.0, 96.2, 73.0, 72.5, 68.6, 68.3, 43.9, 39.4, 35.7, 32.1, 31.7, 29.9, 29.8, 29.5, 28.6, 26.3, 
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22.9, 14.3. [α]D20 -24.40 (c 0.4, CHCl3); IR (thin film, neat) 2925, 2854, 1736, 1656, 1456, 1378, 
1260, 1168, 1120, 1045, 986, 888, 803, 735, 698 cm-1. HRMS (APCI) calcd for C29H42O3I 
[M+H] +: 565.2179, found: 565.2200. 
 
 (2R,6R,8S)-4-((benzyloxy)methyl)-8-((E)-1-iodoprop-1-en-1-yl)-10-
methylene-2-octyl-1,7-dioxaspiro[5.5]undec-4-ene. The iodination 
procedure was followed with 2.113 (5 mg, 7 μmol), NIS (2.5 mg, 0.01 
mmol), THF (600 μL). The crude mixture was purified by flash 
chromatography (10 % ether in pentane) to give the desired product (3.4 mg, 88%). 1H NMR 
(601 MHz, CDCl3) δ 7.36 – 7.33 (m, 4H), 7.30 – 7.27 (m, 1H), 6.41 (q, J = 7.1 Hz, 1H), 5.70 (s, 
1H), 4.85 (s, 1H), 4.82 (s, 1H), 4.49 (ABq, 2H, ΔδAB = 0.01, JAB = 11.9 Hz), 4.08 (dd, J = 11.2, 
2.9 Hz, 1H), 3.94 (s, broad, 2H), 3.86 – 3.81 (m, 1H), 2.41 – 2.35 (m, 1H), 2.33 (dd, J = 3.6, 1.9 
Hz, 1H), 2.30 – 2.27 (m, 1H), 2.10 (ddd, J = 13.4, 2.9, 1.5 Hz, 1H), 1.93 – 1.90 (m, 2H), 1.76 (d, 
J = 7.2 Hz, 3H), 1.29 – 1.22 (m, 14H), 0.89 – 0.87 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 
140.2, 138.3, 138.1, 137.5, 128.6, 128.0, 127.9, 125.7, 111.3, 107.2, 96.3, 73.0, 72.4, 68.6, 68.3, 
43.9, 40.3, 35.8, 32.1, 31.7, 30.5, 29.9, 29.8, 29.5, 26.3, 22.9, 14.3. [α]D20 -5.9 (c 0.3, CHCl3); IR 
(thin film, neat) 2925, 2854, 1737, 1456, 1377, 1259, 1165, 1022, 985, 888, 800, 734, 697 cm-1. 
HRMS (ESIP) calcd for C29H42O3I [M+H] +: 565.2173, found: 565.21769. 
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 (2R,6R,8S)-4-((benzyloxy)methyl)-8-((E)-2-methyl-4-phenylbut-
1-en-1-yl)-10-methylene-2-octyl-1,7-dioxaspiro[5.5]undec-4-ene 
(2.114) 
Suzuki coupling: To a solution of (2-iodoethyl) benzene (4 μL, 0.02 
mmol) in diethyl ether (400 μL) at –78 °C was added t-BuLi (1.7 M, 
35 μL, 0.05 mmol). After 5 min, 9-BBN-OMe (65 μL, 0.065 mmol) was added dropwise 
followed by THF (400 μL). The mixture was allowed to warm up to rt over 1.5 h. A solution of 
K3PO4•H2O (3M, 22 μL, 0.06 mmol) was added followed by the spiroketal vinyl iodide (4.5 mg, 
8 μmol), dissolved in DMF (400 μL). PdCl2(dppf) (3 mg, 3.68 μmol) was added in one portion 
and the mixture was allowed to stir at rt for 18 h. The mixture was quenched with NH4Cl (100 
μL), then the organic layer was extracted with EtOAc (2 x 5 mL) and dried with Na2SO4. The 
crude mixture was purified by flash chromatography (5% EtOAc in hexane) to give the desired 
product (2.7 mg, 60%) as a colorless oil. 1H NMR (601 MHz, CDCl3) δ 7.36 – 7.31 (m, 4H), 
7.28 (dd, J = 7.2, 5.5 Hz, 3H), 7.17 (dd, J = 11.5, 7.4 Hz, 3H), 5.69 (s, 1H), 5.23 (d, J = 8.6 Hz, 
1H), 4.82 (s, 1H), 4.79 (s, 1H), 4.56 (ddd, J = 11.4, 8.6, 2.8 Hz, 1H), 4.48 (ABq, 2H, ΔδAB = 
0.02, JAB = 11.9 Hz), 3.94 (ABq, 2H, ΔδAB = 0.01, JAB = 13.3 Hz), 3.90 – 3.85 (m, 1H), 2.79 – 
2.68 (m, 2H), 2.30 (m, 3H), 2.15 (dd, J = 13.5, 2.7 Hz, 1H), 2.04 (t, J = 12.6 Hz, 2H), 1.93 (d, J 
= 6.6 Hz, 2H), 1.73 (s, 3H), 1.33 – 1.24 (m, 14H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (151 MHz, 
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CDCl3) δ 142.4, 141.5, 138.8, 138.4, 137.5, 128.6, 128.5, 127.9, 127.8, 126.0, 126.0, 125.9, 
110.4, 95.9, 73.2, 72.4, 68.1, 67.9, 44.0, 41.7, 40.1, 35.8, 34.5, 32.1, 31.8, 30.0, 29.9, 29.8, 29.5, 
26.3, 22.9, 17.1, 14.3; [α]D20 –7.0 (c 0.3, CHCl3); IR (thin film, neat) 2925, 2854, 1739, 1657, 
1455, 1380, 1261, 1153, 1096, 1041, 987, 884, 802, 744, 698 cm–1; HRMS (ESIP) calcd for 
C37H51O3 [M+H]+: 543.3833, found: 543.3842. 
 
 
 
 ((Z)-1-((2S,6R,8R)-10-((benzyloxy)methyl)-4-methylene-8-octyl-1,7-
dioxaspiro[5.5]undec-10-en-2-yl)prop-1-en-1-yl)tributylstannane 
(2.115) 
To an oven dried vial charged with alkynal spiroketal 2.104 (6.6 mg, 0.02 
mmol) was added CH2Cl2 (500 μL) followed by [Cp*Ru(MeCN)3]PF6 (1 mg, 2 μmol) under Ar. 
Tributyltin hydride (5 μL, 0.02 mmol) was added dropwise over 2 min. The reaction was stirred 
at rt for 1 h and filtered through celite and concentrated. The crude mixture was purified by flash 
chromatography (10% ether in pentane) to give the product (5.3 mg, 55%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 7.37 – 7.34 (m, 3H), 7.33 (m, 2H), 6.26 (q, J = 6.5 Hz, 1H), 5.62 (s, 
1H), 4.80 (s, 1H), 4.78 (s, 1H), 4.47 (ABq, 2H, ΔδAB = 0.01, JAB = 12.0 Hz), 4.27 (dd, J = 11.5, 
2.8 Hz, 1H), 3.93 (s, broad, 1H), 3.85 – 3.77 (m, 1H), 2.28 (s, broad, 2H), 2.13 (dd, J = 13.3, 3.0 
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Hz, 1H), 2.00 (t, J = 12.2 Hz, 1H), 1.92 – 1.86 (m, 2H), 1.72 (d, J = 6.4 Hz, 3H), 1.53 – 1.41 (m, 
6H), 1.36 – 1.24 (m, 26H), 0.90 – 0.84 (m, 12H). 13C NMR (126 MHz, CDCl3) δ 147.3, 141.9, 
138.5, 136.8, 134.7, 128.6, 127.9, 127.8, 126.6, 110.2, 95.8, 78.5, 73.0, 71.9, 67.4, 43.8, 41.7, 
35.6, 32.2, 31.9, 29.9, 29.8, 29.6, 29.4, 27.6, 26.0, 22.9, 19.3, 14.3, 14.0, 11.7. [α]D20 -11.9 (c 0.3, 
CHCl3); IR (thin film, neat) 2955, 2925, 2854, 1723, 1456, 1376, 1261, 1149, 1112, 1072, 1032, 
988, 887, 734, 696 cm-1. HRMS (ESIP) calcd for C41H69O3Sn [M+H] +: 729.4263, found: 
729.4280. 
 
 
 
 (3R,4R)-3-Benzyl-4-methyl-3,4-dihydro-2H-pyran-4-ol (2.116) 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 3H), 7.24 – 7.16 (m, 2H), 6.37 (d, 
J = 6.0 Hz, 1H), 4.82 (d, J = 6.0 Hz, 1H), 3.85 (dt, J = 10.9, 3.6 Hz, 1H), 3.64 (appt, J = 11.2 Hz, 
1H), 3.04 (dd, J = 14.2, 3.6 Hz, 1H), 2.40 (dd, J = 14.3, 11.0 Hz, 1H), 1.97 (tt, J = 11.2, 3.6 Hz, 
1H), 1.40 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 145.6, 140.4, 129.3, 128.8, 126.5, 109.0, 66.1, 
65.6, 45.8, 31.9, 27.8. IR (thin film) 3434, 2925, 1733, 1642, 1495, 1455, 1379, 1243, 1136, 
1064, 965, 742, 700 cm–1; HRMS (ASAP) calcd for C13H15O [M–OH]+: 187.1123, found: 
187.1124.  
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3-(((2R,5R)-5-benzyl-4-methyl-5,6-dihydro-2H-pyran-2-
yl)methyl)but-3-en-1-ol (2.117) 
1H NMR (601 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H), 7.23 – 7.16 (m, 3H), 
5.43 (s, 1H), 4.98 (s, 2H), 4.30 – 4.25 (m, 1H), 3.77 – 3.70 (m, 2H), 3.66 (dd, J = 11.4, 4.3 Hz, 
1H), 3.40 (dd, J = 11.4, 5.8 Hz, 1H), 3.02 (dd, J = 13.6, 4.2 Hz, 1H), ), 2.46 (dd, J = 13.6, 10.8 
Hz, 1H), 2.36 (dt, J = 9.7, 6.3 Hz, 2H), 2.31 (dd, J = 14.3, 9.2 Hz, 2H), 2.20 (dd, J = 14.4, 4.8 
Hz, 1H), 1.81 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 143.4, 140.3, 136.1, 129.2, 128.6, 126.3, 
124.7, 114.8, 73.0, 65.4, 60.7, 41.1, 40.5, 39.7, 36.6, 21.5. IR (thin film, neat)  3411, 2929, 1645, 
1495, 1454, 1380, 1126, 1047, 895, 700 cm-1; HRMS (ASAP) calcd for C18H25O2 [M+H] +: 
273.1855, found: 273.1856.  
 
 (3S,6R)-3-Benzyl-4-methyl-10-methylene-1,7-dioxaspiro[5.5]undec-4-
ene (2.120) 
The general cyclization procedure was followed with 2.73 (44 mg, 0.19 
mmol), 2.116 (30 mg, 0.15 mmol), TMSOTf (2 mol%, 30 μL, 3.0 μmol), NaHCO3 (sat) (60 μL, 
0.06 mmol), 4Å MS (90 mg), dichloromethane (0.9 mL), and DDQ (200 mg, 0.88 mmol). The 
oxidation proceeded at rt for 2 h. The crude mixture was purified by flash chromatography (25% 
EtOAc in hexane) to give the desired product (24 mg, 61%) as a 10:1 mixture of diastereomers. 
Major diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.26 – 7.22 (m, 3H), 
5.45 (s, 1H), 4.89 (s, 1H), 4.82 (s, 1H), 3.81 (m, 2H), 3.76 (m, 1H), 3.60 (d, J = 11.3 Hz, 1H), 
2.86 (dd, J = 13.6, 4.0 Hz, 1H), 2.71 (dd, J = 13.6, 10.1 Hz, 1H), 2.38 – 2.32 (m, 2H), 2.24 (m, 
1H), 2.22 – 2.17 (m, 1H), 1.95 (dt, J = 10.0, 3.6 Hz, 1H), 1.83 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 141.8, 140.8, 140.3, 129.6, 128.6, 126.3, 124.7, 110.7, 95.1, 61.6, 61.1, 44.6, 41.3, 
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36.8, 34.1, 22.0; IR (thin film) 3026, 2927, 1657, 1495, 1454, 1379, 1252, 1172, 1120, 1070, 
1051, 1015, 986, 872, 740, 700 cm–1; HRMS (ASAP) calcd for C18H23O2 [M+H]+: 271.1698, 
found: 271.1689.  
 
General protocol for Ferrier reaction of 5’, 6’-disubstitued pyranol  
 
To a oven dried flask charged with the tertiary pyranol (1 equiv) and allyl silane (1.35 equiv) was 
added CH2Cl2 (~0.10 M) followed by cooling to –78°C. Neat TMSOTf (1.2 equiv) was added 
the reaction was stirred at that temperature for 1h. The reaction was quenched at that temperature 
with a saturated aqueous solution of NaHCO3 (1.2 equiv) and allowed to warm up to rt. After 
concentration under vacuum, the reaction was purified by flash column chromatography to give 
the desired product. 
 
 
 
(2S,3S)-3-(benzyloxy)-2-methyl-4-phenyl-3,4-dihydro-2H-pyran-4-ol (2.121) 
Formed as a (~1:1) mixture of diastereomers: 1H NMR (500 MHz, CDCl3) δ 7.54 
(d, J = 7.4 Hz, 2H), 7.44 (d, J = 7.8 Hz, 2H), 7.35 – 7.25 (m, 14H), 6.95 (dd, J = 6.5, 2.9 Hz, 
2H), 6.45 (d, J = 5.9 Hz, 1H), 6.43 (d, J = 6.1 Hz, 1H), 4.91 (d, J = 11.6 Hz, 1H), 4.78 (d, J = 5.9 
Hz, 1H), 4.69 (d, J = 11.6 Hz, 1H), 4.63 (d, J = 6.1 Hz, 1H), 4.12 (dq, J = 10.2, 6.3 Hz, 1H), 4.07 
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– 4.05 (m, 1H), 3.84 (d, J = 10.6 Hz, 1H), 3.80 (dq, J = 10.1, 6.4 Hz, 1H), 3.60 (d, J = 10.0 Hz, 
1H), 3.53 (d, J = 10.1 Hz, 1H), 1.29 (d, J = 6.3 Hz, 3H), 1.16 (d, J = 6.4 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 146.1, 146.0, 144.1, 142.8, 138.3, 137.1, 128.6, 128.6, 128.5, 128.5, 128.3, 
127.9, 127.8, 127.7, 127.4, 106.7, 106.2, 85.2, 83.9, 76.7, 75.3, 75.1, 72.9, 71.5, 71.0, 18.0, 17.8; 
[α]D20 -111.2 (c 2.5, CHCl3); IR (thin film, neat) 3462, 3061, 3030, 2974, 2932, 1648, 1494, 
1450, 1239, 1099, 1030, 984, 700, 623 cm-1; HRMS (ESIP) calcd for C19H19O2 [M–OH]+: 
271.1380, found: 271.1376. 
 
Ferrier coupling (5’-OBn pyranol): The general Ferrier reaction procedure for 5’-OBn pyranol 
was followed with pyranol 2.121 (32 mg, 0.11 mmol), silane 2.73 (36 mg, 0.15 mmol), TMSOTf 
(25 μL, 0.12 mmol), NaHCO3 (sat) (130 μL, 0.14 mmol). The crude mixture was purified by 
flash chromatography (15% EtOAc in hexane) to give a mixture of 2.122 and 2.123  (26 mg, 
64%) in 5.9:1 dr ratio.  
 
3-(((2S,5R,6S)-5-(benzyloxy)-6-methyl-4-phenyl-5,6-dihydro-2H-
pyran-2-yl)methyl)but-3-en-1-ol (2.122) 
Major diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.40 (m, 2H), 
7.36 – 7.31 (m, 2H), 7.31 – 7.27 (m, 1H), 7.27 – 7.24 (m, 3H), 7.16 (dd, J = 7.4, 2.0 Hz, 2H), 
6.20 (d, J = 2.1 Hz, 1H), 5.06 (s, 1H), 5.04 (s, 1H), 4.49 (ddt, J = 7.7, 5.5, 2.0 Hz, 1H), 4.55 
(ABq, 2H, ΔδAB = 0.023, JAB = 11.4 Hz), 4.43 (qd, J = 6.8, 2.3 Hz, 1H), 4.12 (t, J = 2.1 Hz, 1H), 
3.82 – 3.74 (m, 2H), 2.53 – 2.44 (m, 2H), 2.42 (t, J = 6.2 Hz, 2H), 1.30 (d, J = 6.8 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) δ 142.9, 139.5, 138.4, 134.0, 130.1, 128.6, 128.5, 128.3, 127.8, 127.8, 
126.2, 115.1, 74.7, 70.7, 70.2, 68.4, 60.7, 41.1, 39.8, 16.6; [α]D20 -64.6 (c 2.1, CHCl3); IR (thin 
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film, neat) 3435, 3030, 2931, 1644, 1496, 1453, 1377, 1152, 1064, 897, 763, 698 cm-1; HRMS 
(ESIP) calcd for C24H29O3 [M+H] +: 365.2111, found: 365.2099. 
 
3-(((2R,5R,6S)-5-(benzyloxy)-6-methyl-4-phenyl-5,6-dihydro-2H-
pyran-2-yl)methyl)but-3-en-1-ol (2.123) 
Minor diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.44 – 7.41 (m, 2H), 
7.38 – 7.33 (m, 2H), 7.33 – 7.30 (m, 1H), 7.19 – 7.17 (m, 3H), 6.86 (dd, J = 6.4, 3.0 Hz, 2H), 
5.99 (t, J = 1.4 Hz, 1H), 5.01 (d, J = 3.3 Hz, 2H), 4.44 (td, J = 6.4, 3.3 Hz, 1H), 4.41 – 4.39 (m, 
1H), 4.28 (ABq, 2H, ΔδAB = 0.03, JAB = 10.4 Hz), 3.88 (dq, J = 8.3, 6.2 Hz, 1H), 3.81 – 3.71 (m, 
2H), 2.45 – 2.32 (m, 4H), 1.44 (d, J = 6.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 142.8, 139.4, 
139.2, 138.1, 130.6, 128.5, 128.4, 128.1, 127.8, 127.6, 127.3, 115.3, 77.9, 74.3, 73.2, 70.8, 60.7, 
41.8, 40.1, 19.3; [α]D20 -13.5 (c 0.3, CHCl3); IR (thin film, neat) 3431, 2963, 2927, 1729, 1645, 
1495, 1446, 1261, 1091, 801, 699 cm-1; HRMS (ESIP) calcd for C24H29O3 [M+H] +: 365.2111, 
found: 365.2101. 
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 (2S,3S)-3-((tert-butyldimethylsilyl)oxy)-2-methyl-4-phenyl-3,4-dihydro-
2H-pyran-4-ol (2.132) 
Formed as a single diastereomers: 1H NMR (601 MHz, CDCl3) δ 6.51 (d, J = 6.0 Hz, 1H), 4.73 
(d, J = 6.1 Hz, 1H), 3.87 – 3.82 (m, 2H), 1.24 (d, J = 5.7 Hz, 3H), 0.78 (s, 9H), 0.22 (s, 3H), 0.09 
(s, 3H); 13C NMR (151 MHz, CDCl3) δ 144.0, 142.7, 128.8, 127.4, 127.3, 106.1, 78.0, 75.5, 
74.1, 26.2, 18.3, 18.2, -3.3, -4.4; [α]D20 -142.8 (c 1.8, CHCl3); IR (thin film, neat) 3469, 2931, 
2858, 1650, 1449, 1388, 1256, 1037, 917, 838, 702. 620 cm-1; HRMS (ESIP) calcd for C18H27O2 
Si [M–OH] +: 303.1775, found: 303.1772. 
 
Ferrier coupling (5’-OTBS pyranol): The general Ferrier reaction procedure for 5’-OTBS 
pyranol was followed with pyranol 2.132 (44 mg, 0.14 mmol), silane 2.73 (43 mg, 0.19 mmol), 
TMSOTf (30 μL, 0.15 mmol), NaHCO3 (sat) (160 μL, 0.18 mmol). The crude mixture was 
purified by flash chromatography (15% EtOAc in hexane) to give a mixture of 2.133 and 2.134  
(33 mg, 61%) in 2.4:1 dr ratio. 
 
3-(((2S,5R,6S)-5-((tert-butyldimethylsilyl)oxy)-6-methyl-4-phenyl-5,6-
dihydro-2H-pyran-2-yl)methyl)but-3-en-1-ol (2.133) 
Major diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.31 (m, 4H), 
7.28 – 7.25 (m, 1H), 5.89 (d, J = 2.2 Hz, 1H), 5.04 (s, 1H), 5.01 (s, 1H), 4.44 (ddt, J = 7.3, 5.3, 
2.0 Hz, 1H), 4.22 (dd, J = 2.6, 1.7 Hz, 1H), 4.10 (qd, J = 6.8, 2.6 Hz, 1H), 3.82 – 3.72 (m, 2H), 
2.51 – 2.45 (m, 3H), 2.44 – 2.37 (m, 1H), 1.28 (d, J = 6.8 Hz, 3H), 0.76 (s, 9H), -0.06 (s, 3H), -
0.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 143.4, 140.4, 137.2, 128.5, 128.4, 127.6, 127.1, 
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115.1, 73.8, 69.9, 68.6, 60.7, 40.7, 39.9, 25.9, 18.3, 16.5, -4.1, -4.3; [α]D20 -62.8 (c 1.4, CHCl3); 
IR (thin film, neat) 3400, 2930, 2857, 1645, 1472, 1446, 1361, 1255, 1093, 836, 776, 698 cm-1; 
HRMS (ESIP) calcd for C23H37O3Si [M+H] +: 389.2507, found: 389.2496. 
 
3-(((2R,5R,6S)-5-((tert-butyldimethylsilyl)oxy)-6-methyl-4-phenyl-5,6-
dihydro-2H-pyran-2-yl)methyl)but-3-en-1-ol (2.134) 
Minor diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 6H), 
5.77 (m, 1H), 4.99 (m, 1H), 4.43 (ddd, J = 8.0, 2.7, 1.1 Hz, 1H), 4.41 – 4.36 (m, 1H), 3.81 – 3.69 
(m, 2H), 3.63 (dq, J = 7.9, 6.2 Hz, 1H), 2.42 – 2.33 (m, 2H), 2.32 – 2.29 (m, 2H), 1.39 (d, J = 6.2 
Hz, 3H), 0.67 (s, 9H), -0.15 (s, 3H), -0.47 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 142.83, 
141.42, 140.10, 129.51, 128.30, 127.90, 127.40, 115.25, 76.39, 74.04, 72.48, 60.68, 41.77, 40.11, 
26.01, 19.56, 18.41, -3.81, -3.91; [α]D20 -20.5 (c 0.9, CHCl3); IR (thin film, neat) 3411, 2930, 
2857, 1472, 1361, 1255, 1094, 879, 835, 775, 699 697 cm-1; HRMS (ESIP) calcd for C23H37O3Si 
[M+H] +: 389.2507, found: 389.2494. 
 
General protocol for DDQ mediated oxidative cyclization reaction 
 
To a solution of the 5’, 6’-disubstitued Ferrier intermediates in CH2Cl2 (~0.10 M) under nitrogen 
was added DDQ (1–1.5 equiv) in one portion at rt. The reaction was monitored by TLC and 
quenched by Et3N upon complete consumption of starting material. After concentration under 
vacuum, the reaction was purified by flash column chromatography to give the desired product.  
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DDQ annulation (5’-OBn pyranol):  
The general cyclization procedure was followed with alcohol 2.122 (11 mg, 0.03 mmol), DDQ (7 
mg, 0.03 mmol) in (300 μL) of CH2Cl2. The crude mixture was purified by flash chromatography 
(5% EtOAc in hexane) to give a mixture of 2.127 and 2.128  (8 mg, 72%) in 10:3 dr ratio. 
The general cyclization procedure was followed with alcohol 2.123 (10 mg, 0.03 mmol), DDQ 
(7mg, 0.03 mmol) in (300 μL) of CH2Cl2. The crude mixture was purified by flash 
chromatography 15% EtOAc in hexane) to give a mixture of spiroketals 2.127 and 2.128  (7 mg, 
69%) in 10:3 dr ratio. 
 
 (2S,3R,6R)-3-(benzyloxy)-2-methyl-10-methylene-4-phenyl-1,7-
dioxaspiro[5.5]undec-4-ene (2.127) 
Major diastereomer: 1H NMR (601 MHz, CDCl3) δ 7.47 (dd, J = 7.0, 1.6 
Hz, 2H), 7.38 – 7.31 (m, 4H), 7.16 (dd, J = 4.8, 1.9 Hz, 2H), 6.82 (dd, J = 6.5, 2.8 Hz, 2H), 5.98 
(s, 1H), 4.87 (s, 1H), 4.81 (s, 1H), 4.45 (dd, J = 9.2, 1.6 Hz, 1H), 4.33 – 4.27 (m, 1H), 4.30 (d, J 
= 10.6 Hz, 1H), 4.18 (d, J = 10.5 Hz, 1H), 3.88 – 3.80 (m, 2H), 2.45 – 2.36 (m, 3H), 2.23 (dd, J 
= 13.7, 2.6 Hz, 1H), 1.44 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 142.6, 140.7, 
138.3, 138.1, 129.9, 128.5, 128.4, 128.0, 127.7, 127.3, 111.1, 95.6, 77.3, 69.1, 65.5, 62.0, 44.5, 
34.0, 18.7; [α]D20 -92.1 (c 1.5, CHCl3); IR (thin film, neat) 3031, 2931, 1657, 1496, 1454, 1384, 
1336, 1253, 1175, 1100, 1069, 1049, 1017, 990, 887, 763, 698 cm-1; HRMS (ESIP) calcd for 
C24H27O3 [M+H] +: 363.1955, found: 363.1942. 
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(2S,3R,6S)-3-(benzyloxy)-2-methyl-10-methylene-4-phenyl-1,7-
dioxaspiro[5.5]undec-4-ene (2.128) 
Minor diastereomer: 1H NMR (601 MHz, CDCl3) δ 7.49 – 7.47 (m, 2H), 
7.35 – 7.30 (m, 3H), 7.30 – 7.25 (m, 3H), 7.21 (dd, J = 7.6, 1.6 Hz, 2H), 6.21 (s, 1H), 4.91 (s, 
1H), 4.84 (s, 1H), 4.56 (s, 2H), 4.57 (dd, J = 7.2, 1.8 Hz, 2H), 4.13 (d, J = 1.7 Hz, 1H), 4.07 – 
4.02 (m, 1H), 3.80 (ddd, J = 10.8, 6.1, 1.6 Hz, 1H), 2.49 – 2.37 (m, 3H), 2.27 – 2.23 (m, 1H), 
1.37 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 141.3, 138.9, 138.3, 135.3, 128.9, 
128.7, 128.5, 128.3, 128.2, 127.9, 126.3, 110.9, 95.2, 74.3, 71.5, 70.1, 61.7, 45.1, 34.1, 19.4; 
[α]D20 -32.3 (c 0.8, CHCl3); IR (thin film, neat) 3063, 3030, 2931, 2879, 1656, 1496, 1454, 1376, 
1318, 1177, 1153, 1070, 1052, 1021, 985, 888, 742, 697 cm-1; HRMS (ESIP) calcd for C24H27O3 
[M+H] +: 363.1955, found: 363.1942. 
 
DDQ annulation (5’-OTBS pyranol):  
The general cyclization procedure was followed with alcohol 2.133 (9 mg, 0.02 mmol), DDQ (5 
mg, 0.02 mmol) in (500 μL) of CH2Cl2. The crude mixture was purified by flash chromatography 
(5% EtOAc in hexane) to give a mixture of spiroketals 2.135 and 2.136  (4 mg, 55%) in 10:3 dr 
ratio. 
 
 tert-butyldimethyl(((2S,3R,6R)-2-methyl-10-methylene-4-phenyl-1,7-
dioxaspiro[5.5]undec-4-en-3-yl)oxy)silane (2.135) 
Major diastereomer : 1H NMR (601 MHz, CDCl3) δ 7.32 – 7.25 (m, 5H), 
5.70 (d, J = 1.4 Hz, 1H), 4.85 (m, 1H), 4.80 (m, 1H), 4.38 (dd, J = 8.7, 1.5 Hz, 1H), 4.01 (dq, J = 
8.7, 6.3 Hz, 1H), 3.86 – 3.80 (m, 2H), 2.40 – 2.34 (m, 4H), 2.21 (dt, J = 13.6, 2.2 Hz, 1H), 1.38 
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(d, J = 6.2 Hz, 3H), 0.66 (s, 9H), -0.14 (s, 3H), -0.46 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
145.0, 140.9, 139.5, 128.4, 128.2, 128.1, 127.7, 110.9, 95.4, 72.5, 69.1, 61.9, 44.5, 34.0, 26.0, 
19.1, 18.4, -3.8, -3.9; [α]D20 -57.0 (c 1.9, CHCl3); IR (thin film, neat) 2929, 2854, 1255, 1145, 
1174, 1096, 1069, 1046, 989, 886, 863, 837, 779, 700 cm-1; HRMS (ESIP) calcd for C23H35O3Si 
[M+H] +: 387.2350, found: 387.2336. 
 
 tert-butyldimethyl(((2S,3R,6S)-2-methyl-10-methylene-4-phenyl-1,7-
dioxaspiro[5.5]undec-4-en-3-yl)oxy)silane (2.136) 
Minor diastereomer: 1H NMR (601 MHz, CDCl3) δ 7.43 – 7.40 (m, 2H), 
7.36 – 7.32 (m, 2H), 7.31 – 7.27 (m, 1H), 5.94 (s, 1H), 4.89 (d, J = 2.0 Hz, 1H), 4.80 (d, J = 1.9 
Hz, 1H), 4.24 (d, J = 2.2 Hz, 1H), 4.21 (qd, J = 6.9, 2.2 Hz, 1H), 4.04 (ddd, J = 12.4, 10.8, 3.0 
Hz, 1H), 3.78 (ddd, J = 10.7, 6.0, 1.5 Hz, 1H), 2.45 (dd, J = 13.3, 1.4 Hz, 1H), 2.41 – 2.35 (m, 
3H), 2.23 (ddt, J = 13.4, 2.9, 1.5 Hz, 1H), 1.31 (d, J = 6.9 Hz, 3H), 0.80 (s, 9H), -0.01 (s, 3H), -
0.20 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 141.5, 128.5, 128.0, 127.5, 126.9, 95.1, 74.8, 69.4, 
61.6, 34.2, 25.9, 19.1, -4.2, -4.3; [α]D20 -44.5 (c 0.3, CHCl3); IR (thin film, neat) 2929, 2856, 
1657, 1462, 1361, 1255, 1176, 1155, 1103, 1071, 1022, 984, 837, 775, 697 cm-1; HRMS (ESIP) 
calcd for C23H35O3Si [M+H] +: 387.2350, found: 387.2338. 
 
Dihydropyran preparation 
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 (((2R,3R,4R)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-3,4-dihydro-2H-
pyran-3,4-diyl)bis(oxy))bis(tert-butyldimethylsilane) (2.137) 
 
1H NMR (601 MHz, CDCl3) δ 6.32 (d, J = 6.3 Hz, 1H), 4.69 (ddd, J = 5.9, 4.5, 1.2 Hz, 1H), 3.99 
(dtd, J = 5.1, 3.7, 1.4 Hz, 1H), 3.93 (dd, J = 11.3, 7.4 Hz, 1H), 3.89 (t, J = 3.8 Hz, 1H), 3.79 (td, 
J = 3.7, 1.2 Hz, 1H), 3.76 (dd, J = 11.3, 3.6 Hz, 1H), 0.90 (s, 9H), 0.89 (s, 9H), 0.89 (s, 9H), 0.10 
(s, 6H), 0.08 (s, 3H), 0.08 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
143.3, 101.7, 80.4, 70.5, 67.0, 62.1, 26.3, 26.2, 26.2, 18.8, 18.4, 18.3, –3.9, –4.0, –4.1, –4.4, –4.9, 
–4.9. These data are consistent with literature values.8  
 
 (((2S,3S,4R)-2-methyl-3,4-dihydro-2H-pyran-3,4-diyl)bis(oxy))bis(tert-
butyldimethylsilane) (2.142) 
 
1H NMR (500 MHz, CDCl3) δ 6.28 (d, J = 6.2 Hz, 1H), 4.66 (dd, J = 6.2, 3.2 
Hz, 1H), 4.07 (t, J = 4.0 Hz, 1H), 3.94 (p, J = 6.7 Hz, 1H), 3.57 (dd, J = 6.4, 4.9 Hz, 1H), 1.32 
(d, J = 6.7 Hz, 3H), 0.90 (s, 18H), 0.11 (s, 3H), 0.10 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 143.3, 103.1, 75.4, 74.9, 69.5, 26.2, 26.2, 18.4, 18.3, 17.4, –3.5, –3.7, –4.0, 
–4.0; [α]D20 +49.2 (c 1.20, CHCl3); IR (thin film) 2956, 2931, 2888, 2858, 1651, 1472, 1390, 
1361, 1251, 1116, 1074, 1047, 939, 838, 777 cm–1; HRMS (ASAP) calcd for C18H37O3Si2 [M–
H]–: 357.2281, found: 357.2283. These data are consistent with literature values.9  
 
 
                                                 
8 Shuto, S.; Yahiro, Y.; Ichikawa, S.; Matsuda, A. J. Org. Chem. 2000, 65, 5547. 
9 Paquette, L. A.; Oplinger, J. A. Tetrahedron 1989, 45, 107.  
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tert-Butyldimethyl(((2S,3R,4R)-3-methyl-2-octyl-3,4-dihydro-2H-pyran-4-
yl)oxy)silane (2.144) 
 
1H NMR (601 MHz, CDCl3) δ 6.24 (d, J = 4.7 Hz, 1H), 4.50 (m, 2H), 3.88 – 
3.85 (m, 1H), 1.86 (dd, J = 14.1, 7.2 Hz, 1H), 1.75 – 1.69 (m, 1H), 1.45 – 1.38 (m, 1H), 1.33 – 
1.24 (m, 12H), 0.92 (m, 3H), 0.90 (s, J = 2.4 Hz, 9H), 0.87 (d, J = 2.8 Hz, 3H), 0.07 (s, 3H), 0.06 
(s, 3H); 13C NMR (151 MHz, CDCl3) δ 143.9, 104.8, 78.7, 36.6, 32.2, 29.9, 29.8, 29.6, 29.5, 
26.2, 26.0, 23.0, 18.5, 14.4, 7.2, 7.1, 6.7,–4.4, –4.5; IR (thin film) 3066, 2928, 2857, 1644, 1464, 
1390, 1360, 1255, 1230, 1119, 1084, 1006, 893, 776, 726, 673 cm–1; HRMS (ASAP) calcd for 
C20H39O2Si [M-H]+: 339.2719, found: 339.2703.  
 
Aryl iodide synthesis 
 
 
 
Triethyl((2-iodobenzyl)oxy)silane (2.145) 
1H NMR (601 MHz, CDCl3) δ 7.77 (dd, J = 7.8, 1.2 Hz, 1H), 7.53 (dd, J = 
7.7, 1.6 Hz, 1H), 7.36 (td, J = 7.5, 1.2 Hz, 1H), 6.96 (td, J = 7.6, 1.6 Hz, 1H), 4.64 (s, 2H), 1.00 
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(t, J = 8.0 Hz, 9H), 0.69 (q, J = 8.0 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 143.2, 138.9, 128.8, 
128.5, 127.7, 96.2, 69.4, 7.1, 4.8; IR (thin film) 2955, 2910, 2876, 1459, 1413, 1375, 1239, 1203, 
1092, 1117, 1012, 804, 745 cm–1; HRMS (ASAP) calcd for C13H20OSiI [M–H]+: 347.0328, 
found: 347.0327. 
 
Triethyl(2-iodophenethoxy)silane (2.138) 
1H NMR (601 MHz, CDCl3) δ 7.81 (d, J = 7.9 Hz, 1H), 7.27 (s, J = 1.7 Hz, 
2H), 6.90 (ddd, J = 7.9, 5.6, 3.5 Hz, 1H), 3.80 (dd, J = 9.1, 5.4 Hz, 2H), 3.04 – 2.96 (m, 2H), 
0.94 (t, J = 8.0 Hz, 9H), 0.59 (q, J = 7.9 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 141.9, 139.7, 
130.9, 128.5, 128.4, 101.0, 62.7, 44.4, 7.1, 4.7; IR (thin film) 2954, 2910, 2875, 1466, 1436, 
1414, 1238, 1096, 1009, 913, 846, 745 cm–1; HRMS (ASAP) calcd for C14H24OSiI [M+H]+: 
363.0641, found: 363.0636. 
 
 
 
 (R)-Triethyl((1-(2-iodophenyl)pentan-2-yl)oxy)silane (2.147) 
1H NMR (601 MHz, CDCl3) δ 7.82 (dd, J = 7.9, 1.2 Hz, 1H), 7.28 – 7.23 
(m, 2H), 6.91 (ddd, J = 7.9, 6.9, 2.1 Hz, 1H), 4.03 – 3.98 (m, 1H), 2.94 (dd, J = 13.4, 4.8 Hz, 
1H), 2.80 (dd, J = 13.4, 8.2 Hz, 1H), 1.55 – 1.47 (m, 3H), 1.45 – 1.40 (m, 1H), 0.97 – 0.91 (m, 
9H), 0.91 – 0.83 (m, 3H), 0.50 – 0.38 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 142.5, 139.5, 
132.2, 128.2, 128.1, 101.1, 71.7, 48.4, 40.3, 18.8, 14.6, 7.1, 5.1; [α]D20 –26.2 (c 0.86, CHCl3); IR 
(thin film) 2956, 2875, 1465, 1377, 1238, 1071, 1011, 929, 741 cm–1; HRMS (ASAP) calcd for 
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C11H12I [M-OH]+: 270.9984, found: 270.9980. The ee of this material was determined to be 
approximately 85% by Mosher ester analysis (see below). 
 
1H NMR (400 MHz, CDCl3) δ 7.78 (dd, J = 7.9, 1.2 Hz, 1H), 7.42 – 7.34 
(m, 3H), 7.34 – 7.27 (m, 2H), 7.13 – 7.06 (m, 1H), 7.04 (dd, J = 7.6, 1.8 Hz, 
1H), 6.87 (td, J = 7.6, 1.8 Hz, 1H), 5.85 (ddt, J = 17.3, 10.4, 7.0 Hz, 1H), 
5.52 (dq, J = 7.3, 6.0 Hz, 1H), 5.21 – 5.15 (m, 2H), 3.44 (s, 3H), 3.04 (s, 1H), 3.02 (d, J = 2.1 
Hz, 1H), 2.53 (ddd, J = 6.6, 2.7, 1.3 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 166.3, 139.9, 139.8, 
133.1, 132.5, 131.3, 129.7, 128.9, 128.6, 128.6, 127.6, 119.3, 101.1, 75.9, 55.8, 44.4, 38.7; 19F 
NMR (CDCl3) δ –71.22 (minor), δ –71.37 (major). The dr of this (S)-Mosher ester was 
determined to be >14:1 by both 1H and 19F NMR. 
 
1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 7.9 Hz, 1H), 7.35 – 7.24 (m, 
1H), 7.23 – 7.18 (m, 4H), 7.14 (d, J = 7.3 Hz, 1H), 7.10 (dd, J = 7.6, 1.9 Hz, 
1H), 6.87 (td, J = 7.6, 1.9 Hz, 1H), 5.75 – 5.63 (m, 1H), 5.43 (dq, J = 8.0, 
5.7 Hz, 1H), 5.06 – 5.02 (m, 2H), 3.32 (s, 3H), 3.02 (d, J = 1.4 Hz, 1H), 3.00 (d, J = 3.9 Hz, 1H), 
2.43 (t, J = 6.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 166.4, 140.1, 132.6, 132.5, 131.5, 129.7, 
129.0, 128.7, 128.6, 127.7, 119.3, 101.1, 76.1, 55.6, 44.3, 38.6; 19F NMR (CDCl3) δ –71.22 
(major), –71.37 (minor). The dr of this (R)-Mosher ester was determined to be 12.5:1 by both 1H 
and 19F NMR analysis. 
 
General protocol Heck reaction-based [n+1] annulations 
 
One-pot procedure: The glycal derivative (1 equiv) and aryl iodide (1.5-2.0 equiv) were 
dissolved in 1,2-dichloroethane (nitrogen-purged) to give a (~0.10 M) solution. Pd(OAc)2 (10-20 
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mol%), Cu(OAc)2 (1.5- 2.0 equiv) and Ag2CO3 (1.0-1.5 equiv) were added sequentially under an 
argon atmosphere. The reaction was stirred at 40 °C for 18h, then was cooled to rt and DDQ 
(5.0-8.0 equiv) was added directly portion-wise every 15 min until complete conversion of the 
TBS-enol silane into the enone as monitored by TLC. TsOH•H2O (1.0-1.5 equiv) was added and 
stirred for ~45 min. The mixture was filtered through a plug of Celite, then was concentrated 
under vacuum and purified by flash column chromatography to give the desired product. 
 
Two-pot protocol: The crude mixture from the Heck coupling was filtered through a plug of 
silica gel and rinsed with a minimal volume of 1,2-dichloroethane (DCE). DDQ (3.0-5.0 equiv) 
was added portion-wise every 15 min until complete conversion of the enolsilane into the enone 
as monitored by TLC. Acid-catalyzed spiroketaliztion, work-up, and purification proceeded as 
above. 
 
 (1R,5'R,6'R)-5'-((tert-Butyldimethylsilyl)oxy)-6'-(((tert-
butyldimethylsilyl)oxy)methyl)-5',6'-dihydrospiro[isochromane-
1,2'-pyran]-4'(3'H)-one (2.141) 
 
The general cyclization procedure was followed with 2.137 (50 
mg, 0.10 mmol), 2.138 (73 mg, 0.20 mmol), Pd(OAc)2 (20 mol%, 4.5 mg, 0.02 mmol), 
Cu(OAc)2 (37 mg, 0.21 mmol), Ag2CO3 (30 mg, 0.11 mmol), dichloroethane (1.5 mL). After 
filtration, DDQ (116 mg, 0.51 mmol) and TsOH•H2O (23 mg, 0.12 mmol) was added. The 
resultant mixture was stirred at rt for 40 min, then was quenched by Et3N. The crude mixture was 
purified by flash chromatography (5% EtOAc in hexane) to give the desired product (31 mg, 
62%) as a white solid (mp = 89 – 90 °C). 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.35 (m, 1H), 
7.28 – 7.23 (m, 2H), 7.13 (dd, J = 6.4, 2.4 Hz, 1H), 4.50 (dd, J = 9.1, 1.1 Hz, 1H), 3.99 – 3.86 
(m, 5H), 3.09 (dd, J = 13.7, 1.2 Hz, 1H), 3.10 – 3.02 (m, 1H), 2.61 (d, J = 13.5 Hz, 1H), 2.57 
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(dq, J = 3.8, 1.9 Hz, 1H), 0.94 (s, 9H), 0.89 (s, 9H), 0.22 (s, 3H), 0.07 (s, 3H), 0.02 (s, 3H), –0.01 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 205.5, 135.6, 134.3, 128.8, 128.4, 127.0, 126.6, 100.1, 
74.2, 62.3, 58.9, 51.6, 28.5, 26.1, 26.1, 18.7, 18.6, –4.0, –4.8, –5.1, –5.4; mp: 89.0 – 90.0 °C; 
[α]D20 +5.5 (c 2.08, CHCl3); IR (thin film) 2929, 2856,1738, 1471, 1312, 1253, 1133, 1105, 837, 
780, 683 cm–1; HRMS (EI) calcd for C26H45O5Si2 [M+H]+: 493.2806, found: 493.2823. 
 
 (1R,5'S,6'S)-5'-((tert-Butyldimethylsilyl)oxy)-6'-methyl-5',6'-
dihydrospiro[isochromane-1,2'-pyran]-4'(3'H)-one (2.148) 
 
The general cyclization procedure was followed with 2.138 (148 mg, 
0.41 mmol), 2.142 (75 mg, 0.21 mmol), Pd(OAc)2 (20 mol%, 9.5  mg, 0.042 mmol), Cu(OAc)2 
(74 mg, 0.41 mmol), Ag2CO3 (68 mg, 0.25 mmol), and dichloroethane (3.0 mL). After filtration, 
DDQ (140 mg, 0.61 mmol) and TsOH•H2O (51 mg, 0.27 mmol) was added. The resultant 
mixture was stirred at rt for 40 min, then was quenched by Et3N. The crude mixture was purified 
by flash chromatography (5% EtOAc in hexane) to give the desired product (45 mg, 61%) as a 
white solid (mp = 81.0 – 83.5 °C). 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.38 (m, 1H), 7.31 – 
7.23 (m, 2H), 7.17 – 7.10 (m, 1H), 4.14 – 3.89 (m, 4H), 3.15 (dd, J = 13.8, 1.1 Hz, 1H), 3.08 
(ddd, J = 16.0, 10.7, 5.8 Hz, 1H), 2.64 (d, J = 13.7 Hz, 1H), 2.59 (ddd, J = 16.5, 2.7, 1.3 Hz, 1H), 
1.43 (d, J = 5.9 Hz, 3H), 0.95 (s, 9H), 0.21 (s, 3H), 0.08 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
204.3, 135.5, 134.3, 129.1, 128.6, 127.0, 126.6, 99.8, 80.6, 72.23, 58.9, 51.7, 28.4, 26.0, 19.5, 
18.8, –3.9, –5.3; mp: 81.0 – 83.5 °C; [α]D20 –57.1 (c 3.48, CHCl3); IR (thin film) 2931, 2857, 
1739, 1463, 1377, 1312, 1251, 1136, 834, 781, 680 cm–1; HRMS (EI) calcd for C20H31O4Si 
[M+H]+: 363.1992, found: 363.1996.  
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 (1S,5'R,6'S)-5'-Methyl-6'-octyl-5',6'-dihydrospiro[isochromane-1,2'-
pyran]-4'(3'H)-one (2.149) 
The general cyclization procedure was followed with 2.138 (85 mg, 0.24 
mmol), 2.144 (40 mg, 0.12 mmol), Pd(OAc)2 (10 mol%, 6 mg, 0.024 mmol), Cu(OAc)2 (43 mg, 
0.24 mmol), Ag2CO3 (47 mg, 0.17 mmol), and dichloroethane (1.8 mL). After filtration, DDQ 
(80 mg, 0.35 mmol) and TsOH•H2O (25 mg, 0.13 mmol) was added. The resultant mixture was 
stirred at rt for 30 min, then was quenched by Et3N. The crude mixture was purified by flash 
chromatography (5% EtOAc in hexane) to give the desired product (25 mg, 58%) as a colorless 
oil. 1H NMR (601 MHz, CDCl3) δ 7.38 – 7.34 (m, 1H), 7.30 – 7.24 (m, 2H), 7.13 (dd, J = 7.8, 
4.9 Hz, 1H), 4.21 (ddd, J = 7.9, 4.8, 2.7 Hz, 1H), 4.01 – 3.96 (m, 1H), 3.90 (dd, J = 11.1, 6.0 Hz, 
1H), 3.17 (d, J = 14.7 Hz, 1H), 3.11 – 3.05 (m, 1H), 2.58 (dd, J = 16.4, 2.6 Hz, 1H), 2.45 (d, J = 
14.6 Hz, 2H), 1.32 – 1.21 (m, 17H), 0.87 (t, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
210.8, 136.6, 134.4, 129.0, 128.4, 127.0, 126.8, 99.5, 71.7, 58.8, 48.6, 32.0, 31.7, 29.8, 29.7, 
29.5, 28.6, 26.1, 22.8, 14.3, 10.9; IR (thin film) 2926, 2855, 1722, 1456, 1318, 1111, 1081, 1039, 
1016, 972, 755 cm–1; HRMS (ESI) calcd for C22H33O3 [M+H]+: 345.2424, found: 345.2435. 
 
 (1R,3R,5'R,6'R)-5'-((tert-Butyldimethylsilyl)oxy)-6'-(((tert-
butyldimethylsilyl)oxy)methyl)-3-propyl-5',6'-
dihydrospiro[isochromane-1,2'-pyran]-4'(3'H)-one (2.150) 
 
The general cyclization procedure was followed with 2.137 (68 mg, 
0.17 mmol), 2.147 (38 mg, 0.08 mmol), Pd(OAc)2 (15 mol%, 2.5  mg, 11 μmol), Cu(OAc)2 (40 
mg, 0.22 mmol), Ag2CO3 (31 mg, 0.11 mmol), and dichloroethane (0.85 mL). After filtration, 
DDQ (75 mg, 0.33 mmol) and TsOH•H2O (31 mg, 0.17 mmol) were added. The resultant 
mixture was stirred at rt for 30 min, then was quenched by Et3N. The crude mixture was purified 
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by flash chromatography (5% EtOAc in hexane) to give the desired product (30 mg, 70%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.34 (m, 1H), 7.26 – 7.21 (m, 2H), 7.13 – 
7.08 (m, 1H), 4.46 (dd, J = 9.0, 1.1 Hz, 1H), 3.97 – 3.82 (m, 4H), 3.06 (dd, J = 13.7, 1.2 Hz, 1H), 
2.74 – 2.56 (m, 4H), 1.71 – 1.24 (m, 4H), 0.96 – 0.87 (m, 21H), 0.21 (s, 3H), 0.07 (s, 3H), 0.01 
(s, 3H), –0.03 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 205.3, 135.7, 134.7, 128.7, 128.3, 126.9, 
126.5, 100.7, 74.3, 68.6, 62.5, 51.9, 37.7, 34.5, 26.1, 19.0, 18.7, 18.6, 14.3, –3.9, –4.8, –5.1, –
5.3; [α]D20 +67.2 (c 0.9, CHCl3); IR (thin film) 2930, 2857, 1739, 1463, 1409, 1309, 1253, 1124, 
1025, 990, 837, 780, 673 cm–1; HRMS (ASAP) calcd for C29H51O5Si2 [M+H]+: 535.3275, found: 
535.3286. 
 
 (1R,5'R,6'R)-5'-((tert-Butyldimethylsilyl)oxy)-6'-(((tert-
butyldimethylsilyl)oxy)methyl)-5',6'-dihydro-3H-
spiro[isobenzofuran-1,2'-pyran]-4'(3'H)-one (2.151) 
 
The general cyclization procedure was followed with 2.145 (50 mg, 
0.14 mmol), 2.137 (35 mg, 0.07 mmol), Pd(OAc)2 (20 mol%, 3.5  mg, 0.014 mmol), Cu(OAc)2 
(26 mg, 0.14 mmol), Ag2CO3 (30 mg, 0.11 mmol), and dichloroethane (1.0 mL). After flash 
column chromatography, the enolsilane was dissolved in dichloroethane (1.0 mL), followed by 
addition of DDQ (49 mg, 0.22 mmol) and TsOH•H2O (21 mg, 0.11 mmol). The resultant mixture 
was stirred at rt for 40 min, then was quenched by Et3N. The crude mixture was purified by flash 
chromatography (5% EtOAc in hexane) to give the desired product (16 mg, 47%) as a colorless 
oil. 1H NMR (601 MHz, CDCl3) δ 7.43 – 7.38 (m, 1H), 7.38 – 7.35 (m, 2H), 7.31 – 7.27 (m, 1H), 
5.10 (ABq, 2H, ΔδAB = 0.07, JAB = 12.6 Hz), 4.55 (d, J = 9.4 Hz, 1H), 4.07 (dt, J = 9.5, 2.2 Hz, 
1H), 3.98 (dd, J = 11.6, 3.0 Hz, 1H), 3.85 (dd, J = 11.6, 1.7 Hz, 1H), 3.18 (d, J = 13.5 Hz, 1H), 
2.71 (d, J = 13.5 Hz, 1H), 0.96 (s, J = 3.3 Hz, 9H), 0.90 (s, J = 3.6 Hz, 9H), 0.23 (s, 3H), 0.10 (s, 
3H), 0.04 (s, 3H), –0.02 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 205.0, 139.7, 139.6, 129.6, 
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128.0, 122.3, 121.5, 110.9, 78.0, 74.2, 72.2, 62.4, 50.2, 26.2, 26.2, 18.8, 18.7, –3.9, –4.6, –5.0, –
5.3. IR (thin film) 2954, 2930, 2886, 2857, 1471, 1738, 1471, 1363, 1308, 1254, 1130, 999, 964, 
879, 779, 674 cm–1; [α]D20 +62.5 (c 1.50, CHCl3); HRMS (ASAP) calcd for C20H43O5Si2 
[M+H]+: 479.2649, found: 479.2671. 
 
3'-Hydroxy-5',6'-dihydro-3H-spiro[isobenzofuran-1,2'-pyran]-
4'(3'H)-one (2.153)  
Enol silane formation: A 10 mL flask was charged with THF (150 
μL) and was cooled to –78°C. LiHMDS (1.0M, 85 μL, 0.08 mmol) was added to the solution 
followed by TESCl (15 μL, 0.08 mmol). Spirocyclic ketone 2.151 (0.05 mmol, 26 mg) in THF 
(100 μL) was added drop-wise over 5 min. The resultant mixture was stirred at –78°C for 40 
min, then was quenched with NH4Cl (200 μL) and warmed to rt. The crude enol silane spiroketal 
was used directly in the next step without further purification. 
Epoxidation procedure: To a suspension of m-CPBA (16.5 mg, 0.07 mmol) and NaHCO3 (10.5 
mg, 0.12 mmol) in toluene (600 μL) and water (120 μL) at 0 °C was added the crude enol silane 
in toluene (100 μL) dropwise over 5 min. The mixture was allowed to stir for 1h at 0 °C, then 
was warmed to rt and stirred for 30 min. NaHSO3 (50 mg) in water (200 μL) was subsequently 
added. The mixture was stirred for 30 min, then was extracted with EtOAc (2 x 5mL). The 
organic layers were combined, washed with satd. NaHCO3 (5 mL), and brine (5 mL), then was 
concentrated. The oil was dissolved in a solvent mixture of THF, H2O, and MeOH (1.4 mL) in a 
5:1:1 ratio and stirred overnight. The crude mixture was purified by flash chromatography (20% 
EtOAc in hexane) to give the desired product (18 mg, 67%) as a colorless oil over 2 steps. 1H 
NMR (601 MHz, CDCl3) δ 7.48 – 7.47 (m, 2H), 7.46 (s, 1H), 7.44 (s, 1H), 7.38 – 7.33 (m, 1H), 
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5.66 (s, 1H), 4.62 (ABq, 2H, ΔδAB = 0.03, JAB = 12.9 Hz), 4.48 (ddd, J = 12.3, 7.2, 2.2 Hz, 1H), 
4.30 (d, J = 12.3 Hz, 1H), 4.20 (dd, J = 11.4, 2.3 Hz, 1H), 4.00 (dd, J = 11.4, 7.2 Hz, 1H), 3.24 
(s, 1H), 0.93 (s, 9H), 0.92 (s, 9H), 0.27 (s, J = 4.0 Hz, 3H), 0.12 (d, J = 1.8 Hz, 9H); 13C NMR 
(151 MHz, CDCl3) δ 193.4, 172.6, 140.3, 132.9, 131.7, 131.0, 129.5, 128.3, 104.1, 84.1, 70.4, 
64.0, 63.5, 26.1, 26.1, 18.8, 18.7, –3.6, –5.2, –5.2, –5.4; [α]D20 +116.3 (c 1.1, CHCl3); IR (thin 
film, neat) 2929, 2857, 1736, 1684, 1604, 1463, 1369, 1253, 1151, 1005, 837, 780 cm–1; HRMS 
(ESI) calcd for C25H41O5Si2 [M–OH]+: 477.2487, found: 477.2509. 
 
  (1S,3'S,4'R,5'S,6'R)-5'-((tert-butyldimethylsilyl)oxy)-6'-(((tert-
butyldimethylsilyl)oxy)methyl)-3',4',5',6'-tetrahydro-3H-
spiro[isobenzofuran-1,2'-pyran]-3',4'-diol (2.154) 
To a solution of 2.153 (1 mg, 2.7 µmol) in MeOH (100 µL) at –10 °C was added NaBH4 (1 mg, 
0.03 mmol). The resultant mixture was allowed to stir at that temperature for 25 min, then was 
quenched by water. The crude mixture was purified by flash chromatography (20% EtOAc in 
hexane) to give the desired product (0.3 mg, 22%). 1H NMR (601 MHz, CDCl3) δ 5.00 (d, J = 
2.9 Hz, 1H), 4.58 (dd, J = 12.3, 6.0 Hz, 1H), 4.52 (dd, J = 12.2, 8.3 Hz, 1H), 4.31 (td, J = 6.4, 2.8 
Hz, 1H), 4.15 – 4.04 (m, 2H), 3.83 (dd, J = 10.8, 6.9 Hz, 1H), 3.76 (dd, J = 8.7, 6.4 Hz, 1H), 
0.93 (s, 8H), 0.91 (s, J = 6.4 Hz, 10H), 0.20 (s, 2H), 0.15 (s, 2H), 0.09 (s, 3H), 0.09 (s, 2H). 
 
 (((2R,3R,6S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-6-(2-(2-
((triethylsilyl)oxy)ethyl)phenyl)-3,6-dihydro-2H-pyran-3,4-
diyl)bis(oxy))bis(tert-butyldimethylsilane) (2.156) 
The general cyclization procedure was followed with 2.137 (25 mg, 
0.05 mmol), 2.138 (37 mg, 0.10 mmol), Pd(OAc)2 (20 mol%, 2 mg, 0.01 mmol), Cu(OAc)2 (19 
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mg, 0.10 mmol), Ag2CO3 (17 mg, 0.06 mmol), dichloroethane (700 μL). The resultant mixture 
was stirred at 45 °C for 18h, filtered through a plug of celite and concentrated. The crude mixture 
was purified by flash chromatography (2% EtOAc in hexane) to give the desired product (33 mg, 
89%) as a colorless oil. Formed as a single diastereomer: 1H NMR (601 MHz, CDCl3) δ 7.56 – 
7.53 (m, 1H), 7.21 – 7.19 (m, 2H), 7.19 – 7.16 (m, 1H), 5.47 (dd, J = 2.7, 1.3 Hz, 1H), 4.82 (d, J 
= 2.6 Hz, 1H), 4.10 (dd, J = 2.8, 1.3 Hz, 1H), 3.87 – 3.70 (m, 5H), 3.04 (ddd, J = 13.4, 8.8, 6.6 
Hz, 1H), 2.94 – 2.89 (m, 1H), 0.95 (s, 9H), 0.93 (s, 3H), 0.92 (s, 9H), 0.90 – 0.88 (m, 15H), 0.57 
(q, J = 8.0 Hz, 6H), 0.18 (s, 3H), 0.16 (s, 3H), 0.14 (s, 3H), 0.12 (s, 3H), 0.06 – 0.05 (m, 6H); 13C 
NMR (151 MHz, CDCl3) δ 148.9, 139.8, 137.1, 130.5, 129.3, 128.0, 126.7, 106.3, 79.4, 69.8, 
67.1, 64.5, 62.4, 36.3, 26.2, 26.1, 18.6, 18.4, 18.3, 7.0, 4.6, -3.7, -3.9, -4.3, -5.2; [α]D20 +14.1 (c 
0.8, CHCl3); IR (thin film, neat) 2955, 2858, 1668, 1471, 1388, 1361, 1330, 1256, 1200, 1089, 
1007, 933, 837, 778, 672 cm-1; HRMS (ESIP) calcd for C38H75O5 Si4 [M+H]+: 723.4681, found: 
723.4678 
 
 (2R,3R)-3-((tert-butyldimethylsilyl)oxy)-2-(((tert-
butyldimethylsilyl)oxy)methyl)-6-(2-(2-
((triethylsilyl)oxy)ethyl)phenyl)-2,3-dihydro-4H-pyran-4-one 
(2.160b) 
To a solution of 2.156 (188 mg, 0.26 mmol) in CH2Cl2 (3.5 mL) was added 4Å MS (188mg, 100 
wt%) and the mixture was allowed to stir at rt for 15 min. DDQ (180 mg, 0.78 mmol) was then 
added portion wise every 15 min. The resultant yellow suspension was allowed to stir at rt for 
1.5h, then was quenched by Et3N. The crude mixture was purified by flash chromatography 
(15% EtOAc in hexane) to give the desired product (138 mg, 88%) as a colorless oil. 1H NMR 
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(601 MHz, CDCl3) δ 7.37 – 7.33 (m, 2H), 7.30 (dd, J = 7.7, 1.3 Hz, 1H), 7.23 (td, J = 7.5, 1.3 
Hz, 1H), 5.52 (s, 1H), 4.49 (d, J = 12.0 Hz, 1H), 4.36 (ddd, J = 12.1, 3.6, 2.3 Hz, 1H), 4.07 (dd, J 
= 11.7, 2.4 Hz, 1H), 4.04 (dd, J = 11.7, 3.6 Hz, 1H), 3.77 (t, J = 6.9 Hz, 2H), 3.08 (dt, J = 13.6, 
6.8 Hz, 1H), 2.89 (dt, J = 13.7, 6.9 Hz, 1H), 0.94 (s, J = 2.9 Hz, 9H), 0.89 – 0.86 (m, 18H), 0.52 
(q, J = 7.9 Hz, 7H), 0.27 (s, 3H), 0.14 (d, J = 3.2 Hz, 3H), 0.04 (d, J = 3.6 Hz, 3H), 0.03 (s, 3H); 
13C NMR (101 MHz, CDCl3) δ 194.2, 173.3, 138.1, 134.0, 131.4, 130.5, 129.3, 126.5, 104.6, 
84.3, 69.4, 63.7, 61.9, 37.2, 26.1, 26.1, 18.8, 18.6, 6.9, 4.5, -3.7, -5.0, -5.1, -5.4; [α]D20 +123.0 (c 
3.0, CHCl3); IR (thin film, neat) 2954, 2930, 2880, 2858, 1688, 1603, 1463, 1365, 1253, 1151, 
1107, 1007, 974, 837, 780, 745, 673 cm-1; HRMS (ESIP) calcd for C32H59O5Si3 [M+H]+: 
607.3665, found: 607.3651. 
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APPENDIX B 
TOTAL SYNTHESIS OF CLAVOSOLIDE A: A SHOWCASE OF OXIDATIVE 
OXOCARBENIUM CATION COMPATIBILITY WITH CYCLOPROPANE 
General Information 
Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were recorded on a 
Bruker Avance 300 spectrometer at 300 MHz and 75 MHz, a Bruker Avance 400 spectrometer at 
400 MHz and 100 MHz, a Bruker Avance 500 spectrometer at 500 MHz, a Bruker Avance 600 
spectrometer at 600 MHz if specified. The chemical shifts are reported in parts per million (ppm) 
on the delta (δ) scale. The solvent peak was used as a reference value, for 1H NMR: CDCl3 = 
7.26 ppm, DMSO = 2.50, for 13C NMR: CDCl3 = 77.23, DMSO = 39.52. Data are reported as 
follows:  (s = singlet; d = doublet; t = triplet; q = quartet; sept = septet; dd = doublet of doublets; 
ddd = doublet of doublet of doublets; dddd = doublet of doublet of doublet of doublet; td = triplet 
of doublets; dtd = doublet of triplet of doublets; br = broad). High resolution and low resolution 
mass spectra were recorded on a VG 7070 spectrometer. Infrared (IR) spectra were collected on 
a Mattson Cygnus 100 spectrometer. Samples for IR were prepared as a thin film on a NaCl plate 
by dissolving the compound in CH2Cl2 and then evaporating the CH2Cl2. Tetrahydrofuran and 
diethyl ether were distilled from sodium and benzophenone. Methylene chloride and tBuOMe 
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were distilled from CaH2 under a N2 atmosphere prior to use. CuI was purchased from Avacado 
Chemical research Ltd. (R)-TolBINAP was purchased from Strem chemical Inc. Grignard 
reagent (MeMgBr) was purchased from Sigma-Aldrich. Analytical TLC was performed on E. 
Merck pre-coated (25 mm) silica gel 60F-254 plates. Visualization was done under UV (254 
nm). Flash chromatography was done using ICN SiliTech 32-63 60 Å silica gel. Reagent grade 
ethyl acetate, diethyl ether, toluene and hexanes (commercial mixture) were purchased from EM 
Science and used as is for chromatography. All reactions were performed using oven or flame-
dried glassware under N2 with magnetic stirring unless otherwise noted.  
 
General procedure for enol acetate preparation 
 
A mixture of Na2CO3 (15% mol equiv.), [(p-cymene)RuCl2]2 (0.04 equiv), tri(2-furyl)phosphine 
(0.08 equiv), acetic acid (2.0 equiv), and 1-decyne (2.0 equiv) in toluene was heated to 80 °C and 
stirred for 1 h. Another portion of acetic acid (2.0 equiv.) and the alkyne substrate (1.0 equiv.) 
were dissolved in toluene and added to the mixture (~0.15 M final substrate concentration). The 
reaction was stirred at 80 °C for 8 h. Then the crude mixture was concentrated on a rotary 
evaporator and purified by flash column chromatography to give the desired enol acetate 
product. 
General procedure for [Cp*Ru(MeCN)3]PF6 catalyzed alkyne hydrosilylation 
 
Alkyne (1 eq) and silane (1.2 eq) were dissolved in acetone to give a ~0.5 M solution. 
[Cp*Ru(MeCN)3]PF6 (0.02 eq) was added to the mixture at 0 °C. The reaction was monitored by 
TLC at 0 °C and, upon starting material consumption, was concentrated and purified by flash 
chromatography to give the (Z)-vinylsilane. 
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General procedure for H2PtCl6•6H2O catalyzed alkyne hydrosilylation 
 
To a stirred solution of alkyne (1 eq) in THF was added the silane (1.1 eq) and a 0.001 M 
solution of H2PtCl6•6H2O (0.001 eq) in THF (~0.53 M final substrate concentration). The 
mixture was heated at 50 °C for 5 h unless specified, cooled and filtered through Celite with 
Et2O. The solvent was removed under vacuum and purified by flash chromatography to give the 
(E)-vinylsilane. 
 
General procedure for DDQ cyclization reactions 
The substrate (1 equiv), 2,6-dichloropyridine (2 equiv) and 4 Å molecular sieves (200 wt%) were 
dissolved in anhydrous 1,2-dichloroethane (~0.1 M). The mixture was stirred at room 
temperature for 15 min, followed by the addition of LiClO4 (0.2 equiv). After 5 min, DDQ (4 
equiv) was added. The reaction was monitored by TLC at rt or 45 °C unless otherwise specified 
and, upon starting material consumption, was quenched with 5% aqueous NaHCO3. The mixture 
was extracted with CH2Cl2 (3x), and the combined organic layers were dried over NaHCO3. The 
filtrate was concentrated in vacuo and purified by flash column chromatography to give the 
desired product. 
 
 
 159 
 
 
1-(3-(but-3-yn-1-yloxy)prop-1-yn-1-yl)-2-heptylcyclopropane 
(3.18a) 
1H NMR (400 MHz, CDCl3) δ 4.14 (d, J = 2.0 Hz, 2H), 3.62 (t, J = 7.0 
Hz, 2H), 2.49 (td, J = 7.0, 2.7 Hz, 2H), 1.99 (t, J = 2.7 Hz, 1H), 1.46 – 1.35 (m, 2H), 1.35 – 1.20 
(m, 10H), 1.05 (ddt, J = 15.1, 12.8, 5.6 Hz, 1H), 0.96 (dtd, J = 10.5, 4.5, 2.0 Hz, 1H), 0.88 (t, J = 
6.9 Hz, 3H), 0.84 – 0.79 (m, 1H), 0.55 (ddd, J = 8.4, 5.9, 4.3 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 90.5, 81.4, 71.2, 69.5, 67.8, 59.1, 33.8, 32.1, 29.5, 29.5, 29.3, 22.9, 22.8, 19.9, 15.6, 
14.3, 6.7; IR (thin film, neat) 2926, 2855, 2226, 1710, 1459, 1256, 1130 cm-1. 
 
4-((3-(2-heptylcyclopropyl)prop-2-yn-1-yl)oxy)but-1-en-2-yl 
acetate (3.18b)  
The general enol acetate preparation procedure was followed with 
Na2CO3 (8 mg, 0.07 mmol, 0.12 equiv.), [(p-cymene)RuCl2]2 (11 mg, 0.019 mmol, 0.04 equiv.), 
tri(2-furyl)phosphine (9 mg, 0.037 mmol, 0.08 equiv.), acetic acid (106 μL, 1.86 mmol, 4 equiv.), 
1-decyne (59 μL, 0.23 mmol, 0.7 equiv) and (108 mg, 0.44 mmol, 1 equiv.) of ether. The 
reaction was stirred for 2.5 h and purified by flash column chromatography (8% EtOAc in 
hexane) to give a colorless oil (41 mg, 30%). 1H NMR (300 MHz, CDCl3) δ 4.87 – 4.76 (m, 2H), 
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4.10 (d, J = 2.0 Hz, 2H), 3.60 (t, J = 6.6 Hz, 2H), 2.52 (td, J = 6.5, 0.6 Hz, 2H), 2.14 (s, 3H), 
1.46 – 1.33 (m, 2H), 1.33 – 1.23 (m, 7H), 1.17 (dd, J = 13.8, 6.7 Hz, 2H), 1.12 – 1.00 (m, 1H), 
0.99 – 0.91 (m, 1H), 0.88 (t, J = 6.7 Hz, 3H), 0.84 – 0.77 (m, 2H), 0.55 (ddd, J = 8.4, 5.8, 4.2 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 169.4, 153.5, 103.2, 90.4, 71.4, 66.6, 59.0, 33.9, 33.8, 32.1, 
29.5, 29.5, 29.3, 22.9, 22.8, 21.3, 15.6, 14.3, 6.7; IR (thin film neat) 2925, 2854, 1758, 1666, 
1368, 1214, 1184, 1100, 1020 cm-1; HRMS (ESI) calcd for C19H31O3 [M+H]+: 307.2273, found: 
307.2281.  
 
(Z)-4-(3-(Dimethyl(phenyl)silyl)-3-(2-
heptylcyclopropyl)allyloxy)but-1-en-2-yl acetate (3.19) 
 
The general trans-hydrosilylation reaction procedure was followed 
with enol acetate ether 3.18b (60 mg, 0.2 mmol, 1.0 equiv.), [Cp*Ru(MeCN)3]PF6 (2 mg, 0.004 
mmol, 0.02 equiv.) and dimethylphenylsilane (32 μL, 0.21 mmol, 1.05 equiv.) in 0.5 mL of 
acetone. Purification by flash column chromatography (5% EtOAc in hexane) afforded (86.2 mg, 
66%) of the desired product as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.50 (m, 
2H), 7.36 – 7.32 (m, 3H), 5.97 (td, J = 6.6, 1.4 Hz, 1H), 4.75 (d, J = 1.5 Hz, 1H), 4.71 (d, J = 1.5 
Hz, 1H), 3.80 (dd, J = 6.6, 0.9 Hz, 2H), 3.26 (t, J = 6.7 Hz, 2H), 2.36 (t, J = 6.5 Hz, 1H), 2.11 (s, 
3H), 1.47 – 1.38 (m, 1H), 1.37 – 1.21 (m, 10H), 1.18 – 1.12 (m, 1H), 1.11 – 1.01 (m, 1H), 0.88 
(t, J = 6.9 Hz, 3H), 0.81 – 0.71 (m, 1H), 0.70 – 0.64 (m, 1H), 0.45 – 0.41 (m, 6H), 0.41 – 0.35 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 169.3, 153.6, 143.1, 139.4, 136.3, 133.9, 129.1, 128.0, 
103.0, 70.1, 67.1, 34.5, 34.0, 32.1, 29.7, 29.5, 25.4, 22.9, 21.7, 21.3, 14.3, 13.6, -0.8, -0.8; IR 
(thin film neat) 2957, 2924, 2854, 1759, 1667, 1428, 1368, 1250, 1214, 1185, 1109, 1020, 834, 
816, 772, 732 cm-1;HRMS (ESI) calcd for C25H42O3Si [M+Na]+: 465.2801, found: 465.2794.  
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(Z)-2-(2-(dimethyl(phenyl)silyl)-2-(2-heptylcyclopropyl)vinyl)-
tetrahydropyran-4-one (3.21) 
The general oxidative cyclization reaction procedure was followed 
with 4 (21 mg, 0.047 mmol), 2,6-dichloropyridine (14 mg, 0.094 mmol), 4 Å molecular sieves 
(42 mg), 1,2 dichloroethane (0.7 mL), LiClO4 (1.5 mg, 0.014 mmol), and DDQ (32 mg, 0.14 
mmol). The reaction was stirred at 45 °C for 8 h, then was quenched with 5% aqueous NaHCO3. 
The crude mixture was extracted with CH2Cl2, concentrated, and purified by flash 
chromatography (5%-15% EtOAc in hexane) to give the desired product (11 mg, 54%). 1H NMR 
(400 MHz, CDCl3) δ 7.54 – 7.48 (m, 2H), 7.35 (dd, J = 5.5, 1.7 Hz, 3H), 5.80 (ddd, J = 8.8, 3.5, 
1.4 Hz, 1H), 4.12 – 4.03 (m, J = 11.5, 7.3, 1.0 Hz, 1H), 3.99 – 3.91 (m, 1H), 3.17 – 3.07 (m, 1H), 
2.53 – 2.40 (m, 1H), 2.30 – 2.20 (m, 1H), 2.18 – 2.05 (m, 1H), 1.35 – 1.17 (m, 13H), 1.15 – 1.00 
(m, 1H), 0.94 – 0.79 (m, 4H), 0.74 – 0.64 (m, 1H), 0.46 – 0.45 (m, 3H), 0.43 – 0.42 (m, 3H); 13C 
NMR (101 MHz, CDCl3) δ 206.5, 145.7, 139.0, 137.3, 137.2, 133.9, 129.4, 128.2, 76.7, 66.1, 
48.3, 48.2, 42.1, 34.4, 34.4, 32.1, 29.9, 29.5, 25.3, 25.2, 22.9, 22.4, 21.9, 14.3, 14.1, 13.7, -0.7, -
0.7, -0.9; IR (thin film neat) 2955, 2923, 2853, 1721, 1462, 1427, 1374, 1249, 1154, 1111, 1080, 
832 cm-1; HRMS (EI) calcd for C25H37O2Si [M–H]+: 397.2563, found: 397.2549.  
 
 (E)-4-((3-(Dimethyl(phenyl)silyl)-3-(2-
heptylcyclopropyl)allyl)oxy)but-1-en-2-yl acetate (3.20a) 
The general cis-hydrosilylation reaction procedure was followed with 
enol acetate ether 3.18b (31 mg, 0.11 mmol, 1.0 equiv.), H2PtCl6•6H2O (0.06 mg, 0.001 mmol, 
0.001 equiv.) and dimethylphenylsilane (20 μL, 0.12 mmol, 1.1 equiv.) in 0.5 mL of THF. 
Purification by flash column chromatography (5% Et2O in hexane) afforded (19 mg, 42%) of the 
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desired product as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.50 – 7.46 (m, 2H), 7.34 – 7.30 
(m, 3H), 5.96 (td, J = 5.5, 1.7 Hz, 1H), 4.81 (t, J = 1.8 Hz, 2H), 4.28 (ddd, J = 5.3, 1.7, 1.0 Hz, 
2H), 3.59 (t, J = 6.6 Hz, 2H), 2.54 (t, J = 6.6 Hz, 2H), 2.13 (s, 3H), 1.33 – 1.15 (m, 12H), 1.12 – 
0.95 (m, 2H), 0.70 – 0.59 (m, 1H), 0.46 – 0.37 (m, 1H), 0.35 (s, 6H); 13C NMR (101 MHz, 
CDCl3) δ 169.4, 153.7, 142.8, 140.8, 139.3, 134.0, 129.0, 127.9, 103.1, 69.0, 67.7, 34.7, 34.2, 
32.1, 29.7, 29.5, 29.4, 22.9, 21.3, 20.6, 19.9, 14.3, 13.7, –1.7, –1.7; IR (thin film, neat) 2955, 
2924, 2854, 1722, 1674, 1462, 1372, 1250, 1181, 1120, 815 cm-1; HRMS (ESI) calcd for 
C27H42NaO3Si [M+Na]+: 465.2801, found: 465.2794.  
 
 (E)-4-((2-(dimethyl(phenyl)silyl)-3-(2-heptylcyclopropyl)allyl)oxy)but-1-
en-2-yl acetate (3.20b) 
The general cis-hydrosilylation reaction procedure was followed with enol 
acetate ether 3.18b (31 mg, 0.11 mmol, 1.0 equiv.), H2PtCl6•6H2O (0.06 mg, 0.001 mmol, 0.001 
equiv.) and dimethylphenylsilane (20 μL, 0.12 mmol, 1.1 equiv.) in 0.5 mL of THF. Purification 
by flash column chromatography (5% Et2O in hexane) afforded (19 mg, 44%) of the desired 
product as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.52 – 7.49 (m, 2H), 7.32 (dd, J = 4.2, 
2.3 H, 2H), 5.19 (d, J = 9.9 Hz, 1H), 4.73 (dd, J = 11.8, 1.5 Hz, 2H), 4.21 (qd, J = 11.3, 1.2, 1.0 
Hz, 2H), 3.42 (t, J = 6.8 Hz, 2H), 2.40 (dd, J = 7.1, 6.4 Hz, 2H), 2.12 (s, 3H), 1.42 (qd, J = 8.5, 
4.5, 1H), 1.36 (d, J = 2.8 Hz, 2H), 1.25 (s, broad, 10H), 0.88 (t, J = 6.8, 3H), 0.83 (s, 1H), 0.80 – 
0.69 (m, 1H), 0.63 – 0.57 (m, 1H), 0.57 – 0.52 (m, 1H), 0.34 (s, 6H); 13C NMR (101 MHz, 
CDCl3) δ 169.3, 153.8, 149.0, 139.4, 134.3, 133.2, 128.8, 127.7, 103.0, 69.9, 67.3, 33.9, 32.1, 
29.9, 29.6, 22.9, 22.2, 21.3, 19.6, 15.5, 14.3, –2.2 ; IR (thin film, neat) 2953, 2920, 2852, 1720, 
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1663, 1460, 1378, 12542, 1185, 815 cm-1; HRMS (ESI) calcd for C27H42NaO3Si [M+Na]+: 
465.2801, found: 465.2832.  
 
 (E)-2-(2-(dimethyl(phenyl)silyl)-2-(2-
heptylcyclopropyl)vinyl)dihydro-2H-pyran-4(3H)-one (3.22) 
The general cyclization reaction procedure was followed with 3.20a (10 
mg, 0.023 mmol), 2,6-dichloropyridine (21 mg, 0.14 mmol), 4 Å molecular sieves (21 mg), 1,2 
dichloroethane (0.5 mL), LiClO4 (0.7 mg, 0.007 mmol), and DDQ (16 mg, 0.069 mmol). The 
reaction was stirred at 45 °C for 4 h, then was quenched with 5% aqueous NaHCO3. The crude 
mixture was extracted with CH2Cl2, concentrated, and purified by flash chromatography (5%-
15% EtOAc in hexane) to give the desired product as a 3.6:1 mixture of diastereomers (5.1 mg, 
56%). Major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.43 (m, 2H), 7.37 – 7.30 (m, 
3H), 5.87 (dt, J = 7.2, 1.3 Hz, 1H), 4.80 – 4.72 (m, 1H), 4.37 – 4.31 (m, 1H), 3.75 (tt, J = 11.9, 
2.7 Hz, 1H), 2.64 (ddd, J = 13.8, 12.6, 7.4 Hz, 1H), 2.54 – 2.31 (m, 3H), 1.25 (s, br, 12H), 0.92 – 
0.84 (m, 5H), 0.68 – 0.60 (m, 1H), 0.51 (dt, J = 8.3, 4.9 Hz, 1H), 0.36 (s, br, 6H). For the 
mixture of inseparable diastereomers: 13C NMR (126 MHz, CDCl3) δ 206.83, 206.78, 144.4, 
144.2, 141.7, 141.6, 138.7, 134.0, 133.9, 129.4, 129.2, 128.2, 128.0, 75.6, 75.4, 66.9, 66.1, 48.0, 
47.8, 42.5, 34.63, 34.58, 32.1, 29.6, 29.5, 29.4, 29.3, 22.88, 22.9, 20.8, 20.5, 20.2, 20.0, 14.34, 
14.29, 14.1, 13.8, -0.7, -0.8, -1.68, -1.72; IR (thin film neat) 2956, 2924, 2854, 1759, 1666, 1612, 
1462, 1428, 1368, 1246, 1213, 1184, 1109, 1019, 815, 833 cm-1; HRMS (ESI) calcd for 
C25H39O2Si [M+H]+: 399.2735, found: 399.2735.  
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 (E)-5-Chloropent-3-en-2-one (3.27) 
 
To a stirred solution of acetyl chloride (6.9 mL, 100 mmol) and allyl chloride 
(16.3 mL, 200 mmol) in CH2Cl2 was added AlCl3 (16 g, 120 mmol, 1.2 equiv.) in portions over 
20 min. The mixture was stirred for 2 h at 0 °C and for 1 h at rt. The reaction was quenched by 
pouring the mixture onto crushed ice (100 g). The organic layer was separated, dried with 
Na2SO4, and filtered. Triethylamine (21 mL, 150 mmol, 1.5 equiv.) was added, then the mixture 
was refluxed for 2 h, cooled to rt and washed successively with HCl (2 x 100 mL), NaHCO3 (2 x 
100 mL), H2O (1 x 200 mL) and brine (1 x 200 mL). The combined organic extracts were dried 
with Na2SO4 and concentrated. Purification by flash chromatography (10:90 EtOAc: hexane) 
yielded the desired product (4.03 g, 34%). 1H NMR (500 MHz, CDCl3) δ 6.79 (dt, J = 15.7, 6.1 
Hz, 1H), 6.31 (d, J = 15.7 Hz, 1H), 4.19 (dd, J = 6.1, 1.4 Hz, 2H), 2.30 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 197.8, 140.4, 132.5, 42.9, 27.6. IR (thin film, neat) 1701, 1680, 1636, 1424, 
1362, 1254, 977 cm-1. These data are consistent with literature values.10 
 
 (S)-5-Chloro-4-methylpentan-2-one (3.29) 
 
The catalyst was prepared by stirring CuI (76 mg, 0.40 mmol,) and (R)-TolBINAP (407 mg, 0.60 
mmol) in anhydrous tBuOMe (320 mL) for 1 h to give a clear yellow solution. The mixture was 
cooled to −78 °C and MeMgBr (2.7 M solution in Et2O, 17 mL, 46 mmol) was added. After 
stirring for 10 min, a solution of 3.27 (4.74 g, 40 mmol) in anhydrous CH2Cl2 (320 mL) was 
added over 2 h with a syringe pump. The mixture was stirred for 4 h (including addition time) at 
−78 °C. The reaction was quenched at −78 °C with EtOH (16 mL, 0.4 mL/mmol substrate), 
followed by a 1 M aq. NH4Cl-solution (80 mL, 2 mL/mmol substrate), and was allowed to warm 
                                                 
10 Kulinkovich, O. G.; Tischenko, I. G.; Sorokin, V. L. Synthesis 1985, 1058. 
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to room temperature. A 1 M aq. NH4Cl-solution (200 mL, 5 mL/mmol substrate) and Et2O (100 
mL, 2.5 mL/mmol substrate) were added and the layers were separated. After extraction with 
Et2O (2 x 200 mL, 5 mL/mmol substrate), the combined organic extracts were dried and 
carefully concentrated to a yellow oil. Purification by flash chromatography (10:90 EtOAc: 
hexane) yielded the desired product (3.9 g, 72%). 1H NMR (500 MHz, CDCl3) δ 3.56 (dd, J = 
10.8, 4.8 Hz, 1H), 3.47 (dd, J = 10.8, 5.4 Hz, 1H), 2.69 (dd, J = 17.1, 5.8 Hz, 1H), 2.43 (td, J = 
11.9, 5.5 Hz, 1H), 2.35 (dd, J = 17.1, 7.1 Hz, 1H), 2.16 (s, 3H), 1.03 (d, J = 6.7 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) δ 207.5, 50.6, 47.2, 31.1, 30.6, 17.9. [α]D20 +4.7 (c 0.95, CHCl3); IR 
(thin film, neat) 2962, 1714, 1459, 1440, 1408, 1366, 1299, 1159 cm-1.  
 
 
Figure 3.10 HPLC traces for conjugate addtion product of 3.29: Enantioenriched sample (pink) and racemic 
mixture (black) 
Ee was determined to be >90% by chiral HPLC analysis using a Phenomenex Lux 5μ Cellulose-
3 column (250 x 4.60 mm) with isopropanol/Hexane (0.5/95.5, v/v); 25 °C over 30 min; 0.7mL/ 
min; retention times (min): 10.2 min (S-addition product), 10.5 min (R-addition product). 
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1-((1R,2R)-2-Methylcyclopropyl)ethanone (3.30)11 
To a solution of NaOH (3.54 g, 0.088 mmol) in of H2O (4.4 mL) was added the 
chloro ketone 3.29 (7.9 g, 59 mmol) over 20 min with a 10 mL syringe. The reaction mixture 
was stirred for 1 h (including addition time) at 80 °C. H2O (8.7 mL) was added slowly to the 
reaction mixture over a 20 min period, and the mixture heated under reflux for an additional 
hour. Upon cooling to rt, the reaction mixture was extracted with Et2O (2 x 15 mL). The aqueous 
layer of the extraction was saturated with K2CO3 and extracted with additional Et2O (15 mL). 
The combined organic layers were dried over Na2SO4 and concentrated at 0 °C under reduced 
pressure (168 mm Hg) to yield the desired compound (5.55 g, 96%). 1H NMR (400 MHz, 
CDCl3) δ 2.22 (s, 3H), 1.67 (ddd app dt, J = 8.1, 4.2, 4.2 Hz, 1H), 1.46-1.36 (m, 1H), 1.23 (ddd, 
J = 8.5, 4.5, 3.8 Hz, 1H), 1.11 (d, J = 6.0 Hz, 3H), 0.72 (ddd, J = 7.9, 6.5, 3.7 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ 208.7, 30.6, 30.5, 20.3, 19.6, 18.3. IR (thin film neat) 2923, 1706, 1601, 
1451, 1195, 1114, 808 cm-1; [α]D20 –125.7 (c 0.82, CHCl3).  
 
3-((1R,2R)-2-Methylcyclopropyl)prop-2-yn-1-ol (3.32) 
 
To a solution of LDA prepared at 0 °C from diisopropylamine (2.98 mL, 
21.2 mmol) and n-butyllithium in hexane (1.56M, 13.6 mL, 21.2 mmol) in dry THF (40 mL) at  
−78 °C was added 3.30 (1.98 g, 20.2 mmol) in THF (25 mL). The solution was stirred for 1 h, 
then diethyl chlorophosphate (3.51 mL, 24.2 mmol) was added. The mixture was allowed to 
warm to rt slowly over 2-3 h, then was added dropwise over 45 min to a solution of LDA in THF 
(46.5 mmol) prepared at 0 °C as described above. The reaction was allowed to stir at 0 °C for 30 
                                                 
11 Cannon, G. W.; Ellis, R. C.; Leal, J. R., Organic Synth. 1963, 4, 597. 
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min, producing a brown-black color and a precipitate. HMPA (13 mL, 71 mmol) was added and 
the mixture was warmed to 5 °C. Paraformaldehyde (1.87 g, 61 mmol, 3.0 equiv.) was added and 
the mixture was refluxed for 1 h. The reaction was quenched with saturated NH4Cl (100 mL) and 
EtOAc (100 mL). After extraction with EtOAc (2x 75 mL), the combined yellow-orange organic 
extracts were dried and concentrated. Purification by flash chromatography (15% EtOAc in 
hexane) yielded the desired product (1.36 g, 61%). 1H NMR (500 MHz, CDCl3) δ 4.22 (s, 2H), 
1.51 (s, br, 1H), 1.11 – 1.04 (m, 4H), 0.93 (dddd, J = 8.6, 4.9, 2.0, 2.0 Hz, 1H), 0.85 – 0.81 (m, 
1H), 0.54 (ddd, J = 7.0, 4.4, 4.4 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 89.7, 74.1, 51.7, 18.5, 
17.0, 16.7, 7.7; [α]D20 –117.8 (c 0.93, CHCl3); IR (thin film, neat) 3333, 3055, 2955, 2929, 2868, 
2227, 1444, 1377, 1308, 1068, 1013, 965, 908, 848, 775 cm-1; HRMS (EI) calcd for C7H10O 
[M]+: 110.0732, found: 110.0699 cm-1.  
 
3-((1R,2R)-2-Methylcyclopropyl)prop-2-ynyl methanesulfonate (3.33) 
 
To the cyclopropyl homopropargylic alcohol (50 mg, 0.45 mmol) 
in CH2Cl2 (1 mL) at 0 °C followed by Et3N (130 µL, 0.91 mmol) and of methanesulfonyl 
chloride (45 µL, 0.55 mmol). The reaction was stirred for 1 h then was quenched with sat. aq. 
NaHCO3 solution. The mixture was allowed to warm to room temperature, then was 
concentrated in vacuo and diluted with H2O (5 mL) and Et2O (10 mL). The organic layer was 
separated, dried (MgSO4), filtered and concentrated to yield the desired product (63 mg, 73%), 
which was used without further purification. Characterization was not performed on this 
intermediate due to its instability and volatility. 
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 (S)-4-Trimethylsilyl-3-butyn-2-ol  
 
To 4-(trimethylsilyl)-3-butyn-2-one (3.12 g, 22.2 mmol) in CH2Cl2 (65 mL) 
was added (S,S)-Noyori-TsDPEN catalyst (280 mg, 0.445 mmol) in CH2Cl2 (3 mL) and NEt3 (9.4 
mL, 68 mmol). The mixture was cooled to 10 °C and formic acid (6 mL, 155 mmol) was added 
dropwise over 2 h.  The reaction was stirred at rt overnight. CH2Cl2 was partially removed under 
reduced pressure. The mixture was diluted with 80 mL of pentane, and K2CO3 (13g) and MgSO4 
(8g) were added. The slurry was stirred vigorously for 2 h at rt, then was filtered through a plug 
of silica gel and concentrated under reduced pressure to yield the desired product (3.04 g, 96%). 
1H NMR (300 MHz, CDCl3) δ 4.52 (dt, J = 13.0, 6.6 Hz, 1H), 1.79 (d, J = 5.2 Hz, 1H), 1.45 (d, J 
= 6.6 Hz, 3H), 0.17 (s, 9H). [α]D20 -23.8 (c 0.93, CHCl3). The dr of the (R)-Mosher ester of this 
material was found to be > 95:5 by 19F NMR analysis. [δ –72.02 (major) and δ –71.66 (minor), 
in CDCl3]. These data are consistent with literature values.12 
 
 (S)-3-Butyn-2-yl Mesylate (3.35) 
 
To (S)-4-trimethylsilyl-3-butyn-2-ol (1.84 g, 12.9 mmol) in CH2Cl2 (155 
mL) at −78 °C was added Et3N (3.7 mL, 26.1 mmol) and methanesulfonyl chloride (1.6 mL, 19.8 
mmol). The solution was stirred at −78 °C for 1 h then was quenched with sat. aq. NaHCO3 
solution. The mixture was allowed to warm to room temperature, concentrated in vacuo and then 
diluted with H2O (100 mL) and Et2O (50 mL). The organic layer was separated, dried over 
MgSO4, filtered and concentrated to the desired product (2.65 g, 93%), which was used without 
further purification. 1H NMR (400 MHz, CDCl3) δ 5.24 (q, J = 6.7 Hz, 1H), 3.10 (s, 3H), 1.61 
(d, J = 6.7 Hz, 3H), 0.19 – 0.15 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 101.4, 93.8, 68.7, 39.3, 
                                                 
12 Marshall, J. A.; Chobanian, H. R.; Yanik, M. M. Org. Lett. 2001, 3, 3369. 
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22.6, -0.3. [α]D20 –109.3 (c 1.18, CHCl3); lit [α]D20 –113.5 (c 1.18, CHCl3); er > 90:10 based on 
optical rotation. These data are consistent with literature values.12 
 
 (3S,4R)-4-Methyl-1-(triisopropylsilyloxy)-6-(trimethylsilyl)hex-5-
yn-3-ol (3.36) 
 
To a solution of Pd(OAc)2 (107 mg, 0.48 mmol) in THF (67 mL) at 
−78 °C was added PPh3 (125 mg, 0.48 mmol). Mesylate 3.35 (3.48 g, 11.4 mmol) and aldehyde 
3.34 (2.20 g, 9.52 mmol) were added, followed by Et2Zn (1M in hexane, 28.6 mL, 28.6 mmol, 
added dropwise over 15 min). The resulting yellow solution was immediately warmed to −20 °C 
and stirred for 16 h. The reaction was quenched by pouring into a rapidly stirring solution of sat. 
aq. NH4Cl (50 mL). After 15 min the phases were separated and the aqueous layer was extracted 
with (2 x 50 mL) Et2O. The combined organic layers were washed with brine, dried over 
MgSO4, filtered, and concentrated. Purification by flash chromatography (10% EtOAc in 
hexane) provided the desired product (3.08 g, 82%) as an inseparable 8:1 mixture with the syn-
diastereomer. 1H NMR (400 MHz, CDCl3) δ 4.01 – 3.87 (m, 2H), 3.78 (dt, J = 7.5, 3.5 Hz, 1H), 
3.14 (s, 1H), 2.62 (qd, J = 7.0, 4.3 Hz, 1H), 1.86 – 1.69 (m, 2H), 1.21 (d, J = 7.1 Hz, 3H), 1.06 
(dd, J = 6.4, 3.7 Hz, 21H), 0.15 (d, J = 3.5 Hz, 9H). 13C NMR (101 MHz, CDCl3) δ 108.5, 86.8, 
73.7, 62.7, 36.2, 34.0, 18.2, 16.5, 12.0, 0.4. [α]D20 +6.6 (c 1.11, CHCl3); IR (thin film, neat) 
3502, 2944, 2893, 2867, 2165, 1463, 1385, 1249, 1100, 1012, 994, 921, 843, 759 cm-1; HRMS 
(ASAP+) calcd for C19H39OSi2 [M–OH]+: 339.2539, found: 339.2546. 
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 (3S,4R)-4-Methyl-1-((triisopropylsilyl)oxy)hex-5-yn-3-ol  
For analytical purpose of determining e.r., (20 mg, 0.056 mmol, 1.0 equiv.) of 
3.36 was dissolved in 0.5 mL of MeOH and (24 mg, 0.056 mmol, 1.0 equiv) 
of K2CO3 was added at rt. After 1.5 h, the reaction was quenched with 1 mL of sat. NH4Cl and 
extracted with (3 x 5 mL) of Et2O. The combined extracts were washed with H2O (2 x 5 mL) and 
dried over MgSO4. Purification by flash column chromatography (10% Et2O in hexane) to yield 
a clear oil (12 mg, 75%) of the major desilylated anti-homopropargylic alcohol. 1H NMR (500 
MHz, CDCl3) δ 4.03 (ddd, J = 9.4, 5.4, 1.5 Hz, 1H), 3.95-3.90 (m, 1H), 3.86 (s, J = 2.3 Hz, 
1H), 3.74 – 3.69 (m, 1H), 2.56 – 2.49 (m, 1H), 2.06 (dd, J = 2.4, 1.7 Hz, 1H), 1.95 (ddd, J = 6.5, 
3.3, 1.7 Hz, 1H), 1.92 (ddd, J = 6.5, 3.3, 1.7 Hz, 1H), 1.79 (dddd, J = 10.9, 9.3, 4.2, 1.6 Hz, 1H), 
1.23 (d, J = 7.0 Hz, 3H), 1.06-1.00 (m, 21 H). The ee of this material was found to be 87% by 19F 
NMR analysis. [δ –71.49 (minor) and δ –71.60 (major), in CDCl3] of the (R)-Mosher ester.  
 
Triisopropyl((3S,4R)-4-methyl-3-(3-((1R,2R)-2-
methylcyclopropyl)prop-2-ynyloxy)hex-5-ynyloxy)silane  
 
To the homopropargylic alcohol 3.36 (660 mg, 1.84 mmol) and mesylate 3.35 (289 mg, 1.54 
mmol) in THF (4 mL) at 0 °C was added 15-crown-5 (425 µL, 2.15 mmol). The reaction stirred 
for 15 min, then NaH (85 mg, 2.1 mmol) was added portion wise (17 mg/5 mins). The reaction 
was warmed to rt and stirred overnight. The reaction was quenched with brine (3 mL) and 
extracted with Et2O (3 x 5mL). The combined organic extracts were dried and the solvent was 
concentrated in vacuo. Purification by flash chromatography (5% EtOAc in hexane) provided the 
desired product (414 mg, 63%). 1H NMR (400 MHz, CDCl3) δ 4.18 (d, J = 2.0 Hz, 2H), 3.81 
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(dd, J = 7.1, 5.5 Hz, 2H), 3.68 (dt, J = 8.3, 4.2 Hz, 1H), 2.80 (dtd, J = 6.9, 4.4, 1.4 Hz, 1H), 2.06 
(d, J = 2.5 Hz, 1H), 1.93 – 1.83 (m, 1H), 1.81 – 1.71 (m, 1H), 1.21 (d, J = 7.0 Hz, 3H), 1.09 – 
1.04 (m, 25H), 0.95 – 0.87 (m, 1H), 0.85 – 0.77 (m, 1H), 0.54 – 0.48 (m, 1H); 13C NMR (101 
MHz, CDCl3) δ 89.5, 86.2, 78.2, 72.2, 69.9, 60.3, 58.3, 34.6, 29.5, 18.5, 18.2, 16.8, 16.6, 16.0, 
12.2, 7.8; [α]D20 –37.2 (c 0.90, CHCl3); IR (thin film, neat) 3311, 2943, 2866, 2239, 1462, 1379, 
1250, 1100, 1060, 882, 847 cm-1; HRMS (ESI) calcd for C23H40O2Si [M+H]+: 377.2876, found: 
377.2881.  
 
 (3S,4S)-3-Methyl-4-(3-((1R,2R)-2-methylcyclopropyl)prop-2-
ynyloxy)-6-(triisopropylsilyloxy)hex-1-en-2-yl acetate (3.37) 
A mixture of Na2CO3 (13 mg, 0.12 mmol), [(p-cymene)RuCl2]2 
(20 mg, 0.033 mmol), tri(2-furyl)phosphine (0.08 equiv), acetic acid (190 µL, 3.3 mmol), and 1-
decyne (300 µL, 1.67 mmol) in toluene (1 mL) was heated to 80 °C and stirred for 1 h. The 
alkyne substrate (311 mg, 0.83 mmol) was dissolved in toluene (1 mL) and added to the mixture. 
The reaction was stirred at 80 °C for 6 h. The crude mixture was concentrated and purified by 
flash chromatography (5% EtOAc in hexane) to give the desired product (357 mg, 55%).  1H 
NMR (400 MHz, CDCl3) δ 4.78 (s, br, 2H), 4.11 – 4.05 (m, 2H), 3.73 (dd, J = 7.5, 4.8 Hz, 3H), 
2.70 (dd, J = 6.8, 4.7 Hz, 1H), 2.09 (s, 3H), 1.68 – 1.61 (m, 1H), 1.57 – 1.50 (m, 1H), 1.10 – 0.94 
(m, 27H), 0.89 – 0.83 (m, 1H), 0.79 – 0.73 (m, 1H), 0.49 – 0.44 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 169.2, 157.5, 102.5, 89.4, 76.2, 72.2, 60.2, 58.0, 40.3, 33.4, 21.3, 18.5, 18.3, 16.9, 16.6, 
12.2, 7.8; [α]D20 –24.4 (c 0.8, CHCl3); IR (thin film, neat) 2943, 2866, 1762, 1661, 1463, 1368, 
1220, 1180, 1097, 1057, 882 cm-1; HRMS (ESI) calcd for C25H44NaO4Si [M+Na]+: 459.2907, 
found: 459.2948.  
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 (3S,4S)-4-(((E)-3-Acetoxy-3-((1R,2R)-2-
methylcyclopropyl)allyl)oxy)-3-methyl-6-
((triisopropylsilyl)oxy)hex-1-en-2-yl acetate (3.38) 
A mixture of Na2CO3 (40 mg, 0.36 mmol), [(p-cymene)RuCl2]2 (52 
mg, 0.085 mmol), tri(2-furyl)phosphine (40 mg, 0.17 mmol), acetic acid (495 µL, 8.54 mmol), 
and 1-decyne (610 µL, 2.85 mmol) was stirred at 80 °C for 1 h. The ether (536 mg, 1.42 mmol) 
was added and the reaction was stirred for 12 h at 80 °C. The mixture was purified by flash 
chromatography (20% EtOAc in hexane) to give the desired product (487 mg, 69%). 1H NMR 
(500 MHz, CDCl3) δ 5.30 (t, J = 7.3 Hz, 1H), 4.84 (app d, J = 4.9 Hz, 1H), 4.23 (dd, J = 11.6, 
7.3 Hz, 1H), 4.15 – 4.10 (m, 1H), 3.83 – 3.75 (m, 2H), 3.73 (ddd, J = 9.6, 4.8, 2.6 Hz, 1H), 2.79 
– 2.73 (m, 1H), 2.13 (s, 3H), 2.08 (s, 3H), 1.74 – 1.67 (m, 1H), 1.59 – 1.52 (m, 1H), 1.44 – 1.39 
(m, 1H), 1.14 – 1.03 (m, 27H), 1.02 – 0.94 (m, 1H), 0.77 – 0.73 (m, 1H), 0.48 (dt, J = 8.7, 5.1 
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 169.4, 169.3, 157.6, 151.4, 114.9, 102.5, 76.3, 64.9, 
60.1, 40.3, 33.6, 21.3, 21.0, 19.1, 18.6, 18.3, 13.7, 13.6, 12.2, 12.1; [α]D20 –21.3 (c 0.31, CHCl3); 
IR (thin film, neat) 2943, 2866, 1761, 1663, 1463, 1369, 1218, 1178, 1098, 1068, 882 cm-1; 
HRMS (ESI) calcd for C27H48O6Si [M+Na]+: 519.3118, found: 519.3097.  
 
 (3S,4S)-4-(((Z)-3-(Dimethyl(phenyl)silyl)-3-((1R,2R)-2-
methylcyclopropyl)allyl)oxy)-3-methyl-6-
((triisopropylsilyl)oxy)hex-1-en-2-yl acetate (3.39) 
To a solution of with enol acetate ether 3.37 (8 mg, 0.02 mmol) and dimethylphenylsilane (5 µL, 
0.02 mmol) in acetone (0.5 mL) was added [Cp*Ru(MeCN)3]PF6 (0.2 mg, 0.0004 mmol). The 
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mixture was stirred for 3 h then was purified by flash column chromatography (5% ether in 
hexane) to provide the desired product (7.4 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 7.52 – 7.48 
(m, 2H), 7.35 – 7.31 (m, 3H), 5.98 (td, J = 6.6, 1.6 Hz, 1H), 4.77 (s, 2H), 3.91 (dd, J = 12.1, 6.9 
Hz, 1H), 3.77 – 3.74 (m, 1H), 3.71 (dd, J = 7.6, 4.4 Hz, 2H), 3.48 (ddd, J = 9.6, 4.6, 2.6 Hz, 1H), 
2.48 (qd, J = 6.9, 4.4 Hz, 1H), 2.06 (s, 3H), 1.61 (dtd, J = 10.3, 7.7, 2.6 Hz, 1H), 1.55 – 1.43 (m, 
1H), 1.04 (s, 24H), 0.93 (d, J = 7.0 Hz, 3H), 0.90 (dd, J = 6.9, 4.1 Hz, 1H), 0.77 – 0.70 (m, 1H), 
0.69 – 0.63 (m, 1H), 0.43 (s, 3H), 0.42 (s, 3H), 0.35 – 0.29 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 169.1, 157.5, 141.4, 139.3, 137.2, 133.9, 129.1, 128.1, 102.4, 69.5, 60.2, 40.2, 33.5, 
26.9, 21.3, 19.3, 18.3, 15.6, 14.0, 12.2, 11.9, –0.8, –0.9; [α]D20 –11.4 (c 0.74, CHCl3); IR (thin 
film, neat) 2944, 2866, 1761, 1462, 1368, 1220, 1179, 1098, 834 cm-1; HRMS (ESI) calcd for 
C33H57O4Si2 [M+H]+: 573.3795, found: 573.3810.  
 
 (E)-2-((2S,5S,6S)-5-Methyl-4-oxo-6-(2-
((triisopropylsilyl)oxy)ethyl)tetrahydro-2H-pyran-2-yl)-1-
((1S,2S)-2-methylcyclopropyl)vinyl acetate (3.40) 
The general cyclization reaction procedure was followed with 3.38 
(90 mg, 0.18 mmol), 2,6-dichloropyridine (54 mg, 0.36 mmol), 4 Å molecular sieves (180 mg), 
1,2 dichloroethane (5 mL), LiClO4 (6 mg, 0.05 mmol), and DDQ (165 mg, 0.73 mmol). The 
reaction was stirred at rt for 1.5 h, then was quenched with 5% aqueous NaHCO3. The crude 
mixture was extracted with CH2Cl2, concentrated, and purified by flash chromatography (5% 
EtOAc in hexane) to give the desired product (81 mg, 62%). 1H NMR (400 MHz, CDCl3) δ 5.25 
(d, J = 8.3 Hz, 2H), 4.51 (ddd, J = 10.0, 8.2, 4.1 Hz, 1H), 3.95 – 3.84 (m, 2H), 3.58 – 3.51 (m, 
1H), 2.55 – 2.50 (m, 2H), 2.40 (dq, J = 12.6, 6.4 Hz, 1H), 2.11 (s, 3H), 2.01 (dddd, J = 14.6, 8.5, 
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6.1, 2.1 Hz, 1H), 1.76 (app dq, dddd,  J = 8.9, 8.9, 8.9, 4.4 Hz, 1H), 1.39 – 1.34 (m, 1H), 1.09 (d, 
J = 2.4 Hz, 3H), 1.07 (s, 24H), 1.00 – 0.89 (m, 1H), 0.87 – 0.81 (m, 1H), 0.51 (dt, J = 8.6, 5.1 
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 208.4, 169.0, 151.3, 117.8, 79.6, 73.5, 59.5, 50.2, 48.5, 
37.6, 21.0, 19.4, 18.6, 18.2, 13.9, 13.8, 12.2, 9.5; [α]D20 –31.8 (c 0.63, CHCl3); IR (thin film, 
neat) 2943, 2867, 1762, 1717, 1462, 1369, 1209, 1098, 1067, 883 cm-1; HRMS (ESI) calcd for 
C25H44NaO5Si [M+Na]+: 475.2856, found: 475.2855. 
 
 (2S,3S)-6-((Z)-2-(Dimethyl(phenyl)silyl)-2-((1R,2R)-2-
methylcyclopropyl)vinyl)-3-methyl-2-(2-
((triisopropylsilyl)oxy)ethyl)dihydro-2H-pyran-4(3H)-one 
(3.41) 
The general cyclization reaction procedure was followed with 3.39 (7.4 mg, 0.013 mmol), 2,6-
dichloropyridine (16 mg, 0.11 mmol), 4 Å molecular sieves (21 mg), 1,2 dichloroethane (0.5 
mL), LiClO4 (1 mg, 0.01 mmol), and DDQ (12 mg, 0.052 mmol). The reaction was stirred at 45 
°C for 4 h, then was quenched with 5% aqueous NaHCO3. The crude mixture was extracted with 
CH2Cl2, concentrated, and purified by flash chromatography (5%-15% ether in hexane) to give 
the desired product (3.5 mg, 51%). 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.45 (m, 2H), 7.35 – 
7.31 (m, 3H), 5.81 (dd, J = 8.9, 1.5 Hz, 1H), 4.05 (ddd, J = 11.4, 9.0, 2.6 Hz, 1H), 3.84 (ddd, J = 
9.7, 6.8, 4.9 Hz, 1H), 3.74 (ddd, J = 10.0, 7.7, 6.0 Hz, 1H), 3.07 (ddd, J = 10.5, 8.5, 2.4 Hz, 1H), 
2.30 – 2.21 (m, 2H), 2.06 (dd, J = 14.0, 2.6 Hz, 1H), 1.87 (dtd, J = 9.7, 7.4, 2.4 Hz, 1H), 1.72 
(ddt, J = 14.1, 8.5, 5.5 Hz, 1H), 1.36 – 1.24 (m, 1H), 1.13 – 1.02 (m, 24H), 0.92 (d, J = 6.6 Hz, 
1H), 0.90 – 0.83 (m, 1H), 0.82 – 0.76 (m, 1H), 0.68 – 0.56 (m, 1H), 0.44 (s, 3H), 0.42 (s, 3H), 
0.35 (dt, J = 8.1, 4.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 208.3, 144.1, 138.9, 138.1, 133.9, 
129.3, 128.2, 79.5, 76.2, 60.0, 49.9, 48.0, 37.6, 26.7, 19.2, 18.3, 16.2, 14.2, 12.2, 9.5, –0.6, –0.8. 
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[α]D20 –47.8 (c 0.32, CHCl3); IR (thin film, neat) 2944, 2865, 1717, 1462, 1250, 1096, 835, 771, 
732 cm-1; HRMS (ASAP+) calcd for C31H52O3Si2 [M+H]+: 529.3533, found: 529.3541. 
 
2-((2S,4S,5R,6S)-6-(2-(tert-butyldimethylsilyloxy)ethyl)-4-
hydroxy-5-methyl-tetrahydro-2H-pyran-2-yl)-1-((1R,2R)-2-
methylcyclopropyl)ethanone 
 
To a solution of 3.40 (7.3 mg, 0.018 mmol) in MeOH (0.8 mL) at –10 °C was added NaBH4 (0.5 
mg, 0.01 mmol, 0.7 equiv.) in one portion. The mixture was stirred at –10 °C for 15 min, then 
was quenched with H2O. After concentration, the crude product was used directly in the next 
step without further purification. To a solution of the ketone in MeOH (0.5 mL) at 0 °C was 
added K2CO3 (13 mg, 0.09 mmol) in one portion. The mixture was stirred for 30 min at 0 °C, 
then was quenched with NH4Cl (5 mL) and extracted with Et2O (2 x 10 mL). The combined 
organic layers were dried over MgSO4 and purified by flash chromatography (15% to 25% 
EtOAc in hexane) to afford the desired product (6.1 mg, 81%, two steps). 1H NMR (500 MHz, 
CDCl3) δ 3.85 – 3.72 (m, 3H), 3.37 (td, J = 10.4, 4.7 Hz, 1H), 3.14 (td, J = 9.6, 2.2 Hz, 1H), 2.80 
(dd, J = 15.6, 6.7 Hz, 1H), 2.55 (dd, J = 15.6, 6.0 Hz, 1H), 2.03 – 1.99 (m, 1H), 1.95 – 1.88 (m, 
1H), 1.69 (dt, J = 8.3, 4.3 Hz, 1H), 1.61 – 1.51 (m, 1H), 1.43 – 1.36 (m, 1H), 1.28 – 1.22 (m, 
4H), 1.11 (d, J = 6.0 Hz, 3H), 1.06 (s, br, 21H), 0.98 (d, J = 6.5 Hz, 3H), 0.71 (td, J = 7.2, 3.7 
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 208.3, 78.1, 73.5, 71.8, 60.2, 49.7, 43.8, 41.2, 36.5, 
30.5, 20.4, 19.6, 18.3, 18.2, 13.1, 12.2; [α]D20 –45.0 (c 2.54, CHCl3); IR (thin film, neat) 3443, 
2942, 2866, 1693, 1463, 1404, 1381, 1094 cm-1; HRMS (ESI) calcd for C23H45O4Si [M+H]+: 
413.3087, found: 413.3091.   
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2-((2S,4S,5S,6S)-5-Methyl-6-(2-
((triisopropylsilyl)oxy)ethyl)-4-(((2S,3R,4S,5R)-3,4,5-
trimethoxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-
pyran-2-yl)-1-((1R,2R)-2-methylcyclopropyl)ethanone (3.44) 
 
To a solution of the keto alcohol (199 mg, 0.484 mmol) in CH2Cl2 (13 mL) were added 
trichloroacetimidate 3.43 (0.5 M solution in CH2Cl2, 1.45 mL, 0.726 mmol) and 4Å MS (300 
mg). The mixture was stirred for 30 min at rt then was cooled to –20 °C. TMSOTf (1.0 M 
solution in CH2Cl2, 65 µL, 0.063 mmol) was added dropwise. The reaction was stirred at –20 °C 
for 30 min then was warmed to rt slowly over 1 h. The reaction was quenched with Et3N (5 
drops) and purified by flash chromatography (25% EtOAc in hexane) to yield the desired product 
(148 mg, 52%). 1H NMR (500 MHz, CDCl3) δ 4.29 (d, J = 7.7 Hz, 1H), 3.97 (dd, J = 11.6, 5.2 
Hz, 1H), 3.85 – 3.73 (m, 3H), 3.63 (s, 3H), 3.61 (s, 3H), 3.48 (s, 3H), 3.31 – 3.23 (m, 2H), 3.17 
(td, J = 9.6, 2.2 Hz, 1H), 3.13 – 3.06 (m, 2H), 2.98 (dd, J = 9.1, 7.6 Hz, 1H), 2.79 (dd, J = 15.7, 
6.9 Hz, 1H), 2.55 (dd, J = 15.7, 5.7 Hz, 1H), 2.16 (ddd, J = 12.5, 4.9, 1.9 Hz, 1H), 1.93 (dtd, J = 
13.8, 7.6, 2.2 Hz, 1H), 1.70 (dt, J = 8.2, 4.2 Hz, 1H), 1.61 – 1.54 (m, 1H), 1.45 – 1.37 (m, 2H), 
1.29 – 1.23 (m, 2H), 1.12 (d, J = 6.0 Hz, 3H), 1.06 (s, br, 21H), 1.02 (d, J = 6.4 Hz, 3H), 0.72 
(ddd, J = 7.8, 6.4, 3.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 208.3, 105.7, 85.7, 84.0, 83.6, 
79.6, 78.3, 71.8, 63.4, 60.9, 60.2, 58.9, 49.7, 42.3, 40.4, 36.6, 30.5, 20.3, 19.5, 18.3, 18.2, 13.0, 
12.2; [α]D20 –23.8 (c 0.66, CHCl3); IR (thin film, neat) 3373, 3246, 2927, 2865, 1693, 1614, 
1462, 1381, 1106, 834 cm-1; HRMS (ESI) calcd for C31H59O8Si [M+H]+: 587.3979 found: 
587.3990. 
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 (S)-2-((2R,4S,5S,6S)-5-Methyl-6-(2-
((triisopropylsilyl)oxy)ethyl)-4-(((2S,3R,4S,5R)-3,4,5-
trimethoxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-
pyran-2-yl)-1-((1R,2R)-2-methylcyclopropyl)ethanol (3.46) 
A solution of catalyst 3.45 (1M in toluene, 125 µL, 0.049 
mmol) was dried on a high vacuum pump for 1 h. The catalyst was dissolved in THF (3.5 mL) 
the resulting solution was cooled to –20 °C. A solution of BH3•SMe2 in THF (1M, 495 µL, 0.495 
mmol) was added. The mixture was stirred for 30 min at –20 °C, then the ketone 3.44 (144 mg, 
0.245 mmol) in THF (1 mL) was added dropwise over 10 min. The reaction was stirred at –20 
°C for 12h then was quenched with MeOH (5 mL, dropwise). Saturated NH4Cl (15 mL) and 
EtOAc (20 mL) were added. After extraction with EtOAc (2 x 20 mL), the combined organic 
extracts were dried and concentrated. Purification by flash chromatography (20% EtOAc in 
hexane) provided the desired product (113 mg, 78%) and its diastereomer (13 mg, 9%). 1H NMR 
(400 MHz, CDCl3) δ 4.30 (d, J = 7.6 Hz, 1H), 3.97 (dd, J = 11.6, 5.2 Hz, 1H), 3.85 – 3.74 (m, 
3H), 3.64 (s, 3H), 3.62 (s, J = 1.6 Hz, 3H), 3.49 (s, 3H), 3.29 – 3.23 (m, 4H), 3.15 – 3.09 (m, 
2H), 3.00 (dd, J = 9.1, 7.6 Hz, 1H), 2.12 – 2.07 (m, 1H), 1.94 (tdd, J = 8.7, 6.6, 2.5 Hz, 1H), 1.84 
– 1.74 (m, 1H), 1.74 – 1.66 (m, 1H), 1.64 – 1.56 (m, 1H), 1.53 – 1.44 (m, 2H),  1.08 (s br, 24H), 
1.04 (d, J = 6.5 Hz, 3H), 0.81 – 0.71 (m, 1H), 0.61 (tt, J = 8.6, 4.4 Hz, 1H), 0.37 – 0.28 (m, 1H), 
0.20 (dt, J = 8.4, 4.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 105.9, 85.8, 84.1, 83.5, 79.6, 78.4, 
76.0, 75.9, 63.4, 61.0, 61.0, 59.8, 59.0, 42.9, 42.2, 41.0, 36.4, 26.4, 18.9, 18.3, , 13.1, 12.2, 11.3, 
10.5. [α]D20 –19.6 (c 1.14, CHCl3); IR (thin film, neat) 3490, 2942, 2866, 1731, 1463, 1369, 
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1162, 1095, 989, 884 cm-1; HRMS (ESI) calcd for C31H60O8NaSi [M+Na]+: 611.3955 found: 
611.3951. 
 
 (S)-2-((2R,4S,5S,6S)-6-(2-Hydroxyethyl)-5-methyl-4-
(((2S,3R,4S,5R)-3,4,5-trimethoxytetrahydro-2H-pyran-2-
yl)oxy)tetrahydro-2H-pyran-2-yl)-1-((1R,2R)-2-
methylcyclopropyl)ethanol 
To a solution of the silyl ether 3.46 (108 mg, 0.184 mmol) in 
EtOH (6.4 mL) was added 1% HCl (1.95 mL). The solution was stirred at rt for 5h. The reaction 
was quenched with saturated NaHCO3 (5 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organic layers were dried over MgSO4 and purified by flash chromatography (35% to 
20% hexane in EtOAc) to afford the desired product (80 mg, 100%). 1H NMR (400 MHz, 
CDCl3) δ 4.27 (d, J = 7.6 Hz, 1H), 3.95 (dd, J = 11.5, 5.2 Hz, 1H), 3.79 – 3.72 (m, 2H), 3.61 (s, J 
= 2.5 Hz, 3H), 3.59 (s, 3H), 3.47 (s, J = 2.7 Hz, 3H), 3.28 – 3.20 (m, 3H), 3.12 – 3.04 (m, 3H), 
2.97 (dd, J = 9.1, 7.6 Hz, 1H), 2.09 (ddd, J = 12.7, 4.8, 2.0 Hz, 1H), 1.99 – 1.88 (m, 1H), 1.81 
(dt, J = 14.4, 9.1 Hz, 1H), 1.72 – 1.58 (m, 2H), 1.53 – 1.35 (m, 2H), 1.05 (d, J = 5.9 Hz, 3H), 
1.00 (d, J = 6.5 Hz, 3H), 0.79 – 0.69 (m, 1H), 0.64 – 0.57 (m, 1H), 0.31 (dt, J = 8.4, 4.7 Hz, 1H), 
0.22 (dt, J = 8.3, 4.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 105.8, 85.8, 84.0, 83.2, 81.1, 79.6, 
76.0, 75.7, 63.5, 61.1, 61.0, 60.6, 59.1, 42.8, 42.5, 35.2, 26.9, 18.9, 14.4, 13.0, 11.4, 10.8; [α]D20 
–20.5 (c 0.57, CHCl3); IR (thin film, neat) 3427, 2930, 1455, 1372, 1326, 1162, 1090, 988 cm-1; 
HRMS (ESI) calcd for C22H40NaO8 [M+Na]+: 455.2621 found: 455.2620.  
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2-((2S,3S,4S,6R)-6-((S)-2-Hydroxy-2-((1R,2R)-2-
methylcyclopropyl)ethyl)-3-methyl-4-(((2S,3R,4S,5R)-3,4,5-
trimethoxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-
pyran-2-yl)acetic acid (3.47) 
 
To a solution of the diol (10 mg, 0.024 mmol) in CH2Cl2 (110 µL) was added TEMPO (0.2 mg, 
0.001 mmol) and saturated NaHCO3 (60 µL). KBr (5 µL, 0.002 mmol, 0.5M aq. stock solution) 
and Bu4NCl (25 µL, 0.0017 mmol, 0.08M aq stock solution) were added subsequently and the 
mixture was cooled to 0 °C. To the vigorously stirring biphasic solution was added a stock 
solution of sat. NaHCO3 (35 µL), brine (65 µL) and bleach (95 µL, 0.065 mmol, 0.7 M) 
dropwise over 45 min. The mixture was allowed to stir for an additional 30 min at 0 °C upon 
completion of the addition. The solution was then diluted with H2O (5 mL) and EtOAc (5 mL). 
The diluted mixture was acidified with 10% citric acid (4 drops) to pH 3-4. The aqueous layer 
was extracted with EtOAc (3 x 5mL). The combined organic extracts were dried over MgSO4. 
The crude colorless oil (8 mg, 78%) was determined pure by 1H NMR and used without further 
purification. 1H NMR (400 MHz, CDCl3) δ 4.26 (d, J = 7.6 Hz, 1H), 3.94 (dd, J = 11.5, 5.1 Hz, 
1H), 3.61 (s, 3H), 3.58 (s, 3H), 3.46 (s, 3H), 3.30 – 3.20 (m, 3H), 3.13 – 3.07 (m, 3H), 2.97 (dt, J 
= 9.0, 4.8 Hz, 1H), 2.67 (d, br, J = 14.7 Hz, 1H), 2.40 (m, 1H), 2.14 – 2.02 (m, 1H), 1.78 (dt, J = 
15.0, 9.8 Hz, 1H), 1.72 – 1.65 (m, 1H), 1.55 – 1.40 (m, 2H), 1.01 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 
5.8 Hz, 3H), 0.92 – 0.79 (m, 1H), 0.78 – 0.68 (m, 1H), 0.57 (tt, J = 8.7, 4.5 Hz, 1H), 0.28 – 0.20 
(m, 1H), 0.16 (dt, J = 8.7, 4.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 173.7, 105.7, 85.7, 83.9, 
82.6, 79.5, 78.4, 77.63, 76.9, 63.4, 61.0, 61.0, 59.0, 42.1, 41.8, 40.7, 38.7, 25.8, 18.7, 12.8, 12.0, 
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10.4; [α]D20 –24 (c 2.1, CHCl3); IR (thin film, neat) 3455, 2926, 1731, 1457, 1373, 1327, 1257, 
1162, 1091 cm-1; HRMS (ESI) calcd for C22H38NaO9 [M+Na]+: 469.2414 found: 469.2436.  
 
Clavosolide A (3.1) 
To the seco acid 3.47 (6.0 mg, 0.014 mmol) in THF (0.8 mL) 
was added Et3N (40 µL, 0.28 mmol) and 2,4,6-
trichlorobenzoyl chloride (25 µL, 0.14 mmol) dropwise. The 
reaction was allowed to stir for 2.5 h at rt and the Et3N•HCl 
salt was removed by flitration. The filtrate was diluted with 
toluene (0.8 mL) and added dropwise over 5 h to a stirred 
solution of DMAP (16 mg, 0.132 mmol) in toluene (13 mL) at 
90°C via a syringe pump. The reaction was cooled to rt and 
allowed to stir for another 12h. The reaction mixture was quenched with aq. NH4Cl (5 mL), 
extracted with EtOAc (2 x 5mL) and concentrated under vacuum. Purification by flash 
chromatography (45% to 35% hexanes in EtOAc) provided the natural product as a white solid 
(2.6 mg, 44%). 1H NMR (601 MHz, CDCl3) δ 4.42 (td, J = 8.9, 2.0 Hz, 1H), 4.26 (d, J = 7.6 Hz, 
1H), 3.95 (dd, J = 11.6, 5.2 Hz, 1H), 3.61 (s, 3H), 3.58 (s, 3H), 3.46 (s, 3H), 3.44 (qd, J = 4.3, 
1.4 Hz, 2H), 3.27 – 3.21 (m, 1H), 3.09 (ddd, J = 10.1, 7.9, 3.2 Hz, 2H), 2.96 (dd, J = 9.1, 7.6 Hz, 
1H), 2.54 (dd, J = 17.4, 3.6 Hz, 1H), 2.41 (dd, J = 17.3, 6.6 Hz, 1H), 2.04 (ddd, J = 12.7, 4.8, 1.8 
Hz, 1H), 1.89 (dt, J = 15.0, 9.0 Hz, 1H), 1.68 (ddd, J = 15.1, 3.5, 2.1 Hz, 1H), 1.41 – 1.34 (m, 
2H), 0.97 (d, J = 5.1 Hz, 3H), 0.85 – 0.78 (m, 1H), 0.71 (tt, J = 8.8, 4.6 Hz, 1H), 0.34 (dt, J = 
8.4, 4.7 Hz, 1H), 0.22 (dt, J = 8.3, 4.9 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 171.3, 105.7, 
85.8, 84.1, 83.4, 79.6, 77.5, 77.3, 75.1, 63.5, 61.0, 61.0, 59.0, 42.8, 41.5, 40.9, 39.5, 25.0, 18.7, 
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12.8, 12.1, 11.1; [α]D20 –41.3 (c 0.1, CHCl3); IR (thin film, neat) 2945, 1734, 1165, 1089 cm-1; 
HRMS (ESI) calcd for C44H72NaO16 [M+Na]+: 879.4716 found: 879.4739; m.p: 249-252 °C.  
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